**JAMES WILLIAM HARBOUR, MD**

Current Title

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Professor and Chairman
The David Bruton, Jr. Chair in Ophthalmology
Department of Ophthalmology

Member, Harold C. Simmons Comprehensive Cancer Center

University of Texas Southwestern Medical Center

Contact Information & Websites

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Department of Ophthalmology [Department webpage](https://tinyurl.com/4thbpm42)

UT Southwestern Medical Center [Wikipedia webpage](https://en.wikipedia.org/wiki/J._William_Harbour)

5323 Harry Hines Blvd, MC 9057 [Doximity webpage](https://www.doximity.com/cv/j-william-harbour-md-1)

Dallas, TX 75390-9057 [LinkedIn webpage](https://www.linkedin.com/in/jwilliamharbourmd/)

214-648-3407

william.harbour@utsouthwestern.edu

Career Highlights

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

* Discovery of *RB1* mutations in small cell lung cancer
* Discovery of *BAP1* mutations as metastatic driver in uveal melanoma
* Discovery of germline *BAP1* mutation and new BAP1 tumor predisposition syndrome
* Discovery of *SF3B1* mutations as metastatic driver in uveal melanoma
* Discovery of *PRAME* expression as metastatic driver in uveal melanoma
* Discovery of LAG3 as predominant checkpoint protein in uveal melanoma
* Discovery of ESRRG as oncogenic driver in retinoblastoma
* Inventor of commercialized machine learning prognostic test for uveal melanoma
* Founder of Collaborative Ocular Oncology Group and Ocular Oncology Research Society
* Citations of peer-reviewed publications: 22,106 | h-index: 74 | i10-index: 159

Education

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1981-85 Bachelor of Science in Biochemistry (*summa cum laude*)

 Texas A&M University

1985-90 Doctor of Medicine

 Johns Hopkins University School of Medicine

Pre-Doctoral Training

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1987-88 Howard Hughes / NIH Research Scholars Program

 National Institutes of Health, Bethesda, MD

Post-Doctoral Training

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1990-91 Internship in Internal Medicine

 Greater Baltimore Medical Center, Baltimore, MD

1991-94 Residency in Ophthalmology

 Wills Eye Hospital

 Thomas Jefferson Medical College, Philadelphia, PA

1994-95 Clinical Fellowship in Retinal Diseases and Surgery

 Bascom Palmer Eye Institute

 University of Miami School of Medicine, Miami, FL

1995-96 Clinical Fellowship in Ocular Oncology

 Department of Ophthalmology

 University of California, San Francisco

1996-99 Post-Doctoral Research Training in Molecular Oncology

 Division of Molecular Oncology, Department of Medicine

 Washington University School of Medicine

Academic Appointments

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2021-present Professor and Chair, Department of Ophthalmology

 University of Texas Southwestern Medical Center

2015-21 Associate Director for Basic Science, Sylvester Comprehensive Cancer Center

 University of Miami Miller School of Medicine

2012-21 Professor of Ophthalmology, Bascom Palmer Eye Institute

 University of Miami Miller School of Medicine

2012-21 Professor of Biochemistry & Molecular Biology

 University of Miami Miller School of Medicine

2012-21 Vice Chair for Translational Research

 Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

2006-2012 Paul A. Cibis Distinguished Professor of Ophthalmology & Visual Sciences

 Washington University School of Medicine, St. Louis, MO

2006-2012 Professor, Department of Cell Biology & Physiology

 Washington University School of Medicine, St. Louis, MO

2006-2012 Professor, Department of Medicine, Division of Molecular Oncology

 Washington University School of Medicine, St. Louis, MO

2001-06 Associate Professor, Department of Ophthalmology & Visual Sciences

 Washington University School of Medicine, St. Louis, MO

2001-06 Associate Professor, Department of Cell Biology & Physiology

 Washington University School of Medicine, St. Louis, MO

2001-06 Associate Professor, Department of Medicine, Division of Molecular Oncology

 Washington University School of Medicine, St. Louis, MO

2000-01 Assistant Professor, Department of Cell Biology & Physiology

 Washington University School of Medicine, St. Louis, MO

2000-01 Assistant Professor, Department of Medicine, Division of Molecular Oncology

 Washington University School of Medicine, St. Louis, MO

1996-2001 Assistant Professor, Department of Ophthalmology & Visual Sciences
 Washington University School of Medicine, St. Louis, MO

1995-96 Instructor, Department of Ophthalmology

 University of California, San Francisco, CA

Hospital Appointments

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2021- UT William P. Clements Jr. and Zale-Lipshy University Hospitals, Dallas, TX

2021 Parkland Health and Hospital System, Dallas, TX

2021- Children’s Medical Center, Dallas, TX

2018-2021 Nicklaus Miami Children’s Hospital

2012-2021 Bascom Palmer Eye Institute/Anne Bates Leach Eye Hospital, University of Miami

2012-2021 Sylvester Comprehensive Cancer Center, University of Miami

2012-2021 University of Miami Hospital

1996-2012 Barnes-Jewish Hospital, St. Louis, MO

1996-2012 Barnes-Jewish West County Hospital, St. Louis, MO

1996-2012 St. Louis Children’s Hospital, St. Louis, MO

1996-2012 St. Lukes Hospital, St. Louis, MO

Medical Licensure

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2021-present Texas

2012-present Florida

1996-2013 Missouri

1996-2014 Illinois

1995-1996California
1991-1994 Pennsylvania

1990-1991 Maryland

Board Certification

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

American Board of Ophthalmology — May 12, 1996 (Recertified 2016)

Professional Recognition

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

America's Top Doctors, Castle Connolly (2004-present)

America's Top Doctors for Cancer, Castle Connolly

America's Top Ophthalmologists

Best Doctors in America

Best Doctors in St. Louis

Ocular Surgery News Top 150 Innovators in Retina (2016)

The Ophthalmologist Top 50 Power List (2019)

Top Doctors in Miami (Castle Connolly)

Who’s Who in America

Who’s Who in Healthcare

Who's Who in Medical Sciences Education

Professional Societies and Organizations

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

American Academy of Ophthalmology
American Association for Cancer Research

American Association of Ophthalmic Oncologists and Pathologists

American Ophthalmological Society

American Society of Clinical Oncology

American Society of Retina Specialists

Association of American Physicians

Association for Research in Vision and Ophthalmology

Association of University Professors of Ophthalmology

Children’s Oncology Group

Collaborative Ocular Oncology Group (Founder)

Dade County Medical Association

Dallas Academy of Ophthalmology

Dallas County Medical Society

Florida Medical Association

Florida Society of Ophthalmology

International Society of Ocular Oncology
Macula Society

Missouri Ophthalmological Society

Ocular Oncology Research Society (Founder)
Pan-American Ocular Oncology Society

Retina Society

St. Louis Ophthalmological Society
Society of Heed Fellows

Society for Melanoma Research

Texas Medical Association

Texas Ophthalmological Association

Academic Service1

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2024- Member, Cancer Biology Graduate Program, UTSW

2024-25 Member, Faculty Compensation Advisory Committee, UTSW

2023-24 Member, Ambulatory Services Committee, UTSW Medical Group

2022-23 Chair, Non-Compete Covenant Workgroup, UTSW

2022-28 Member, Strategic Plan Clinical Transformation Subcommittee, UTSW

2022- Member, Search Committee, Department of Dermatology Chair, UTSW

2021- Member, Professional Liability Advisory Committee, UTSW

2021- Member, Ambulatory Services Committee, UTSW

2021- Member, Ambulatory Surgery Steering Committee, UTSW

2021- Member, Clinical Chairs Executive Committee, UTSW

2021- Member, Surgical Chairs Study Group, UTSW

2021 Mentor, South Florida Cancer Control Training in Disparities and Equity T32 Training Program, SCCC

2021 Member, Cancer Grand Challenge Taskforce, SCCC

2021 Member, Bioinformatics Taskforce, SCCC

2021 Member, Search Committee, Chief of Medical Oncology, UMMSOM

2020-21 Member, Human Genetics and Genomics Graduate Program, UMMSOM

2020-21 Member, FACCA Organizing Committee, SCCC

2020-21 Member, Translational Pilot Awards Committee, SCCC

2020-21 Chair, Ocular Oncology Training Series, BPEI

2020-21 Member, Task Force on Racial Justice Research Subcommittee, UMMSOM

2020-21 Member, Search Committee for Chair of Department of Health Informatics, UMMSM

2020-21 Mentor, Biochemistry & Molecular Biology Master’s Program, UMMSOM

2019-20 Chair, P01 Team Science Grant Review Committee, SCCC

2019-20 Member, Sylvester Translational Science Grant Program Review Committee, SCCC

2019-21 Poster Judge, MD/PhD Medical Scientist Training Program, UMMSM

2019-21 Mentor, T32 Computational Ocular Genomics Training Program, HIHG

2019-21 Program Director, T32 Cancer Epigenetics Training Program, SCCC

2017-18 Chair, Serious and/or Continuing Non-Compliance Committee, UMMSM

2017-21 Member, Research Building Committee, SCCC

2016-21 Director, Ocular Oncology Fellowship Program, BPEI

2016-21 Mentor, T32 Research Training Program in Surgical Oncology, SCCC

2016-21 Member, Space Committee, SCCC

2016-21 Member, FACCA Review Committee, SCCC

2015-21 Member, Membership Review Committee, SCCC

2015 Member, Decanal Dean Review Committee, UMMSM

2015 Member, Department of Genetics Recruitment Committee, UMMSM

2015-21 Member, Faculty Mentoring Program, SCCC

2015 Member, Bridge Funding Grant Review Committee, SCCC

2015-21 Member, Cancer Epigenetics Research Program, SCCC

2015Member,Internal Advisory Board of Scientific Advisors, SCCC

2015 Member, Institute for Children & Adolescents with Cancer Advisory Board, SCCC

2014-16 Member, Academic Personnel Board Promotions Committee, University of Miami

2014 Chair, Search Committee, Clinical Research Unit Director, BPEI

2014-21 Member, Developmental Grant Program Review Committee, SCCC

2014-21 Team Science Advisor, Miami Clinical & Translational Science Institute, UMMSM

2014-21 Member, Research Laboratory Space Task Force, SCCC

2013-14 Member, Chief of Surgical Oncology Search Committee, SCCC

2013-14 Member, Internal Grant Review Committee, SCCC

2013-14 Member, Retina Faculty Search Committee, BPEI

2013-17 Medical Director, Clinical Research Unit, BPEI

2013-20 Medical Director, Echography Service, BPEI

2013-21 Co-Leader, Research Leadership Committee, BPEI

2013-15 Physician Champion, Epic EMR Implementation Task Force, BPEI

2013-15 Co-Chair, Epic EMR Physician Steering Committee, BPEI

2013-15 Member, Epic EMR Executive Governance Committee, BPEI

2013-15 Member, Epic EMR Operations Committee, BPEI

2013-14 Member, Outstanding Cancer Researcher Award Committee, SCCC

2012-21 Member, Interdisciplinary Stem Cell Institute, UMMSM

2012-21 Faculty, Cancer Biology Graduate Program, UMMSM

2012-21 Faculty, Graduate Program in Biomedical Sciences, UMMSM

2012-21 Director, Ocular Oncology Service, BPEI

2012-21 Member, Vitreoretinal Service, BPEI

2012-21 Member, Executive Committee, SCCC

2012-21 Co-Leader, Skin & Eye Cancer Site Disease Group, SCCC

2012-21 Faculty, Medical Student Ophthalmology Program, BPEI

2012-21 Vice Chairman for Translational Research, BPEI

2012-21 Member, Faculty of 1000 for Research

2012-21 Member, von Hippel-Lindau Multi-Disciplinary Team, SCCC

2012 Senior Founding Editor, American Society of Retina Specialists Image Bank

2010-12 Member, von Hippel-Lindau Multi-Disciplinary Team, WUSM

2010-21 Co-Head, Faculty of 1000 for Ophthalmic Oncology

2009-10 Co-Chair, College of American Pathologists (CAP) Retinoblastoma Protocol

2009-10 Co-Chair, Clinical Trials Section, Ocular Melanoma Foundation Workgroup

2008-12 Research Advisory Committee, DOVS

2008-12 Member, Institute of Clinical and Translational Sciences, WUSM

2006-12 Member, Appointment and Promotions Committee, DOVS

2006-08 Chair, Molecular Biology and Biomarker Subgroup, AJCC Task Force

2005-11 Chair, Research Committee, International Society of Ocular Oncology

2004-05 Member, Program Committee, AACR Annual Meeting

2004 Founder, Ocular Oncology Research Society

2004-12 Lecturer, Cancer Biology Graduate Course, WUSM

2003-12 Member, Division of Biology & Biomedical Sciences, WUSM

2002 Member, ARVO Members-In-Training Program

2002-10 Member, Faculty Search Committee, DOVS

2002-10 Member, Research Space Committee, DOVS

2001-04 Member, Program Committee, ARVO Annual Meeting

2000 Mentor, Siteman Cancer Center Medical Student Summer Research Program

1998-99 Institutional Investigator, Collaborative Ocular Melanoma Study, DOVS

1998-02 Member, Management Committee, Barnes Retina Institute, DOVS

1998-12 Member, Siteman Comprehensive Cancer Center, WUSM

1998-00 Faculty, Molecular Foundations of Medicine Course, WUSM

1998-08 Member, American Joint Committee on Cancer Ophthalmic Task Force

1998-12 Medical Student Advisor, DOVS

1998-12 Director, Retina Section, DOVS

1998-03 Co-Director, Retina Fellowship Program, Barnes Retina Institute & DOVS

1998-03 Director, Ophthalmic Education, DOVS

1998-03 Member, Resident Selection Committee, DOVS

1996-12 Director, Ocular Oncology Service, DOVS

1AACR, American Association for Cancer Research; AAO, American Academy of Ophthalmology; ARVO, Association for Research in Vision and Ophthalmology; BPEI, Bascom Palmer Eye Institute; DOVS, Department of Ophthalmology & Visual Sciences at Washington University in St. Louis; FACCA, Florida Academic Cancer Center Alliance; HIHG, John P. Hussman Institute for Human Genomics; SCCC, Sylvester Comprehensive Cancer Center; UMMSM, University of Miami Miller School of Medicine; UTSW, University of Texas Southwestern Medical Center; WUSM, Washington University School of Medicine

Honors & Awards

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2021 Cancer Prevention and Research Institute of Texas Recruitment Award

2016 Alcon Research Institute Award

2015 Pan-American Association of Ophthalmology Retina Research Foundation/Kayser Global Award for "breakthroughs in genetic and genomic research”

2014 Association for Research in Vision and Ophthalmology (ARVO) Silver Fellow

2014 Research to Prevent Blindness, Inc. Senior Scientific Investigator

2014 Macula Society Paul Henkind Memorial Award and Lecture

2013 American Society of Retina Specialists Honor Award

2013 Florida Society of Ophthalmology Shaler Richardson, MD Service to Medicine Award for “personal contribution to quality patient care by collaborating and integrating ophthalmology into the medical profession on a national level.”

2012 American Academy of Ophthalmology Senior Achievement Award

2011 Ocular Melanoma Foundation Research Award

2008 Macula Society Rosenthal Award for individual under 50 with outstanding promise

2007 Teacher of the Year Award in Research, DOVS, WUSM

2005 Association for Research in Vision and Ophthalmology (ARVO) Cogan Award for a “researcher, 40 years of age or younger, who has made important and worthwhile contributions to research in ophthalmology or visual science that are directly related to disorders of the human eye or visual system, and who shows substantial promise for future research”

2003 American Academy of Ophthalmology Achievement Award

2002 Research to Prevent Blindness, Inc. Physician-Scientist Award

1995-96 Heed-Knapp Ophthalmic Fellowship for support of ocular oncology fellowship

1994-95 Heed Ophthalmic Foundation Fellowship for support of retina fellowship

1991 Greater Baltimore Medical Center Housestaff Research Award

1990 Alpha Omega Alpha Honor Medical Society, Johns Hopkins University

1990 Phi Beta Kappa National Honor Society, Johns Hopkins University

1990 Paul Ehrlich Clinical Research Award, Johns Hopkins University

1985 *Summa Cum Laude*, Texas A&M University

1985 Phi Eta Sigma Academic Scholarship, Johns Hopkins University

1984 Phi Kappa Phi National Honor Society, Texas A&M University

1984 Phi Lambda Upsilon Chemistry Honor Society, Texas A&M University

1983 Beta Beta Beta Biology Honor Society, Texas A&M University

1982-84 Academic scholarships, Texas A&M University

1982-85 University Honors Program, Texas A&M University

1982 Phi Eta Sigma Honor Society, Texas A&M University

1981-85 Dean’s Honor Roll, Texas A&M University

Advisory Positions

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2022- Scientific Advisor, IDEAYA Biosciences

2021- Scientific Advisor, Immunocore, Inc.

2020-21 Scientific Advisor, Translational Drug Development, LLC

2018-19 Scientific Advisor, Aura Biosciences

2018-19 Scientific Advisor, OrbiMed Advisors

2018-19 Scientific Advisor, Arix Biosciences

2018-19 Member, Scientific Advisory Board, Array Biopharma

2015-16 Chair, External Advisory Board, Eye Tumor P50 SPORE Grant, Emory University

2015-18 Member, Scientific Advisory Board, Iconic Therapeutics, Inc.

2014-16 Member, College of American Pathologists Eye Cancer Protocol Review Panel

2011-21 Co-Director, Scientific Steering Committee, Melanoma Research Foundation Cure Ocular Melanoma (CureOM) Initiative

2010- Scientific Advisor, Castle Biosciences, Inc.

External Reviewer

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2020 Health Research Charities Ireland/Health Research Board Ad Hoc Grant Review

2019 Deutsche Forschungsgemeinschaft (German Research Foundation) Grant Review

2017 The Netherlands Organization for Health Research & Development (ZonMw)

2017 NIH Cancer Biomarkers Study Section, Oncology 2 - Translational Clinical Integrated Review Group

2015 NIH Scientific Review Group/Special Emphasis Panel (ZRG1 BDCN-R-2)

2015 Australia Raine Medical Research Foundation

2015 AACR-Ocular Melanoma Foundation Scientific Grant Review Committee

2011- Melanoma Research Alliance Scientific Grants Review Committee

2010 Univ. of Louisville Clinical and Translational Innovative Research Awards

2009 NIH Scientific Review Group/ Special Emphasis Panel (ZRG1 OTC-D)

2009 United KingdomNorthwest Cancer Research Fund Scientific Committee

2008- Melanoma Research Foundation Scientific Grants Review Committee

2007 Ireland Health Research Board

2007 Swiss National Science Foundation

2007 Austrian Science Fund

2007 Dutch Cancer Society

2007 Wellcome Trust, United Kingdom

2007 United KingdomNorthwest Cancer Research Fund Scientific Committee

2006 NIH Scientific Review Group/Special Emphasis Panel (ZRG1 BDCN-F)

2005 German-Israeli Foundation for Scientific Research and Development

2005 NIH Scientific Review Group/VIS-A Study Section *Ad Hoc* (ZRG1 AED 01 Q)

2005 Wellcome Trust Research Fund

2004 NIH Scientific Review Group/Special Emphasis Panel (ZRG1 BDCN-F)

2003 Dutch Cancer Society

2002United KingdomNorthwest Cancer Research Fund Scientific Committee

2002 NIH Scientific Review Group/VIS-C Study Section *Ad Hoc*

Editorial Responsibilities

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Co-Editor *Retina Times, Ocular Oncology Section* (2008-present)

Associate Editor *Melanoma Research* (2008-2021)

 *BMC Cancer* (2008-2010)

Editorial Board *Melanoma Management* (2014-2019)

*Faculty of 1000* (2012-2021)

*Expert Review of Ophthalmology* (2009-present)

*Translational Vision Science & Technology* (2011-present)

 *Archives of Ophthalmology (JAMA Ophthalmology)* (2000-2011)

Ad Hoc Reviewer >30 medical and scientific journals

Research Funding

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2024-27 Research to Prevent Blindness, Inc. Challenge Grant

 $300,000

 Role on project: Principal Investigator

2022-27 Cancer Prevention and Research Institute of Texas (CPRIT)

 Recruitment of Established Investigators Award, RR220010

 $6,000,000

 Role on project: Principal Investigator

2021-26 R01 CA256193 (National Cancer Institute)

"Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis"

 $3,289,658

Role on project: Principal Investigator (Contact Principal Investigator, Dr. Keiran Smalley, Moffitt Cancer Center)

2021-24 Department of Defense Melanoma Research Program Translational Research Award

“Single-Cell Analysis of LAG3 Checkpoint Inhibition in Metastatic Uveal Melanoma”

$921,000

Role on project: Principal Investigator (turned over to Dr. Jose Lutzky upon leaving the University of Miami)

2021 Office of the Executive Dean for Research Internal Administrative Committee Equipment Grant, University of Miami

 “Essential Equipment for Irreplaceable Eye Cancer Cell Lines”

 $8,572.75

 Role on project: Principal Investigator

2021-22 Castle Biosciences Sponsored Research Award

 Participating COOG2 Sites Data Entry Effort

 $250,000

Role on project: Principal Investigator (turned over to Dr. Zelia Correa upon leaving the University of Miami)

2020-25 R01 CA248890 (National Cancer Institute)

 "3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma"

 $2,415,172

Role on project: Principal Investigator (Contact Principal Investigator, Dr. Daniel Paleaz)

2006-22 R01 CA125970 (National Cancer Institute)

 "Molecular predictive testing in uveal melanoma"

 Second Competing Renewal Award: $2,839,740

 First Competing Renewal Award: $904,676

 Initial Award: $1,081,445

 Role on project: Principal Investigator

2020-25 Sylvester NIH Intramural Funding Program- Supplemental Award

 “3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma”

 $160,000

 Role on project: Principal Investigator

2020-22 Sylvester Clinical Trial Acceleration/Trial Translational Mechanism Award

 “Translational studies for ‘A Phase II Study of Nivolumab + BMS-986016

 (Relatlimab) in Patients with Metastatic Uveal Melanoma”

 $29,850

 Role on project: Principal Investigator

2019-24 P30 CA240139-01 (National Cancer Institute)

 "The Sylvester Cancer Center Support Grant (CCSG)"

 $2,148,998

 Role on project: Associate Director for Basic Science

2019-21 Melanoma Research Foundation Established Investigator Award

 “Cellular and genomic landscape of uveal melanoma at single cell resolution”

 $200,000

 Role on project: Principal Investigator

2018-21 The Helman Family-Melanoma Research Alliance Team Science Award

 “Targeting BAP1-dependent alterations in metastatic uveal melanoma”

 $900,000 ($240,000 JWH)

 Role on project: Co-Principal Investigator

 https://doi.org/10.48050/pc.gr.80535

2018-20 Alex’s Lemonade Stand Foundation

 “Molecular landscape for targeted therapy in retinoblastoma”

 $250,000

 Role on project: Principal Investigator

2018-19 A Cure in Sight/Jack Odell-John Dagres Research Award

 “Diverse GNAQ/11 mutations as the basis for new personalized treatment strategies for metastatic diseases in uveal melanoma”

 $100,000

 Role on project: Principal Investigator

2017-20 Bankhead-Coley Cancer Research Program Team Science Award

 “Defining and targeting epigenetic deregulation in uveal melanoma”

 $1,468,200 ($450,000 JWH)

 Role on project: Co-Principal Investigator

2016-17 Florida Academic Cancer Center Alliance (FACCA)

 “Defining and targeting aberrant chromatin function in uveal melanoma”

 $150,000 ($50,000 JWH)

 Role on project: Co-Principal Investigator

2016-17 Alcon Research Institute Basic Sciences Award

 “The Harbour laboratory: outstanding contributions in vision research”

 $100,000

 Role on project: Principal Investigator

2015-18 CA140216 (Department of Defense)

“Development of targeted molecular therapy for cancers harboring BAP1 mutations”

$460,477

Role on project: Principal Investigator

2015-18 Sylvester Cancer Center Cancer Leadership Research Fund

 $211,116

 Role on project: Principal Investigator

2015-17 Sylvester Cancer Center Developmental Program Project Grant

 “Investigation of the BAP1 Tumor Suppressor in Cancer Progression”

 $400,000

 Role on project: Principal Investigator

 Co-Investigators: Mary Lou King, PhD and Ramin Shiekhattar, PhD

2015-16 Sylvester Cancer Center Cancer Professorship

 $50,000

 Role on project: Principal Investigator

2015-16 Sylvester Cancer Center Equipment Grant

 $9,996.95

 Role on project: Principal Investigator

2015-16 2015 Retina Research Foundation/Kayser Global Award

 “The Harbour Laboratory: Two Decades of Discovery in Uveal Melanoma”

 $30,000

 Role on project: Principal Investigator

2014-18 Senior Scientific Investigator Award

 Research to Prevent Blindness, Inc.

“Proteomic Biomarker Validation as a Step Towards Non-Invasive ‘Optical Biopsy’ in Suspicious Uveal Nevus”

 $150,000

 Role on project: Principal Investigator

2013- Dr. Mark J. Daily Endowment

 $500,000

 Role on project: Principal Investigator

2012-13 Ocular Melanoma Foundation Research Award

 $10,000

 Role on project: Principal Investigator

2011-12 Senior Scientific Investigator Award

 Research to Prevent Blindness, Inc.

 $150,000 (partially returned upon move to BPEI)

 Role on project: Principal Investigator

2011-16 R01 CA161870 (National Cancer Institute)

 “Genetics of ocular melanoma”

 $2,351,700

 Role on project: Co-Principal Investigator

2011-14 Melanoma Research Alliance Established Investigator Award (#197417)

 “Targeting the BAP1 Tumor Suppressor Gene in a Mouse Model of Melanoma”

 $150,000

 Role on project: Principal Investigator

 https://doi.org/10.48050/pc.gr.23309

2011-14 Melanoma Research Foundation Established Investigator Award

 “Characterization of the BAP1 Uveal Melanoma Metastasis Suppressor Gene”

 $150,000

 Role on project: Principal Investigator

2011-12 Tumori Foundation

 “Role of BAP1 Mutations in Uveal Melanoma Metastasis”

 $50,000

 Role on project: Principal Investigator

2010-11 Macula Society/Retina Research Foundation Grant

 Development of a Blood Test to Diagnose Uveal Melanoma

 $30,000

 Role on project: Principal Investigator

2008-10 The Kling Family Foundation

 “Molecular Predictive Testing For Ocular Melanoma”

 $260,000

 Role on project: Principal Investigator

2008-09 Tumori Foundation

 “Uveal Melanoma Research”

 $50,000

 Role on project: Principal Investigator

2007-08 The Kling Family Foundation

 “Molecular Predictive Testing For Ocular Melanoma”

 $30,000

 Role on project: Principal Investigator

2006-07 Horncrest Foundation Research Award

 $53,000

 Role on project: Principal Investigator

2005-08 Barnes-Jewish Hospital Foundation

 "A Non-Invasive Molecular Predictive Test for Ocular Tumors"

 $300,000

 Role on project: Principal Investigator

2005-06 Research to Prevent Blindness

 David F. Weeks Professorship in Translational Research

 $57,000

 Role on project: Principal Investigator

2000-09 R01 EY13169 (National Eye Institute)

 "Role of Rb in the Retina and Other Tissues"

 Competing Renewal Award:

 $1,481,836 (not renewed due to change in research direction)

 Initial Award: $1,517,188

 Role on project: Principal Investigator

2004-05 Macula Society Research Award from the Retina Research Foundation/Mills and Margaret Cox Endowment Fund

 $10,000

 Role on project: Principal Investigator

2004-05 Tumori Foundation

 “Uveal Melanoma Research”

 $45,000

 Role on project: Principal Investigator

2002-03 Research to Prevent Blindness, Inc.

 Physician-Scientist Award

 $50,000

 Role on project: Principal Investigator

2000-03 Pharmacia Corporation

 "Molecular Mechanisms of Rb Regulation in Cell Cycle and Tumorigenesis"

 $300,000

 Role on project: Co-Principal Investigator

1998-02 KO8 EY00382 (National Eye Institute)

 "Functional Analysis of the Retinal Regulatory Protein Rb"

 $715,203

 Role on project: Principal Investigator

1996-99 Research to Prevent Blindness

 Career Development Award

 $120,000

 Role on project: Principal Investigator

Research Funding for Harbour Lab Trainees

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2021-22 Research to Prevent Blindness Medical Student Eye Research Fellowship

 (Christopher Kaler, MD/MPH Candidate)

2021-22 University of Miami Dean’s Research Excellence Award in Medicine (DREAM) Program

 (Christopher Kaler, MD/MPH Candidate)

2021-22 University of Miami Institute for Data Science and Computing Fellows Program

 (James Dollar, MD/PhD Candidate)

2021-24 National Eye Institute F30 Fellowship 1F30EY032345-01 “Ruth L. Kirschstein National Research Service Award”

 (Michelle Zhang, MD/PhD Candidate)

2020-22 National Cancer Institute 3R01CA125970-14 “Diversity Supplement for Molecular Predictive Testing in Ocular Melanoma”

 (Anthony Cruz, Diversity Candidate)

2020 Sylvester Comprehensive Cancer Center Trainee Travel Awards

 (Michelle Zhang, MD/PhD Candidate)

 (Michael Durante, MD/PhD Candidate)

 (James Dollar, MD/PhD Candidate)

 (Dawn Owens, Post-Doctoral Fellow)

2020 AACR Minority Scholar in Cancer Research Award

 Presentation at American Association for Cancer Research Meeting

 (Daniel Rodriguez, MD/PhD Candidate)

2019-20 VitreoRetinal Surgery Foundation Research Award

 (Jose Echegaray, MD, BPEI Retina Fellow)

2019-23 National Cancer Institute 1F31CA243426-01 “Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships (F31) to Promote Diversity in Health-Related Research”

 (Daniel Rodriguez, MD/PhD Candidate)

2019-21 Melanoma Research Foundation Career Development Award

 (Stefan Kurtenbach, PhD, Assistant Scientist)

2019-21 T32 CA217835 NCI Cancer Epigenetics Training Program

 (Dawn Owens, PhD, Postdoctoral Fellow)

2019 The Knights Templar Eye Foundation Travel Grant

 Presentation at Association for Research in Vision and Ophthalmology Meeting

 (Daniel Rodriguez, MD/PhD Candidate)

2019 Retina Research Foundation/Joseph M. and Eula C. Lawrence Travel Grant

 Presentation at Association for Research in Vision and Ophthalmology Meeting

 (Matthew Field, MD/PhD Candidate)

2019 Sylvester Comprehensive Cancer Center Travel Award

 Presentation at American Association for Cancer Research Meeting

 (Dawn Owens, Post-Doctoral Fellow)

2018-19 University of Miami Louis J. Elsas Research Award in Biochemical Genetics

 (Michael Durante, MD/PhD Candidate)

2017 Sylvester Comprehensive Cancer Center Travel Award

 (Matthew Field, MD/PhD Candidate)

 (Michael Durante, MD/PhD Candidate)

 (Jeffim Kuznetsov, Post-Doctoral Fellow)

 (Stefan Kurtenbach, Post-Doctoral Fellow)

 (Julia Escandon, PhD Candidate)

2016-17 University of Miami Medical Faculty Association Best Student Research Award

 (Matthew Field, MD/PhD Candidate)

2016-17 University of Miami Center for Computational Science Fellows Program

 (Michael Durante, MD/PhD Candidate)

2016-19 National Cancer Institute F30 Fellowship 1F30CA206430-01 “Ruth L. Kirschstein National Research Service Award”

 (Matthew Field, MD/PhD Candidate)

2015-16 University of Miami Louis J. Elsas Research Award in Biochemical Genetics

 (Matthew Field, MD/PhD Candidate)

2015 AACR-Ocular Melanoma Foundation Fellowship

 (Stefan Kurtenbach, PhD, Post-Doctoral fellow)

2015 Sylvester Comprehensive Cancer Center Travel Award

 Presentation at American Association for Cancer Research Meeting

 (Matthew Field, MD/PhD Candidate)

2014-15 Research to Prevent Blindness, Inc. Medical Student Fellowship

 (Angelica Gabriela Ortiz, MD Candidate)

2014-15 University of Miami Center for Computational Science Fellows Program

 (Matthew Field, MD/PhD Candidate)

2014-15 University of Miami Lois Pope LIFE Development Award

 (Matthew Field, MD/PhD Candidate)

2014-15 Melanoma Research Foundation Medical Student Research Award

 (Matthew Field, MD/PhD Candidate)

2011-12 Joanna M. Nicolay Melanoma Foundation 2011 Research Scholar Award

 (Katie Matatall, PhD Candidate)

2009-10 Howard Hughes Medical Institute Summer Research Fellowship

 (Aeron Small, Undergraduate Student)

2008-10 NIH National Graduate Student Research Festival

 (Rachel Delston, PhD Candidate)

2008-10 Fonds de la recherche en santé Québec

 (Solange Landreville, PhD, Post-Doctoral Fellow)

2006-09 T32 EY13360 NEI Vision Science Training Grant for Graduate Students

 (Rachel Delston, PhD Candidate)

2006-08 Siteman Cancer Center/Washington Univ. Cancer Biology Pathway Grant

 (Katie Golder, PhD Candidate)

2004-06 Siteman Cancer Center/Washington University Cancer Biology Pathway

 Grant for Graduate Students (for Rachel Delston, PhD student)

2004-05 Knights Templar Eye Foundation, Inc. Research Grant

 (Michael Onken, PhD, Post-Doctoral Fellow)

2003-04 T32 EY13360 NEI Vision Science Training Grant

 (Amy Loercher, PhD, Post-Doctoral Fellow)

2001-02 T32 EY13360 NEI Vision Science Training Grant

 (Ping Zhou, PhD, Post-Doctoral Fellow)

2001-02 Siteman Cancer Center Gene Chip Award

 (Duanduan Ma, PhD, Post-Doctoral Fellow)

2001-02 Knights Templar Eye Foundation, Inc. Research Grant

 (Duanduan Ma, PhD, Post-Doctoral Fellow)

2000-01 Howard Hughes Medical Institute Research Scholars Program

 (Michael Cohen, Medical Student)

1998-99 Knights Templar Eye Foundation, Inc. Research Grant
 (Miguel Busquets, MD, Ophthalmology Resident)

Clinical Trials

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2020- Co-Investigator. CA224-094, IND# 152402: A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients with Metastatic Uveal Melanoma. Sylvester Comprehensive Cancer Center. (PI: Jose Lutzky, MD)

2019-21 Co-Investigator. UF-STO-ETI-001: A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Neoplasms. Sylvester Comprehensive Cancer Center. (PI: Peter Hosein, MD)

2018-20 Co-Investigator. Proof of concept study of Vorinostat, a histone deacetylase inhibitor, in patients with Class 2 high risk uveal melanoma. Sylvester Comprehensive Cancer Center. (PI: Lynn Feun, MD)

eProst ID# 20160653

2017-19 Member, Independent Data Monitoring Committee, Immunocore IMCgp100 Metastatic Uveal Melanoma Clinical Trials Program

2016-21     Co-Investigator. ARRAY-818-302 Beacon colorectal study.  A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/ Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

Sylvester Comprehensive Cancer Center.  (PI:  Agustin Pimentel, MD)

eProst ID# 20160886

2016-19 Member, Data Safety and Monitoring Committee, Array Columbus, CMEK162B2301

2015-21 Co-Investigator. Phase 1b trial of AEB071, a PKC inhibitor, in combination with ByL719, a PI3K inhibitor, in patients with metastatic uveal melanoma. Sylvester Comprehensive Cancer Center. (PI: Lynn Feun, MD)

eProst ID# 20140808

2015-17 Member, Data Safety and Monitoring Committee, Pfizer, Inc.

2014-16 Co-Investigator. Novartis MEK inhibitor, MEK162 (binimetinib) in recurrent pediatric solid tumors and hematological malignancies. Sylvester Comprehensive Cancer Center. (PI: John Goldberg, MD)

Patents & Intellectual Property

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Title: “Method for predicting risk of metastasis”

Patent Number: US 9,809,856

Date of Patent Issued: 11/7/2017

Application Number: PCT/US09/041436, Filing date: 04/22/2009

Priority Application No. 61/046,879

Priority filing date (provisional patent application filing date): 4/22/2008

Inventors listed on the application: James William Harbour

Title: “Compositions and methods for detecting cancer metastasis”

Patent Number: US 9,441,277

Date of Patent Issued: 9/13/2016

US Provisional Application No. 61/385,696

Provisional patent application priority filing date: 9/23/2010

Inventors listed on the application: James William Harbour and Anne Bowcock

Clinical Retina Fellows (Subsequent Position)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1995 Daniel Joseph, MD, PhD (Barnes Retina Institute, St. Louis)

 Scott Simpson, MD (Retina Practice, Nevada)

1997 Shalesh Kaushal, MD, PhD (University of Florida)

1998 Filiberto Altomare, MD (University of Toronto)

 Baker Hubbard, MD (Emory University)

1999 Steve Virata, MD (Retina Practice, Indiana)

 Kumar Rao, MD (Washington University)

2000 Tom Sheidow, MD (University of London, Ontario)

 Miguel Busquets, MD (Retina Practice, Pittsburgh)

2001 Richard Corey, MD (Retina Practice, Washington)

 Blake Cooper, MD (Retina Practice, Missouri)

2002 Brett Rosenblatt, MD (Retina Practice, New Jersey)

2003 Michael Mills, MD (Retina Practice, Toronto)

 Henry Lee, MD (Retina Practice, New York)

 Seenu Hariprasad, MD (University of Chicago)

2004 Jason Wickens, MD (Retina Practice, Nevada)

 Leonard Fiener, MD, PhD (Retina Practice, New Jersey)

2005 Mandeep Dhalla, MD (Retina Practice, Florida)

 Asheesh Tewari, MD (Kresge Eye Institute, Detroit)

2006 Brad Smith, MD (Barnes Retina Institute, St. Louis)

 Ramin Shadlu, MD (University of Pennsylvania)

2007 John Davies, MD (Retina Practice, Minnesota)

 David Fintak, MD (Retina Practice, Colorado)

2008 Argavon Almony, MD (University of Missouri)

 Raymond Wee, MD (University of Hawaii)

2009 Kamalesh Ramaiya, MD (Retina Practice, New Mexico)

 Jonathan Jonisch, MD (Retina Practice, New York)

2010 Matthew Aschbrenner, MD (Retina Practice, Wisconsin)

 Bryan Kim, MD (Retina Practice, Illinois)

2011 Rajesh Rao, MD, PhD (University of Michigan)

 Rithwick Rajagopal, MD, PhD (Washington University)

2012 Royce Chen, MD (Columbia University)

 Christina Weng, MD (Baylor College of Medicine)

2013 Amir Mohsenin, MD, PhD (University of Texas, Houston)

 Marco Gonzales, MD (Retina Practice, Florida)

2014 Ella Leung, MD (Baylor College of Medicine)

 Carlos Medina, MD (Retina Practice, California)

2015 Steven Ryder, MD (Retina Practice, North Carolina)

 Tanuj Banker, MD (Retina Practice, Florida)

2016 Nika Bagheri, MD (Retina Practice, California)

 Robert Garoon, MD (Retina Practice, Illinois)

2017 Rehan Hussain, MD (Retina Practice, Chicago)

 James Lin, MD (Albert Einstein Univ.)

2018 Jose Echegaray, MD (Case Western Reserve Univ.)

 Sulaiman Alhumaid, MD (Retina Practice, Miami)

2019 Jose Diaz, MD (Retina Practice, Miami)

 Noy Ashkenazy, MD (UT Southwestern)

2020 Joshua Uhr, MD (Retina Practice, New Jersey)

 Lediana Goduni, MD (Retina Practice, Ohio)

2021 Patrick Staropoli, MD (Current Retina Fellow, BPEI)

 Maria Fernandez, MD (Current Retina Fellow, BPEI)

Ocular Oncology Fellows (Subsequent Position)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2007 Kyung In Woo, MD (Seoul, Korea)

2017 Michael Andreoli, MD (Northwestern Univ.)

2017 Scott Walter, MD (Hartford Hospital, Connecticut)

2020 Eric Hansen, MD (Univ. of Utah)

2021 Nathan Scott, MD (Univ. of California, San Diego)

Ocular Oncology Observers

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2007 Christopher Bergstrom, MD (Emory Univ.)

2007 Virginia Torres, MD (Federal Univ., Sao Paulo, Brazil)

2007 Camila Simoes, MD (Federal Univ., Sao Paulo, Brazil)

2008 Kenneth Hovland, MD, PhD (Denver, CO)

2009 Gholam Peyman, MD (Univ. of Arizona)

2009 Mandy Conway, MD (Univ. of Arizona)

2010 Grant Comer, MD (Univ. of Michigan)

2010 Todd Klesert, MD, PhD (Univ. of Washington)

2010 Brad Smith, MD (Retina Institute, St. Louis)

2012 Amy Sheffler, MD (University of Texas, Houston)

2014 Claus Zehetner, MD (Innsbruck Medical University, Austria)

2014 Rafael Mendoza, MD (Mexico)

2015 Hongfeng Yuan, MD (Third Military University, China)

2017 Ya-mei Lu, MD (Lanzhou Univ. Medical College, China)

2017 Michael Andreoli, MD (Univ. of Illinois, Chicago)

2019 Lin Zhou, MD (People's Hospital of Jiangmen City, China)

Post-Doctoral Research Fellows (Subsequent Position)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1998-02 Duanduan Ma, PhD (Research, MIT)

1999-2002 Ping Zhou, PhD (Research Scientist, WUSM)

2001-02 Jun Wu, MD (Research Scientist, WUSM)

2002-03 Binh Tran, MD (Radiation Oncology, California)

2002-04 Amy Loercher, PhD (Industry, Pennsylvania)

2003-05 Michael Onken, PhD (Faculty, WUSM)

2004-05 Yang Sun, MD, PhD (Faculty, Indiana Univ.)

2008-11 Solange Landreville, PhD (Faculty, Laval Univ., Quebec)

2008-09 Zachary Kneass, MD, PhD (ENT Practice, Colorado)

2013-17 Jeffim Kuznetsov, PhD (Research Scientist, Univ. of Miami)

2014-18 Stefan Kurtenbach, PhD (Faculty, Univ. of Miami)

2015-16 Bercin Tarlan, MD (Faculty, Turkey)

2017-18 Manuel Paez, MD (Ophthalmology Residency, Univ. of Pittsburgh)

2018-22 Dawn Owens, PhD (Faculty, Nova Southeastern Univ.)

2023- Mithalesh Singh, PhD (Current Post-Doctoral Fellow)

PhD Students (Subsequent Position)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2002-04 Jonathan H. Lieman (Faculty, Univ. of Texas)

2004-06 Kenneth Kompass (Post-Doctoral Fellow, UCSF)

2004-10 Rachel Delston (Post-Doctoral Fellow, WUSM)

2006-13 Katie Golder/Matatall (Post-Doctoral Fellow, Baylor Medical College)

2013-17 Matthew Field\* (Ophthalmology Residency, Univ. of Iowa)

2016-18 Julia Escandon (Dermatology Residency, Univ. of Miami)

2016-20 Michael Durante\* (Medicine Residency, Univ. of Miami)

2017-20 Daniel Rodriguez\* (Ophthalmology Residency, Baylor)

2018- Michelle Zhang\* (Current MD/PhD Student)

2018- James Dollar\* (Current MD/PhD Student)

\* MD/PhD Medical Scientist Training Program (MSTP)

PhD Thesis Committees (Advisor)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2002 Jon Lieman (J. William Harbour, WUSM)

2003 Ian Hagemann (Thomas Baranski, WUSM)

2003 Sharon Wong (Jason Weber, WUSM)

2004 Stephany Shockley (Stephen Moerlein, WUSM)

2004 Kenneth Kompass (Rosario Hernandez, WUSM)

2004 Rachel Delston (J. William Harbour, WUSM)

2006 Julie O’Neal (Michael Tomasson, WUSM\)

2007 Anthony Apicelli (Jason Weber, WUSM)

2007 Britney Moss1 (David Piwnica-Worms, WUSM)

2007 Mario Economou2 (Stefan Seregard, Karolinska Institute)

2011 Maximiliaan Schillebeeckx (Robi Mitra, Univ. of Miami)

2012 Julia Escandon (James Gricknik, Univ. of Miami)

2013 Matthew Field (J. William Harbour, Univ. of Miami)

2015 Michael Durante (Alan Pollack, Univ. of Miami)

2017 Tanya Kelley (Stephan Schürer, Univ. of Miami)

2017 Zenith Acosta (Daniel Pelaez, Univ. of Miami)

2017 Rhea Choi3 (Bradley Goldstein, Univ. of Miami)

2017-20 Daniel Rodriguez (J. William Harbour, Univ. of Miami)

2018- Michelle Zhang (J. William Harbour, Univ. of Miami)

2018- James Dollar (J. William Harbour, Univ. of Miami)

2019 Ryan Gallo (Daniel Pelaez, Univ. of Miami)

2020 Robert Suter (Stephan Schürer & Nagi Ayad, Univ. of Miami)

2021 Acadia Moeyersoms (Daniel Pelaez, Univ. of Miami)

2022 Tiffany Yee (Katherine Wert, UTSW)

1Committee Chair; 2External Examiner; 3F30 Co-Mentor

Other Research Trainees (Position)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1997-98 Miguel Busquets, MD (Resident, WUSM)

2000-01 Michael Cohen (MD Student, WUSM)

2001-03 William Foster, MD, PhD (Resident, WUSM)

2003-04 Michael Sinha (Undergraduate, WUSM)

2003-05 Justis Ehlers (MD Student, WUSM)

2005 Yair Elisa (Undergraduate, Indiana Univ.)

2005-06 Erica Person, MD (Resident, WUSM)

2006-07 Kamalesh Ramaiya, MD (Resident, WUSM.)

2006 Matthew Council, MD (Resident, WUSM)

2006-07 Holly Chang, MD (Resident, WUSM)

2007-08 Jessica Winn (Undergraduate, WUSM)

2008-09 Ryan Lee (Undergraduate, WUSM)

2008-09 Aeron Small (Undergraduate, WUSM)

2008-10 Rithwick Rajagopal, MD (Resident, WUSM)

2009-10 David Westrich (Undergraduate, WUSM)

2010-12 Eric Nudleman, MD (Resident, WUSM)

2013-14 Philip Tenzel (MD Student, Univ. of Miami)

2013-14 Nisha Garg (MD/MS Student, Univ. of Miami)

2013-15 Daniel Chao, MD, PhD (Resident, BPEI)

2013-16 Scott Walter, MD (Resident, BPEI)

2013-16 Basil Williams, MD (Resident, BPEI)

2014-17 Erin Ong (MD/MS Student, Univ. of Miami)

2014-16 Angelica Ortiz (MD Student, Univ. of Miami)

2014-17 Louis Cai (Medical Student, Univ. of Miami)

2014-15 Kaleigh Kozak (Undergraduate Student, Univ. of Miami)

2015-16 Swarup Swaminathan, MD (Resident, BPEI)

2015-16 Rohit Reddy (Undergraduate, Univ. of Miami)

2015-16 Karam Alawa (Medical Student, Univ. of Miami)

2015-16 Chen Shen (PhD Student, Univ. of Miami)

2015-17 Christopher Damarkarian (MD Student, Univ. of Miami)

2016-17 Parker Bussies (MD/MS student, Univ. of Miami)

2016-17 Jeff Shuo-Chieh Wu (MD Student, Univ. of Miami)

2018-19 Andy Lopez (MD Student, Univ. of Miami)

2018-21 Christopher Kaler (MD Student, Univ. of Miami)

2019-20 Grant Gordon+ (MS Student, Univ. of Miami)

2020- Anthony Cruz (Pre-Medical Student, Univ. of Miami)

2020-21 Yoseph Sayegh (MD Student, Univ. of Miami)

2020-21 Nicole Jones (BMB Master’s Student, Univ. of Miami)

2020 Sana Chaudhry (PhD Student, Univ. of Miami)

2021 Jesus Ray Castro, Jr. (PhD Student, Univ. of Miami)

\*F30 Co-Mentor with Daniel Pelaez, PhD

Faculty mentorship

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2002-12 P. Kumar Rao, MD (WUSM)

2004-12 Rajendra S. Apte, MD, PhD (WUSM)

2004-05 Sunir Garg, MD (WUSM)

2005-10 Milam A. Brantley, MD, PhD (WUSM)

2005-12 Vladimir Kefalov, PhD (WUSM)

2015-21 Daniel Pelaez, PhD (BPEI & SCCC, Univ. of Miami)

2015-18 Nicolas Acquavella, MD (SCCC, Univ. of Miami)

2016-21 Luis Vazquez, MD, PhD (BPEI, Univ. of Miami)

2017-21 Mohamed Abou Shousha, MD, PhD (BPEI, Univ. of Miami)

2018-21 Alfonso L. Sabater, MD, PhD (BPEI, Univ. of Miami)

2019-21 Neha Goel, MD (SCCC, Univ. of Miami)

2020-21 Andrew Rong, MD (BPEI, Univ. of Miami)

2020-21 Sion Williams, PhD (SCCC, Univ. of Miami)

2020-21 Stefan Kurtenbach, PhD (BPEI & SCCC, Univ. of Miami)

**Bibliography**

Peer-Reviewed Publications

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(Key articles indicated in RED)

1. **Harbour JW**, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in small cell lung cancer. *Science.* 1988; 241:353-7. [PMID:2838909] [PMCID:PMC5480895]

**First report of RB1 mutations in lung cancer. This discovery was surprising but now widely accepted, leading to recognition that RB1 pathway mutations are nearly universal in human cancer.**

1. Leduc F, Brauch H, Hajj C, Dobrovic A, Kaye F, Gazdar A, **Harbour JW**, van de Berg A, Kok K, Campling B, Paquin F, Bradley WEC, Zbar B, Minna J, Buys C, Ayoub J. Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. *Am J Human Genet*.1989; 44:282-7. [PMID:2536219] [PMCID:PMC1715394]
2. **Harbour JW**, Lai S-L, Gazdar AF, Minna JD, Kaye FJ. Expression in lung cancer of a transcribed sequence at the DNF15S2 locus at chromosome 3P21. *Anticancer Res.* 1990; 10:23-8. [PMID:2159253]
3. **Harbour JW**, Lawton MT, Criscuolo GR, Holliday MJ, Mattox DE, Long DM. Clivus chordoma: a report of 12 recent cases and review of the literature. *Skull Base Surg.* 1991; 1:200-6. [PMID:17170837] [PMCID: PMC1656331]
4. **Harbour JW**, DePotter P, Shields CL, Shields JA. Uveal metastasis from carcinoid tumor: clinical observations in nine cases. *Ophthalmology.* 1994; 101:1084-90. [PMID:8008351]
5. **Harbour JW**, Smiddy WE, Rubsamen PE, Murray TG, Davis JL, Flynn HW Jr. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. *Am J Ophthalmol.* 1995; 120:302-7. [PMID:7661201]
6. **Harbour JW**, Augsburger JJ, Eagle RC Jr. Initial management and follow-up of melanocytic iris tumors. *Ophthalmology.* 1995; 102:1987-93. [PMID:9098306]
7. **Harbour JW**, Smiddy WE, Rubsamen PE, Flynn HW Jr. Vitrectomy for diabetic macular edema associated with posterior hyaloidal thickening and contraction. *Am J Ophthalmol.* 1996; 121:405-13. [PMID:8604734]
8. **Harbour JW**, Murray TG, Byrne SF, Hughes JR, Gendron EK, Ehlies F. Intraoperative echographic localization of I-125 episcleral radioactive plaques for posterior uveal melanoma. *Retina*. 1996; 16:129-34. [PMID:8724957]
9. **Harbour JW**. Murray TG, Valor N, Hernandez E, Hamasaki D, Smith B, O’Brien JM. Local carboplatin therapy in transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci.* 1996; 37:1892-8. [PMID:8759359]
10. **Harbour JW**, Rubsamen PE, Palmberg P. Pars plana vitrectomy in the management of phakic and pseudophakic malignant glaucoma. *Arch Ophthalmol*. 1996; 114:1073-8. [PMID:8790091]
11. **Harbour JW**, Char DH, Ljung BM, Luna-Fineman S. Langerhans-cell histiocytosis diagnosed by fine needle biopsy. *Arch Ophthalmol*. 1997; 115:1212-3. [PMID:9298073]
12. **Harbour JW**, Char DH, Kroll S, Quivey JM, Castro J. Metastatic risk for distinct patterns of post-irradiation local recurrence of posterior uveal melanoma. *Ophthalmology.* 1997; 104:1785-93. [PMID:9373108]
13. Char D, Weidner N, Ahn J, **Harbour JW**. Solitary fibrous tumor of the orbit. *Orbit.* 1997; 16:113-8.
14. **Harbour JW**. Overview of RB gene mutations in retinoblastoma: implications for clinical genetic screening. *Ophthalmology.* 1998; 105:1442-7. [PMID:9709755]
15. **Harbour JW**. Tumor suppressor genes in ophthalmology. *Surv Ophthalmol*. 1999; 44:235-46. [PMID:10588442]
16. **Harbour JW**, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell*. 1999; 98:859-69. [PMID:10499802]

**First demonstration of how successive phosphorylation of the retinoblastoma protein progressively induces conformational changes that alter its function, a discovery later validated by crystallographic studies that provided new insights into how aberrations in the RB1 pathway promote tumor progression.**

1. **Harbour JW**, Dean DC. Rb function in cell-cycle regulation and apoptosis. *Nature Cell Biol.* 2000; 2:65-7. [PMID:10783254]
2. **Harbour JW**, Dean DC. The Rb/E2F Pathway: Emerging paradigms and expanding roles. *Genes Dev.* 2000; 14:2393-409. [PMID:11018009]
3. **Harbour JW**, Dean DC. Chromatin remodeling and Rb activity. *Curr Opin Cell Biol.* 2000; 12: 685-9. [PMID:11063932]
4. **Harbour JW**, Dean DC. Corepressors and retinoblastoma protein function. *Curr Top Microbiol Immunol*. 2000; 254: 137-44. [PMID:11190571]
5. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, **Harbour JW**, Dean DC. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. *Cell*. 2000; 101:79-89. [PMID:10778858]
6. Brantley MA, **Harbour JW**. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. *Cancer Res.* 2000; 60: 4320-3. [PMID:10969768] [PMCID:PMC5395201]
7. Brantley MA, **Harbour JW**. Deregulation of the Rb and p53 pathways in uveal melanoma. *Am J Pathol.* 2000; 157:1795-801. [PMID:11106551] [PMCID:PMC1885790]
8. Brantley MA, **Harbour JW**. The molecular biology of retinoblastoma. *Ocul Immunol Inflamm*.2001; 9:1-8. [PMID:11262663]
9. **Harbour JW**. Molecular mechanisms of low penetrance retinoblastoma. *Arch Ophthalmol.* 2001; 119:1699-704. [PMID:11709023]
10. Finger PT, **Harbour JW**, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. *Surv Ophthalmol.* 2002; 47:1-16. [PMID:11801265]
11. Brantley MA, Worley L, **Harbour JW**. Alterations in expression of Rb and p53 in uveal melanomas following plaque radiotherapy. *Am J Ophthalmol.* 2002; 133:242-8. [PMID:11812429]
12. Sheidow T, **Harbour JW**. Photodynamic therapy for choroidal hemangioma. *Can J Ophthalmol.* 2002; 37:314-7. [PMID:12322864]
13. **Harbour JW**, Worley L, Ma D, Cohen M. Transducible peptide therapy for melanoma and retinoblastoma. *Arch Ophthalmol.* 2002 Oct;120(10):1341-6. [PMID:12365913]
14. **Harbour JW**, Ahmad S, El-Bash M. Rate of resolution of exudative retinal detachment following plaque radiotherapy for uveal melanoma. *Arch Ophthalmol.* 2002; 120:1463-9. [PMID:12427058]
15. Ma D, Zhou P, **Harbour JW**. Distinct mechanisms for regulating the tumor suppressor and anti-apoptotic functions of Rb. *J Biol Chem.* 2003; 278:19358-66. [PMID:12646568]
16. Foster WJ, **Harbour JW**, Holekamp NM, Shah GK, Thomas MA. Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma. *Am J Ophthalmol*. 2003; 136:471-6. [PMID:12967800]
17. Foster WJ, Fuller CE, Perry A, **Harbour JW**. Status of the NF1 tumor suppressor locus in uveal melanoma. *Arch Ophthalmol.* 2003; 121:1311-5. [PMID:12963615]
18. Hurst EA, **Harbour JW**, Cornelius LA. Ocular melanoma: a review and the relationship to cutaneous melanoma. *Arch Dermatol*. 2003; 139:1067-73. [PMID:12925397]
19. Loercher AE, **Harbour JW**. Molecular genetics of uveal melanoma. *Current Eye Research.* 2003; 27:69-74. [PMID:14632157]
20. **Harbour JW**, Meredith TA, Thompson P, Gordon G. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. *Ophthalmology* 2003; 110:2207-14. [PMID:14597531]
21. **Harbour JW**. What is the best treatment for retinoblastoma? *Am J Ophthalmol*. 2004; 138:471-3. [PMID:15364232]
22. Kaye FJ, **Harbour JW**. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma surviors. *J Natl Cancer Inst*. 2004; 137:1143-5. [PMID:14996847]
23. Espinoza G, Rosenblatt B, **Harbour JW**. Optical coherence tomography in the evaluation of retinal changes associated with suspicious choroidal melanocytic tumors. *Am J Ophthalmol.* 2004; 137:90-5. [PMID:14700649]
24. **Harbour JW**, Brantley MA, Hollingsworth H, Gordon ME. Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi. *Br J Ophthalmol.* 2004; 88:36-8. [PMID:14693769] [PMCID:PMC1771959]
25. **Harbour JW**, Brantley MA, Hollingsworth H, Gordon ME. Association between choroidal pigmentation and posterior uveal melanoma in a Caucasian population. *Br J Ophthalmol.* 2004; 88:39-43. [PMID:14693770] [PMCID:PMC1771924]
26. **Harbour JW**. Photodynamic therapy for choroidal metastasis from carcinoid tumor. *Am J Ophthalmol* 2004; 137:1143-5. [PMID:15183811]
27. Farkas T, **Harbour JW**, Davila RM. Cytologic diagnosis of intraocular lymphoma in vitreous aspirates. *Acta Cytol* 2004; 48:487-91. [PMID:15296338]
28. **Harbour JW**. What is the best treatment for retinoblastoma? *Am J Ophthalmol*. 2004; 138:471-3. [PMID:15364232]
29. Onken MD, Worley LA, Ehlers JP, **Harbour JW**. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Res.* 2004; 64:7205-9. [PMID:15492234] [PMCID:PMC5407684]

**Landmark article in the field showing that uveal melanomas comprise two basic molecular subtypes that can be distinguished by gene expression profiling, paving the way for an innovative new prognostic test and a new paradigm for understanding the molecular landscape of this cancer type. This discovery has been validated by many other groups and the Tumor Genome Atlas (TCGA) study**

1. Ehlers JP, **Harbour JW**. NBS1 expression as a prognostic marker in uveal melanoma. *Clin Cancer Res.* 2005; 11:1849-53. [PMID:15756009]
2. Singh AD, Damato B, Howard P, **Harbour JW**. Uveal melanoma: genetic aspects. Ophthalmol Clin North Am. 2005 Mar;18(1):85-97, viii. doi: 10.1016/j.ohc.2004.08.004. [PMID:15763194]
3. Loercher AE, Tank EM, Delston RB, **Harbour JW**. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. *J Cell Biol.* 2005;168:35-40 (featured article). [PMID:15623583] [PMCID:PMC2171666]

**Demonstration of mechanistic link between differentiation and cell cycle exit in melanocytes driven by transcription factor MITF, providing new insights into how disruption of the RB1 pathway in melanoma drives tumor progression.**

1. Lieman JH, Worley LA, **Harbour JW**. Loss of Rb-E2F repression results in caspase-8 mediated apoptosis through inactivation of focal adhesion kinase*. J Biol Chem.* 2005; 280:10484-90. [PMID:15640164]
2. Sun Y, Tran BN, Worley LA, Delston RB, **Harbour JW**. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. *Invest Ophthalmol Vis Sci.* 2005; 46:1561-4. [PMID:15851551]
3. Ehlers JP, Worley LA, **Harbour JW**. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. *Clin Cancer Res.* 2005; 11:3609-13 (featured article). [PMID:15897555]
4. Faulkner-Jones BE, Foster WJ, **Harbour JW**, Smith ME, Davila RM. Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. *Acta Cytol*. 2005; 49:297-308. [PMID:15966293]
5. Onken MD, Lin AY, Worley LA, Folberg R, **Harbour JW**. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. *Am J Ophthalmol.* 2005; 140:748-9. [PMID:16226537]
6. Mills MD, **Harbour JW**. Lipid exudation following plaque radiotherapy for posterior uveal melanoma. *Am J Ophthalmol.* 2006; 141:594-5. [PMID:16490526]
7. Ehlers JP, **Harbour JW**. Molecular pathobiology of uveal melanoma. *Int Ophthalmol Clin.* 2006; 46:167-80. [PMID:16365562]
8. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, **Harbour JW.** Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. *Cancer Research.* 2006; 66:4602-9. [PMID:16651410] [PMCID:PMC5407689]

**Transcriptional profiling revealed histopathologic factors associated with poor prognosis to be manifestations of a primitive stem-like phenotype, paving the way for the discovery of BAP1 mutations as the key driver of this phenotypic switch.**

1. **Harbour JW**. Eye cancer: unique insights into oncogenesis. The Cogan Lecture. *Invest Ophthalmol Vis Sci.* 2006; 47:1737-45. [PMID:16638975] [PMCID:PMC1769953]
2. Onken MD, Worley LA, Davila RM, Char DH, **Harbour JW**. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. *J Mol Diagn.* 2006; 8:567-73. [PMID:17065425] [PMCID:PMC1876164]
3. Delston RB, **Harbour JW**. Rb at the interface between cell cycle and apoptotic decisions. *Curr Mol Med.* 2006; 6:713-8. [PMID:17100597]
4. Berenbom A, Davila RM, Lin HS, **Harbour JW**. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. *Eye.* 2007; 21:1198-201. [PMID:16732210]
5. Ramaiya KJ, **Harbour JW**. Molecular prognostic testing in uveal melanoma. *Expert Rev Ophthalmol* 2007; 2:65-9.
6. Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, Perry A, **Harbour JW**. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clin Cancer Res.* 2007; 13:1466-71. [PMID:17332290]
7. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, **Harbour JW**. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. *Clin Cancer Res.* 2007;13:2923-7. [PMID:17504992]
8. **Harbour JW**. Molecular prognostic testing in uveal melanoma: has it finally come to age? *Arch Ophthalmol.* 2007; 125:1122-3. [PMID:17698762]
9. Apte RS, **Harbour JW**. Inhibiting angiogenesis in retinoblastoma. *Ophthalmic Res* 2007; 39:188-90. [PMID:17556838]
10. Ramaiya KJ, **Harbour JW**. Current management of uveal melanoma. *Expert Rev Ophthalmol.* 2007; 2:939-46.
11. Apte RS, **Harbour JW**. Inhibiting angiogenesis in retinoblastoma. *Ophthalmic Res.* 2007; 39:188-190. [PMID:17556838]
12. Sharma KV, Gould JE, **Harbour JW**, Linette GP, Pilgram TK, Dayani PN, Brown DB. Hepatic arterial chemoembolization for management of metastatic melanoma. *AJR Am J Roentgenol.* 2008; 190:99-104. [PMID:18094299]
13. Ehlers JP, Worley LA, Onken MD, **Harbour JW**. Integrative genomic analysis of aneuploidy in uveal melanoma. *Clin Cancer Res*. 2008; 14:115-22. [PMID:18172260]
14. Almony A, Breit S, Zhao H, Garcia-Ramirez J, Mansur D, **Harbour JW**. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. *Arch Ophthalmol*. 2008; 126:65-70. [PMID:18195220]
15. Worley LA, Onken MD, **Harbour JW**. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. *Melanoma Res.* 2008; 18:184-90. [PMID:18477892]
16. Chang SH, Worley LA, Onken MD, **Harbour JW**. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. *Melanoma Res.* 2008; 18:191-200. [PMID:18477893]
17. **Harbour JW**. Comment on "Low penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras" by Park et al. *Cell Cycle*. 2008; 15:2276-7. [PMID:18682685]
18. Zhai J, **Harbour JW**, Smith ME, Davila RM. Correlation study of benign cytomorphology and final clinical diagnosis. *Acta Cytol.* 2008; 52:196-200. [PMID:18499993]
19. Onken MD, Worley LA, **Harbour JW**. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. *Clin Cancer Res.* 2008; 14:3737-45. [PMID:18559591]
20. Landreville S, Agapova OA, **Harbour JW**. Emerging insights into the molecular pathogenesis of uveal melanoma. *Future Oncology* 2008; 4:629-36. [PMID:18922120] [PMCID:PMC2577578]
21. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, **Harbour JW**. Oncogenic mutations in GNAQ occur early in uveal melanoma. *Invest Ophthalmol Vis Sci.* 2008; 49:5230-4. [PMID:18719078] [PMCID:PMC2634606]
22. Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, **Harbour JW**. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival following hepatic arterial chemoembolization. *Arch Ophthalmol.* 2009; 127:628-32. [PMID:19433711]
23. Ainbinder DJ, Albert DM, Armitage JO, Augsburger JJ, Bechrakis NE, Boden JH, Chévez-Barrios P, Coupland SE, Damato B, Desjardins L, Eagle RC, Edward DP, Esmaeli B, Finger PT, Fleming JC, Gallie BL, Gombos DS, Grange JD, Grossniklaus HE, Haik BG, Halligan JB, **Harbour JW**, Harocopos GJ, Holbach LM, Hungerford JL, Jager MJ, Karcioglu ZA, Kivela T, Kujala E, Mallipatna AC, Mazzoli RA, McGowan H, Milman T, Murphree AL, Murray TG, Rootman J, de Wolff-Rouendaal D, Schachat AP, Seregard S, Simpson ER, Singh AD, White VA, Wilson MW, Wittekind CW, Yu G. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. *Arch Pathol Lab Med.* 2009; 133:1197-8. [PMID:19653708]
24. **Harbour JW**. Invited Perspectives Article: Molecular prognostic testing and individualized patient care in uveal melanoma. *Am J Ophthalmol.* 2009; 148:823-9. [PMID:19800609] [PMCID:PMC4470132]
25. Agapova OA, Person E, **Harbour JW**. Id2 deficiency promotes metastasis in a mouse model of ocular cancer. *Clin Exp Metastasis.* 2010; 27:91-6. [PMID:20127274] [PMCID:PMC4467556]
26. Onken MD, Worley LA, Tuscan MD, **Harbour JW**. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. *J Mol Diagn.* 2010;12:461-8. [PMID:20413675] [PMCID:PMC2893630]
27. **Harbour JW**. A transformation in ocular oncology: from megacenter to multicenter. *Arch Ophthalmol.* 2010; 128:367-8. [PMID:20212211]
28. Landreville S, Ma D, Wu J, **Harbour JW**. Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma. *Curr Eye Res* .2010; 35:435-9. [PMID:20450257] [PMCID:PMC5502097]
29. Woo KI, **Harbour JW**. Review of 676 second primary tumors in patients with retinoblastoma: association between age of onset and tumor type. *Arch Ophthalmol.* 2010; 128:865-70. [PMID:20625047]
30. Onken MD, Worley LA, **Harbour JW**. Association between gene expression classification, proliferation and and metastasis in uveal melanoma. *Curr Eye Res.* 2010; 35:857-63. [PMID:20795869] [PMCID:PMC3230327]
31. Delston RB, Matatall KA, Sun Y, Onken MD, **Harbour JW**. p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. *Oncogene.* 2011; 30:588-99 [PMID:20871633] [PMCID:PMC3012146]
32. **Harbour JW**, Onken MD, Roberson EDO, Duan S, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science*. 2010; 330:1410-3. [PMID:21051595] [PMCID:PMC3087380]

**Landmark article in the cancer field describing frequent mutations in the tumor suppressor BAP1 for the first time in a human cancer type, paving the way for discovery of BAP1 mutations in other cancer types. This study established BAP1 mutations as the most important genetic determinant of metastasis in uveal melanoma, and it described the first patient with the novel BAP1 tumor predisposition syndrome. This discovery has been validated by many other groups and the Tumor Genome Atlas (TCGA) study**

1. Rajagopal R, **Harbour JW**. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. *Retina* 2011; 31:435-40. [PMID:21336066]
2. Landreville S, Agapova OA, **Harbour JW**. ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity. *Pigment Cell Melanoma Res.* 2011;24:430-7. [PMID:21575142] [PMCID:PMC3096470]
3. Chan CC, Rubenstein JL, Coupland SE, Davis JL, **Harbour JW**, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. *Oncologist.* 2011; 12:1589-99. [PMID:22045784] [PMCID:PMC3233294]
4. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, **Harbour JW**. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. *Clin Cancer Res.* 2011;18:408-16. [PMID:22038994] [PMCID:PMC3261307]
5. **Harbour JW**. A new mutation with STAGgering effects. *Pigment Cell Melanoma Res*. 2011;24:1081-2. [PMID:22216441]
6. Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WB, Handa J, **Harbour JW**, Eberhart CG. Notch signaling promotes growth and invasion in uveal melanoma. *Clin Cancer Res.* 2012;18:654-5. [PMID:22228632] [PMCID:PMC4648284]
7. **Harbour JW**. The genetics of uveal melanoma: an emerging framework for targeted therapy. *Pigment Cell Melanoma Res.* 2012; 25:171-81. [PMID:22268848] [PMCID:PMC4470256]
8. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, **Harbour JW**. Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. *Ophthalmology.* 2012; 119:1596-603. [PMID:22521086] [PMCID:PMC3404209]

**First multi-center prospective study of a prognostic test ever performed in uveal melanoma. The study validated an innovative molecular test developed by Dr. Harbour to be performed on fine needle biopsy samples from the eye based on microfluidics, gene expression profiling, and machine learning technologies. This test is now the standard of care in the U.S.**

1. Chappell MC, Char DH, Cole TB, **Harbour JW**, Mishra K, Weinberg VK, Phillips TL. Uveal melanoma: molecular pattern, clinical features, and radiation response. *Am J Ophthalmol.* 2012; 154(2):227-232. [PMID:22541662] [PMCID:PMC4966158]
2. **Harbour JW**. Update in uveal melanoma. *Clin Adv Hematol Oncol.* 2012; 10:459-61. [PMID:22895286] [PMCID:PMC4469072]
3. Daniels AB, Lee JE, Macconaill LE, Palescandolo E, Van Hummelen P, Adams SM, Deangelis MM, Hahn WC, Gragoudas ES, **Harbour JW**, Garraway LA, Kim IK. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. *Invest Ophthalmol Vis Sci.* 2012; 53:6991-6. [PMID:22977135] [PMCID:PMC3471553]
4. Asnaghi L, Handa JT, Merbs SL, **Harbour JW**, Eberhart CJ. A role for Jag2 in promoting uveal melanoma dissemination and growth. *Invest Ophthalmol Vis Sci.* 2013; 54:295-306. [PMID:23211831] [PMCID:PMC4604713]
5. **Harbour JW**, Wilson D, Finger PT, Worley LA, Onken MD. Gene expression profiling of iris melanomas. *Ophthalmology.* 2013;120:213. [PMID:23283188] [PMCID:PMC4354954]
6. Dimaras H, Parulekar MV, Kwok G, Simpson ER, Ali A, Halliday W, Shago M, **Harbour JW**, Héon E, Gallie BL, Chan HS. Molecular testing prognostic of low risk in epithelioid uveal melanoma in a child. *Br J Ophthalmol.* 2013;97:323-6. [PMID:23292925] [PMCID:PMC4966167]
7. **Harbour JW**, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. *Nat Genet.* 2013; 45(2):133-5. [PMID:23313955] [PMCID:PMC3789378]

**First report of mutations in the splicing factor SF3B1 as a common driver and important risk factor for late metastasis in uveal melanoma. This discovery expanded the role of splicing factor mutations in cancer, which previously were thought to be rare, and has been validated by many other groups and the Tumor Genome Atlas (TCGA) study.**

1. Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, **Harbour JW**, Hagbi-Levi S, Chowers I, Edwards PA, Baldan A, Parks JS, Ory DS, Apte RS. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. *Cell Metab.* 2013; 17:549-61. [PMID:23562078] [PMCID:PMC3640261]
2. Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, **Harbour JW**. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. *BMC Cancer.* 2013;13:371. [PMID:23915344] [PMCID:PMC3846494]
3. Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat A, Sastre-Garau X, Couturier J, Hupé P, de Koning L, Dubois T, Roman-Roman S, Stern MH, Barillot E, **Harbour JW**, Saule S, Decaudin D. Patient-derived xenografts recapitulate molecular features of human uveal melanomas. *Mol Oncol.* 2013;7:625-36. [PMID:23478236] [PMCID:PMC4966164]
4. **Harbour JW**, Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. *PLoS Curr.* 2013; Apr 9: 5. [PMID:23591547] [PMCID:PMC3625622]
5. **Harbour JW**. Genomic, prognostic, and cell-signaling advances in uveal melanoma. *Am Soc Clin Oncol Educ Book*. 2013; 2013:388-91. [PMID:23714557] [PMCID:PMC4354950]
6. Modi YS, Epstein A, Bhaleeya S, **Harbour JW**, Albini T. Multimodal imaging of sarcoid choroidal granulomas. *J Ophthalmic Inflamm Infect.* 2013; 3:58. [PMID:23968304] [PMCID:PMC3765912]
7. Fu M, Landreville S, Agapova OA, Wiley LA, Shoykhet M, **Harbour JW\***, Heuckeroth RO. Retinoblastoma protein prevents enteric nervous system defects and intestinal pseudo-obstruction. *J Clin Invest.* 2013; 123(12):5152-64. \*Co-Senior Author. [PMID:24177421] [PMCID:PMC3859411]
8. **Harbour JW**. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. *Methods Mol Biol.* 2014;1102:427-40. [PMID:24258991] [PMCID:PMC4476294]
9. Sagoo MS, **Harbour JW**, Stebbing J, Bowcock AM. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. *Oncogene.* 2014;33(39):4722-3. [PMID:24413085] [PMCID:PMC4356624]
10. **Harbour JW**, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. *Ophthalmology.* 2014;121(6):1281-8. [PMID:24480708] [PMCID:PMC4047132]
11. Badiyan SN, Rao RC, Apicelli AJ, Acharya, S, Verma, V, Garsa, AA, Dewees T, Speirs CK, Garcia-Ramirez J, Esthappan J, Grigsby PW, **Harbour JW**. Outcomes of Iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy. *Int J Radiat Oncol Biol Phys.* 2014; 88(4):801-5. [PMID:24462385]
12. Field MG, **Harbour JW.** Recent developments in prognostic and predictive testing in uveal melanoma. *Curr Opin Ophthalmol.* 2014; 25:234-9. [PMID:24713608] [PMCID:PMC4467564]
13. Field MG, **Harbour JW**. GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy? *Cancer Cell.* 2014; 25:714-5. [PMID:24937456] [PMCID:PMC4966161]
14. Villegas VM, Schwartz SG, Flynn HW Jr, Capo H, Berrocal AM, Murray TG, **Harbour JW**. Distinguishing torpedo maculopathy from similar lesions of the posterior segment. *Ophthalmic Surg Lasers Imaging Retina.* 2014; 45, 222-226. [PMID:24738480]
15. Chen RW, **Harbour JW**. Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism. *Graefes Arch Clin Exp Ophthalmol.* 2014; 252:2021-2. [PMID:25212495] [PMCID:PMC4246029]
16. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, **Harbour JW**, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ. Prognostic parameters in uveal melanoma and their association with BAP1 expression. *Br J Ophthalmol.* 2014; 98:1738-43. [PMID:25147369] [PMCID:PMC4966163]
17. Herlihy N, Dogrusoz M, Van Essen TH, **Harbour JW**, Van der Velden PA, Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ. Skewed expression of the genes encoding epigenetic modifiers in high risk uveal melanoma. *Invest Ophthalmol Vis Sci*. 2015;56:1447-58. [PMID:25593028] [PMCID:PMC5102441]
18. Rao RC, Khan M, Badiyan SN, **Harbour JW**. Gene expression profiling and regression rate of irradiated uveal melanomas. *Ophthalmic Surg Lasers Imaging Retina* 2015;46:333-7. [PMID:25856819] [PMCID:PMC4398963]
19. Weng CY, **Harbour JW**. Serous macular detachment following a systemic corticosteroid injection. *JAMA Ophthalmol.* 2015;133:473-4. [PMID:25856642]
20. Chao DL, **Harbour JW**. Hydroxyapatite versus polyethylene orbital implants for patients undergoing enucleation for uveal melanoma. *Can J Ophthalmol*. 2015;50:151-4. [PMID:25863856]
21. Gustafson CB, Yang C, Dickson KM, Shao H, Van Booven D, **Harbour JW**, Liu ZJ, Wang G. Epigenetic reprogramming of melanoma cells by vitamin C treatment. *Clin Epigenetics.* 2015;7:51. [PMID:25977731] [PMCID:PMC4430922]
22. Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, **Harbour JW**, Eberhart CG. EMT-associated factors promote invasive properties of uveal melanoma cells. *Mol Vis.* 2015;21:919-29. [PMID:26321866] [PMCID:PMC4548792]
23. Schwartz SG, **Harbour JW**. Spectral-Domain Optical Coherence Tomography of Presumed Solitary Circumscribed Retinal Astrocytic Proliferation Versus Astrocytic Hamartoma. *Ophthalmic Surg Lasers Imaging Retina.* 2015; 46:586-8. [PMID:26057765]
24. **Harbour JW**. Uveal and conjunctival melanoma: close together-but only distantly related. *Oncology.* 2016;30:44,48. [PMID:26791843]
25. Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, **Harbour JW**. PRAME as an independent biomarker for metastasis in uveal melanoma. *Clin Cancer Res.* 2016;22:1234-42. [PMID:26933176] [PMCID:PMC4780366]

**The first report of cancer-testis antigen PRAME as an oncogene and prognostic factor in uveal melanoma. This work has expanded the recognition of PRAME as an important cancer driver and has attracted intense interest by the pharmaceutic industry in targeting PRAME in uveal melanoma and other cancer types.**

1. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, **Harbour JW**, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunites. *Pigment Cell Melanoma Res.* 2016;29(4):404-16. [PMID:27087480] [PMCID:PMC5228487]
2. Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, **Harbour JW**. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. *JAMA Ophthalmol.* 2016 Jul 1;134(7):728-33. [PMID:27123562] [PMCID:PMC4966162]
3. Walter SD, Chao DL, Feuer W, Schiffman J, Char DH, **Harbour JW**. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. *JAMA Ophthalmol.* 2016 Jul 1;134(7):734-40. [PMID:27123792] [PMCID:PMC4966166]
4. Yoo JH, Shi DS, Grossman AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, **Harbour JW**, Thomas KR, Odelberg SJ, Ostanin K, Li DY. ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma. *Cancer Cell.* 2016 Jun 13;29(6):889-904. [PMID:27265506] [PMCID:PMC5027844]
5. Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, **Harbour JW**, Smalley KS, Forsyth PA. A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. *Melanoma Res.* 2016 Oct;26(5):481-486. [PMID:27285292] [PMCID:PMC5502096]
6. Rao RC, **Harbour JW**. An iris tumor. *JAMA Ophthalmol.* 2016 Sep 1;134(9):1063-4. [PMID:27442779] [PMCID:PMC5016235]
7. Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S, **Harbour JW**. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. *Oncotarget.* 2016 Sep 13;7(37):59209-59219. [PMID:27486988] [PMCID:PMC5312306]
8. Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, Chen S, Yang H, He Y, Li J, Guo Y, Zhang W, Hajiramezanali E, An H, Fajardo D, **Harbour JW**, Ruan Y, Nimer SD, Yu P, Chen X, Xu M, Yang FC. ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. *Sci Adv.* 2017 Jan 20;3(1):e1601602. [PMID:28116354] [PMCID:PMC5249256]
9. Mohney BG, Elner VM, Smith AB, **Harbour JW**, Smith BD, Musch DC, Smith SJ. Preclinical acute ocular safety study of combined intravitreal carboplatin and etoposide phosphate for retinoblastoma. *Ophthalmic Surg Lasers Imaging Retina.* 2017 Feb 1;48(2):151-159. [PMID:28195618]
10. Gezgin G, Luk S, Cao J, Dogrusoz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, **Harbour JW**, Jordanova ES, Heemskerk MHM, Jager MJ. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. *JAMA Ophthalmol.* 2017 Jun 1;135(6):541-549. [PMID:28448663] [PMCID:PMC5509351]
11. Mruthyunjaya P, Seider MI, Stinnett S, Schefler A; Ocular Oncology Study Consortium: Mruthyunjaya P, Seider M, Raufi NN, Berry D, Stinnett S, **Harbour JW**, Berry J, Kim J, Skalet A, Miller A, Materin MA, Liu T, Demirci H, Ozkurt ZG, Hovland P, Aabert T Jr, Schefler A, Kim RS, Tann A. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. *Ophthalmology*. 2017 Oct;124(10):1532-1539. [PMID:28549517]
12. Fernandez MP, Al-Holou SN, Fischer O, Murray T, **Harbour JW**, Dubovy SR, Berrocal AM. Fluorescein angiography findings in diffuse retinoblastoma: two case reports with clinicopathologic correlation. *J AAPOS*. 2017 Aug;21(4):337-339.e2. Epub 2017 Jul 8. [PMID:28694215]
13. Scelfo C, Francis JH, Khetan V, Jenkins T, Marr B, Abramson DH, Shields CL, Pe’er J, Munier F, Berry J, **Harbour JW**, Yarovoy A, Lucena E, Murray TG, Bhagia P, Paysse E, Tuncer S, Chantada GL, Moll AC, Ushakova T, Plager DA, Ziyovuddin I, Leal CA, Materin MA, Li XD, Cursino JW, Polania R, Kiratli H, All-Ericsson C, Kebudi R, Honavar SG, Vishnevskia-Dai V, Epelman S, Daniels AB, Ling JD, Traore F, Ramirez-Ortiz MA. An international survey of classification and treatment choices for group D retinoblastoma. *Int J Ophthalmol.* 2017 Jun 18;10(6):961-967. eCollection 2017. [PMID:28730089] [PMCID:PMC5515152]
14. Schwartz SG, **Harbour JW**. Multimodal imaging of astrocytic hamartomas associated with tuberous sclerosis. *Ophthalmic Surg Lasers Imaging Retina.* 2017 Sept 1;48(9):756-758. [PMID:28902337]
15. **Harbour JW**. Prognostic implications of the largest basal tumor diameter vs the TNM staging system in association with the gene expression profile for uveal melanoma-reply. *JAMA Ophthalmol.* 2017;135(2):175-176. [PMID:28056125]
16. **Harbour JW**. Incorporating clinical, histological, and genetic parameters for choroidal melanoma prognostication-reply. *JAMA Ophthalmol.* 2017 Jul 1;135(7):819-820. [PMID:28542673]
17. **Harbour JW**. Liquid biopsy in retinoblastoma. *JAMA Ophthalmol.* 2017 Nov 1;135(11):1231. [PMID:29049432]
18. **Harbour JW**, Paez-Escamilla M. Letter to the Editor: Comparison of alternative tumor size classifications for posterior uveal melanomas. *Invest Ophthalmol Vis Sci*. 2017 Oct1:58(12):5444. [PMID:29059310]
19. Paez-Escamilla M, Bagheri N, Teira LE, Corrales\_Medina FF, **Harbour JW**. Intracameral Topotecan hydrochloride for anterior chamber seeding of retinoblastoma. *JAMA Ophthalmol.* 2017 Dec 1;135(12):1453-1454. [PMID:29098282]
20. Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, **Harbour JW**, Wahlestedt C, Xu M, Yang FC. Gain-of-function of ASXL truncating protein in the pathogenesis of myeloid malignancies. *Blood.* 2018 Jan 18;131(3):328-341. [PMID:29113963] [PMCID:PMC5774208]
21. Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dubovy SR, **Harbour JW**, Karp CL. Molecular characteristics of conjunctival melanoma using whole-exome sequencing. *JAMA Ophthalmol.* 2017 Dec 1;135(12):1434-1437. [PMID:29121185] [PMCID:PMC5782797]
22. Peng H, Prokop J, Karar J, Park K, Cao L, **Harbour JW**, Bowcock AM, Malkowicz SB, Cheung M, Testa JR, Rauscher FJ. Familial and somatic BAP1 mutations inactivate ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase by targeting multiple independent domains. *Cancer Res.* 2018 Mar 1;78(5):1200-1213. Epub 2017 Dec 28. [PMID:29284740] [PMCID:PMC6167014]
23. Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, **Harbour JW**. Punctuated evolution of canonical genomic aberrations in uveal melanoma. *Nat Commun.* 2018 Jan 9;9(1):116. [PMID:29317634] [PMCID:PMC5760704]

**Groundbreaking article representing the largest NGS analysis reported to date in uveal melanoma. A major finding was that the canonical mutations and chromosome copy number alterations in this cancer type occur very early in tumor evolutionary, thereby explaining the high metastatic rate despite successful treatment of the primary tumor and calling for earlier detection and treatment strategies.**

1. Paez-Escamilla M, Bagheri N, **Harbour JW**. Retinoblastoma with endophytic and exophytic features. *JAMA Ophthalmol*. 2018 Jan 11;136(1):e175064. Epub 2018 Jan 11. [PMID:29327048]
2. Garoon RB, Medina CA, Scelfo C, **Harbour JW**. Retinocytoma with vitreous seeding: new insights from enhanced depth imaging optical coherence tomography and high-resolution posterior segment ultrasonography. *Retina Cases Brief Rep*. 2021 Jan1;15(1):68-70. doi: 10.1097/ICB.0000000000000732. [PMID:29470300]
3. **Harbour JW**, Paez-Escamilla M. Anterior chamber chemotherapy in retinoblastoma- necessary but not sufficient for aqueous seeding control-reply. *JAMA Ophthalmol*. 2018 May 1;136(5):597. [PMID:29596550]
4. Garoon RB, **Harbour JW**. Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization. *Ophthalmic Surg Lasers Imaging Retina*. 2018 Apr 1;49(4):276-277. [PMID:29664987]
5. Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, **Harbour JW**, Xu M, Yang FC. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. *Leukemia*. 2018 Aug;32(8):1834-1837. Epub 2018 Apr 2. [PMID:29743720] [PMCID:PMC6168429]
6. Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, **Harbour JW**. Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma. *Am J Ophthal.* 2018 Nov;195:154-160. Epub 2018 Aug 6. [PMID:30092184] [PMCID:PMC6214741]
7. Lin J, Paez-Escamilla M, Teira LE, Fallas B, **Harbour JW**. Persistent fetal vasculature presenting with axial elongation and platyphakia. *J AAPOS.* 2019 Feb;23(1):51-53. doi: 10.1016/j.jaapos.2018.06.005. Epub 2018 Aug 31. [PMID:30176292]
8. **Harbour JW**, Paez-Escamilla M, Cai L, Walter SD, Augsburger JJ, Correa ZM. Are risk factors for growth of choroidal nevi associated with malignant transformation? Assessment with a validated genomic biomarker (an American Ophthalmological Society thesis). *Am J Ophthal.* 2019 Jan;197:168-179. Epub 2018 Sep 7. [PMID:30195895] [PMCID:PMC6291343]
9. Kurtenbach S, Reddy R, **Harbour JW**. ChIPprimersDB: a public repository of verified qPCR primers for chromatin immunoprecipitation (ChIP). *Nucleic Acids Res.* 2019 Jan 8;47(D1):D46-D49. doi: 10.1093/nar/gky813. [PMID:30202990] [PMCID:PMC6323922]
10. Paez-Escamilla M, Walter SD, Ramaiya KJ, **Harbour JW**. Diagnosis of bilateral retinocytoma in an adolescent patient using multimodal imaging and genetic testing. *Ophthalmic Surg Lasers Imaging Retina.* 2018 Oct 1;49(10):812-814. doi: 10.3928/23258160-20181002-11. [PMID:30395669]
11. Husnain M, Mackrides N, Vega F, Paez-Escamilla M, Markoe AM, **Harbour JW**, Lossos IS. CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. *Leuk Lymphoma.* 2019 May;60(5):1308-1311. doi: 10.1080/10428194.2018.1526376. Epub 2018 Nov 14. [PMID:30424702]
12. Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, **Harbour JW**, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. *J Natl Cancer Inst.* 2018 Dec 1;110(12):1328-1341. doi: 10.1093/jnci/djy171. [PMID:30517737] [PMCID:PMC6292796]
13. Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, **Harbour JW**, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG. Drug and disease signature integration identifies synergistic combinations in glioblastoma. *Nat Commun.* 2018 Dec 14;9(1):5315. doi: 10.1038/s41467-018-07659-z. [PMID:30552330] [PMCID:PMC6294341]
14. Dean MK, Studenski MT, Paez-Escamilla MA, Walter SD, Kwon D, Markoe AM, **Harbour JW**, Samuels SE. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. *Brachytherapy.* 2019 May – Jun;18(3):404-410. doi: 10.1016/j.brachy.2019.01.005. Epub 2019 Feb 20. [PMID:30797699]
15. de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, **Harbour JW**, Lossos IS. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. *Am J Hematol.* 2019 Apr;94(4):455-460. doi: 10.1002/ajh.25414. Epub 2019 Feb 4. [PMID:30663807]
16. Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA 3rd, Baumal CR, Hartnett ME, **Harbour JW**, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y. Longitudinal examination of fellow-eye vascular anomalies in Coats’ Disease with widefield fluorescein angiography: a multicenter study. *Ophthalmic Surg Lasers Imaging Retina*. 2019 Apr 1;50(4):221-227. doi: 10.3928/23258160-20190401-04. [PMID:30998243] [PMCID:PMC6615457]
17. Scott NL, Tran KD, Cernichiaro-Espinosa LA, Russell JF, Hinkle JW, **Harbour JW**, Dubovy SR, Berrocal AM. An eight-year old girl presents with two weeks of vision loss and nightly headaches. *Ophthalmic Surg Lasers Imaging Retina*. 2019 May 1;50(5):314-317. doi: 10.3928/23258160-20190503-09. [PMID:31100163]
18. Fan KC, Tran KD, **Harbour JW**, Dubovy SA, Patel NA, Albini TA. Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma*. J Ophthalmic Inflamm Infect.* 2019 Jun 10;9(1):11. doi: 10.1186/s12348-019-0177-8. [PMID:31183567] [PMCID:PMC6557958]
19. Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, **Harbour JW**. Genomic evolution of uveal melanoma arising in ocular melanocytosis. *Cold Spring Harb Mol Case Stud*. 2019 Aug 1;5(4). pii: a004051. doi: 10.1101/mcs.a004051. Print 2019 Aug. [PMID:31186267] [PMCID:PMC6672022]
20. Anbunathan H, Verstraten R, Singh AD, **Harbour JW**, Bowcock AM. Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a. *Clin Cancer Res.* 2019 Aug 15;25(16):5156-5166. doi: 10.1158/1078-0432.CCR-18-3052. Epub 2019 Jun 21. [PMID:31227497] [PMCID:PMC6697622]
21. Faiao-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, **Harbour JW**, Smalley KSM. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. *Clin Cancer Res.* 2019 15;25(18):5686-5701. doi: 10.1158/1078-0432.CCR-18-3382. Epub 2019 Jun 21. [PMID:31227503] [PMCID:PMC6744978]
22. Field MG, Kuznetsov JN, Bussies PL, Cai LZ, Alawa KA, Decatur CL, Kurtenbach S, **Harbour JW**. BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas. *Clin Cancer Res*. 2019 Sep 15;25(18):5663-5673. doi: 10.1158/1078-0432.CCR-19-0366. Epub 2019 Jul 8. [PMID:31285370] [PMCID:PMC6744995]
23. Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, Rodriguez DA, King ML, **Harbour JW**. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutation cancers. *Sci Adv.* 2019 Sept 18;5(9):eaax1738. doi: 10.1126/sciadv.aax1738. eCollection 2019 Sep. [PMID:31555735][PMCID:PMC6750916]

 **First *in vivo* vertebrate model demonstrating role of BAP1 in pluripotency to differentiation switch in neural crest, ectodermal and mesodermal lineages, providing new insights into how loss of BAP1 leads to tumorigenesis in specific tissue types.**

1. Durante MA, Walter SD, Paez-Escamilla M, Tokarev J, Decatur CL, Dubovy SR, Schefler AC, **Harbour JW**. Intraocular metastasis in unilateral multifocal uveal melanoma without melanocytosis or germline BAP1 mutations. *JAMA Ophthalmol.* 2019 Dec1;137(12):1434-1439. doi: 10.1001/jamaophthalmol.2019.3941. [PMID:31580399] [PMCID:PMC6777244]
2. Paez-Escamilla M, Walter SD, Mohsenin A, Decatur CL, Harocopos GJ, Dubovy S, **Harbour JW**. Intraocular dissemination of uveal melanoma cells following radiotherapy: evolving management over the past decade. *Ophthalmic Surg Lasers Imaging Retina.* 2019 Sep 1;50(9):573-579. doi:10.3928/23258160-20190905-06. [PMID:31589755] [PMCID:PMC6790979]
3. Barsam AS, Gibbons A, McClellan AJ, **Harbour JW**, Smiddy WE. Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi. *Int J Ophthalmol.* 2019 Sep 18;12(9):1456-1464. doi: 10.18240/ijo.2019.09.14. eCollection 2019. [PMID:31544043][PMCID:PMC6739572]
4. Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, **Harbour JW**, Licht JD, Rosângela Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell Melanoma Res.* 2020 May;33(3):507-514. doi: 10.1111/pcmr.12849. Epub 2019 Dec 6. [PMID: 31758842] [PMCID:PMC7180095]
5. Seider MI, Berry DE, Schefler SC, Materin M, Stinnett S, Mruthyunjuya P, Ocular Oncology Study Consortium. Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4. *Graefes Arch Clin Exp Ophthalmol.* 2020 Feb;258(2):427-435. doi: 10.1007/s00417-019-04531-8. Epub 2019 Dec 6. [PMID:31807898]
6. Recker KL, Norton S, Sobh A, Riva A, Chang K, Kuznetsov J, Durante MA, Flores F, Bennett RL, Vakoc C, Smalley K, **Harbour JW**, Licht JD. Synthetic lethal screen to identify molecular mechanisms that drive uveal melanoma. *UF Journal of Undergraduate Research.*2019 Dec 5; 21(1). doi: 10.32473/ufjur.v21i1.108370.
7. Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, **Harbour JW**. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. *Nat Commun.* 2020 Jan 24:11(1):496. doi: 10.1038/s41467-019-14256-1. [PMID:31980621] [PMCID:PMC6981133]

**This article reported the first single cell RNA sequencing analysis in uveal melanoma and demonstrated that the tumor immune microenvironment in uveal melanoma is much more complex than previously recognized. Suppressive immune cell types were strongly enriched in tumors harboring high risk genomic aberrations such as BAP1 mutations. LAG3 was identified as the predominant checkpoint marker in uveal melanoma, leading to new industry sponsored clinical trials.**

1. Studenski MT, Patel NV, Markoe A, **Harbour JW**, Samuels SE. Influence of tumor shape and location in eye plaque brachytherapy dosimetry. *Brachytherapy.* 2020 Mar-Apr;19(2):249-254. doi: 10.1016/j.brachy.2020.01.001. Epub 2020 Feb 13. [PMID:32061535]
2. Durante MA, Kurtenbach S, Sargi ZB, **Harbour JW**, Choi R, Kurtenbach S, Goss GM, Matsunami H, Goldstein BJ. Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. *Nat Neurosci.* 2020 Mar;23(3):323-326. doi:10.1038/s41593-020-0587-9. Epub 2020 Feb 17. [PMID:32066986] [PMCID:PMC7065961]
3. Global Retinoblastoma Study Group, Fabian ID, ... **Harbour JW**, ... Bowman R. Global Retinoblastoma Presentation and Analysis by National Income Level. *JAMA Oncol*. 2020 May 1;6(5):685-695. doi: 10.1001/jamaoncol.2019.6716. Erratum in: JAMA Oncol. 2020 Nov 1;6(11):1815. [PMID: 32105305][PMCID: PMC7047856]
4. Dermarkarian CR, Patel NA, Villegas VM, **Harbour JW**. Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. *Am J Ophthalmol Case Rep.* 2020 Apr 7;18:100691. doi: 10.1016/j.ajoc.2020.100691. eCollection 2020 Jun. [PMID: 32322748][PMCID:PMC7168346]
5. Carbone M, **Harbour JW**, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. *Cancer Discov*. 2020 Aug;10(8):1103-1120. doi: 10.1158/2159-8290.CD-19-1220. Epub 2020 Jul 20. [PMID: 32690542] [PMCID:PMC8006752]
6. Armitage AM, Kundra MA, Ghiam N, Atwal PS, Morel D, Hruska KS, Torene R, **Harbour JW**, Forghani I. Chimerism involving a RB1 pathogenic variant in monochorionic dizygotic twins with twin-twin transfusion syndrome. *Am J Med Genet A*. 2021 Jan;185(1):208-212. doi: 10.1002/ajmg.a.61913. Epub 2020 Oct 9. [PMID:33037780]
7. Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, Bilbao D, Roberts ER, Volmar CH, Wahlestedt C, Brothers SP, **Harbour JW**. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. *Mol Cancer Res*. 2021 Feb:19(2):215-222. doi: 10.1158/1541-7786.MCR-20-0434. Epub 2020 Oct 19. [PMID:33077485] [PMCID:PMC7864865]
8. Rodriguez DA, Sanchez MI, Decatur CL, Correa ZM, Martin ER, **Harbour JW**. Impact of genetic ancestry on prognostic biomarkers in uveal melanoma. *Cancers (Basel).* 2020 Oct 31;12(11):E3208. doi: 10.3390/cancers12113208. [PMID:33142712][PMCID:PMC7693692]
9. Ashkenazy N, Orihuela G, Rodriguez LI, Negron Cl, **Harbour JW**, Berrocal AM. Use of a modified plastic viewing system for safer general anesthesia care in pediatric ophthalmic surgery during the COVID-19 pandemic. *Ophthalmic Surg Lasers Imaging Retina*. 2020 Nov 1;51(11):651-652. doi: 10.3928/23258160-20201104-08. [PMID:33231699]
10. Hatzistergos KE, Durante MA, Valasaki K, Wanschel ACBA, **Harbour JW**, Hare JM. A novel cardiomyogenic role for lsl1+ neural crest cells in the inflow tract. *Sci Adv*. 2020 Dec 2;6(49): eaba9950. doi: 10.1126/sciadv.aba9950. Print 2020 Dec. [PMID:33268364] [PMCID:PMC7821887]
11. Russell JF, Villegas VM, Schwartz SG, Weng CY, Davis JL, Flynn HW Jr, **Harbour JW**. Multimodal imaging in the diagnosis of exophytic juxtapapillary retinal capillary hemangioblastoma. *Am J Ophthalmol.* 2021 May;225:128-136. doi: 10.1016/j.ajo.2021.01.002. Epub 2021 Jan 12. [PMID:33450232]
12. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, **Harbour JW**, Aplin AE. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. *Oncogene*. 2021 Jan;40(3):618-632. doi: 10.1038/s41388-020-01554-y. Epub 2020 Nov 18. [PMID:33208912][PMCID:PMC7856044]. Correction: Oncogene. 2021 Mar;40(9):1753. doi: 10.1038/s41388-021-01645-4. Erratum for: Oncogene. 2021 Jan;40(3):618-632. [PMID: 33510355]
13. Kurtenbach S, Dollar JJ, Cruz AM, Durante MA, Decatur CL, **Harbour JW**. PieParty: visualizing cells from scRNA-seq data as pie charts. *Life Sci Alliance.* 2021 March 5;4(5):e202000986. doi: 10.26508/lsa.202000986. Print 2021 May. [PMID:33674364]
14. **Harbour, JW**. Therapeutic escape in Gaq-mutant uveal melanoma: it’s a FAK. *Clin Cancer Res.* 2021 Mar 25: clincanres.0567.2021. doi: 10.1158/1078-0432.CCR-21-0567. Online ahead of print. [PMID:33766812] [PMCID:PMC8172474]
15. Peng H, Cassel J, McCracken DS, Prokop JW, Semenino E, Cheung M, Collop PR, Polo A, Joshi S, Mandell JP, Ayyanathan K, Kinds D, Malkowicz SB, **Harbour JW**, Bowcock AM, Salvino J, Kennedy EJ, Testa JR, Rauscher FJ. Kinetic characterization of ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase. *Mol Cancer Res*. 2021 Mar 17:molcanres.0080.2020. doi: 10.1158/1541-7786.MCR-20-0080. Online ahead of print. [PMID:33731362]
16. Ashkenazy N, Walter SD, **Harbour JW**. Iris mass in a 14-month-old boy. *JAMA Ophthalmol.* 2021 May 20. doi: 10.1001/jamaophthalmol.2020.5301. Online ahead of print. [PMID:34014279]
17. Kurtenbach S, Cruz AM, Rodriguez DA, Durante MA, **Harbour JW**. Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data. *BMC Genomics*. 2021 June 5;22(1):419. doi: 10.1186/s12864-021-07739-3. [PMID:34090344]
18. Goduni L, Ashkenazy N, Hansen E, Soyano-Muller A, Correa ZM, **Harbour JW**. Iris metastasis from breast cancer successfully treated with Abemaciclib and Letrozole. *Retin Cases Brief Rep*. 2021 Jun 11. doi: 10.1097/ICB. 0000000000001176. Online ahead of print. [PMID:34127625][NIHMSID:1713613]
19. Studenski MT, Markoe A, Samuels SE, Correa ZM, Bossart E, **Harbour JW**. Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry. *Brachytherapy.* 2021 Nov-Dec;20(6):1289-1295. doi: 10.1016/j.brachy.2021.05.013. Epub 2021 Jun 28. PMID: 34193361.
20. Rodriguez DA, Yang J, Durante MA, Shoushtari AN, Moschos SJ, Wrzeszczynski KO, **Harbour JW\*†**, Carvajal RD**†**. Multiregional genetic evolution of metastatic uveal melanoma. *NPJ Genom Med.* 2021 Aug 16;6(1):70. doi: 10.1038/s41525-021-00233-5. [PMID:34400647] **\*Corresponding author**, **†Contributed equally.**
21. Wagley S, Belin PJ, Dollar JJ, **Harbour JW**, Maltry AC, Mruthyunjaya P, Schefler AC, Tang PH. Multiple genetically distinct uveal melanomas arise in the same eye of two patients with melanosis oculi. Unilateral multifocal uveal melanoma in melanosis oculi. *Am J Ophthalmol*. 2021 Jul 17:S0002-9394(21)00366-4. doi: 10.1016/j.ajo.2021.06.037. Online ahead of print. [PMID:34283976]
22. Greenfied JA, Rowlands M, **Harbour JW**. Secondary glaucoma associated with intraocular metastatic cutaneous melanoma. *Ophthalmol Glaucoma.* 2021 Jul 20:S2589-4196(21)00173-3. doi: 10.1016/j.ogla.2021.07.005. Online ahead of print. [PMID:34298197]
23. Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, **Harbour JW**, Aplin AE. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. *Pigment Cell Melanoma Res*. 2021 Aug 4. doi: 10.1111/pcmr.13007. Online ahead of print. [PMID:34347929]
24. Djulbegovic MB, Uversky VN, **Harbour JW**, Galor A, Karp CL. Structural protein analysis of driver gene mutations in conjunctival melanoma. *Genes*. 2021 Oct 15;12(10):1625. doi: 10.3390/genes12101625. PMID: 34681018; PMCID: PMC8535873.
25. Peters VA, Gurayah A, Kwon D, Zhao W, Jin W, Patel NV, Markoe AM, Correa Z, Studenski MT, **Harbour JW**, Samuels S. Clinical Characteristics and post-operative complications as predictors of radiation toxicity after treatment with I125 eye plaque brachytherapy for uveal melanomas. *Int J Radiat Oncol Biol Phys*. 2021 Nov 1;111(3S):e606-e607. doi: 10.1016/j.ijrobp.2021.07.1617. PMID: 34701858.
26. Gurayah A, Peters VA, Kwon D, Zhao W, Jin W, Patel NV, Markoe AM, Correa Z, Studenski MT, **Harbour JW**, Samuels S. Predictors of outcomes in Iodine-125 brachytherapy-treated uveal melanomas: a modern institutional study. *Int J Radiat Oncol Biol Phys*. 2021 Nov 1;111(3S):e395. doi: 10.1016/j.ijrobp.2021.07.1147. PMID: 34701351.
27. Khine KT, Clark WM, **Harbour JW**. Waking up with cloudy vision. *JAMA Ophthalmol*. 2021 Oct 28. doi: 10.1001/jamaophthalmol.2021.1461. Epub ahead of print. PMID: 34709370.
28. Djulbegovic MB, Uversky VN, Karp CL, **Harbour JW**. Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia. *Int J Biol Macromol*. 2021 Nov 24;195:93-101. doi: 10.1016/j.ijbiomac.2021.11.120. Epub ahead of print. PMID: 34838574.
29. Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, **Harbour JW**, Aplin AE. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. *Oncogene*. 2022 Jan 20. doi: 10.1038/s41388-021-02154-0. Epub ahead of print. PMID: 35046531.
30. Alsina KM, Sholl LM, Covington KR, Arnal SM, Durante MA, Decatur CL, Stone JF, Oelschlager KM, **Harbour JW**, Monzon FA, Cook RW, Borman S. Analytical Validation and Performance of a 7-Gene Next-Generation Sequencing Panel in Uveal Melanoma. *Ocul Oncol Pathol*. 2021 Dec;7(6):428-436. doi: 10.1159/000518829. Epub 2021 Aug 4. PMID: 35083209; PMCID: PMC8739387.
31. Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, **Harbour JW**, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. *Cancer Gene Ther*. 2022 Mar 24. doi: 10.1038/s41417-022-00452-7. Epub ahead of print. PMID: 35332245.
32. Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, **Harbour JW**, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. *Mol Cancer Res*. 2022 Apr 15:molcanres.0657.2021. doi: 10.1158/1541-7786.MCR-21-0657. Epub ahead of print. PMID: 35426938.
33. Sanati-Mehrizy A, Ghosh T, Peterson E, Starke RM, **Harbour JW**, Corrales-Medina FF. Hematologic Complications Associated With Intra-arterial Chemotherapy for Retinoblastoma Treatment: A Single Institution Experience. *J Pediatr Hematol Oncol*. 2022 May 1;44(4):181-185. doi: 10.1097/MPH.0000000000002451. Epub 2022 Mar 25. PMID: 35446803.
34. Marquez MA, Fortun J, Iyer P, **Harbour JW**, Haddock LJ. Pseudoangiomatous retinal gliosis (PARG) treated with iodine plaque in patient with chronic retinal detachment. *Am J Ophthalmol* Case Rep. 2022 Jun 11;27:101614. doi: 10.1016/j.ajoc.2022.101614. PMID: 35734079; PMCID: PMC9207220.
35. Goel N, Yadegarynia S, Kwon D, Kesmodel SB, **Harbour JW**, Kobetz E, Merchant N, Rodriguez DA. Translational Epidemiology: An Integrative Approach to Determine the Interplay Between Genetic Ancestry and Neighborhood Socioeconomic Status on Triple Negative Breast Cancer. Ann Surg. 2022 Sep 1;276(3):430-440. doi: 10.1097/SLA.0000000000005554. Epub 2022 Jun 27. PMID: 35758508.
36. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. *Lancet Glob Health*. 2022 Aug;10(8):e1128-e1140. doi: 10.1016/S2214-109X(22)00250-9. PMID: 35839812.
37. Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez MI, Decatur CL, Licht JD, Smalley KSM, Correa ZM, Kurtenbach S, **Harbour JW**. BAP1 Loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in class 2 uveal melanomas. *Cancers* (Basel). 2022 Jul 28;14(15):3678. doi: 10.3390/cancers14153678. PMID: 35954340; PMCID: PMC9367253.
38. Field MG, Kuznetsoff JN, Zhang MG, Dollar JJ, Durante MA, Sayegh Y, Decatur CL, Kurtenbach S, Pelaez D, **Harbour JW**. RB1 loss triggers dependence on ESRRG in retinoblastoma. *Science Adv*. 2022 Aug 19;8(33):eabm8466. doi: 10.1126/sciadv.abm8466. Epub 2022 Aug 19. PMID: 35984874.

**In this study, we performed the largest NGS analysis to date in retinoblastoma and identified ESRRG as a novel oncogenic driver and potential therapeutic target.**

1. Ashkenazy N, Diaz JD, Hansen ED, **Harbour JW**, Correa ZM. Cyst-like recurrence of retinoblastoma diagnosed by multimodal imaging. *Am J Ophthalmol Case Rep*. 2022 Aug 8;27:101678. doi: 10.1016/j.ajoc.2022.101678. PMID: 35990798; PMCID: PMC9385537.
2. Khan S, Lutzky J, Shoushtari AN, Jeter J, Marr B, Olencki TE, Cebulla CM, Abdel-Rahman M, **Harbour JW**, Sender N, Nesson A, Singh-Kandah S, Hernandez S, King J, Katari MS, Dimapanat L, Izard S, Ambrosini G, Surriga O, Rai AJ, Chiuzan C, Schwartz GK, Carvajal RD. Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. *Front Oncol*. 2022 Aug 29;12:976837. doi: 10.3389/fonc.2022.976837. PMID: 36106113; PMCID: PMC9465386.
3. Peters V, Gurayah A, Jin W, Kwon D, Zhao W, Patel NV, Markoe A, Correa Z, Studenski MT, **Harbour JW**, Samuels SE. Clinical characteristics and postoperative complications as predictors of radiation toxicity after treatment with I-125 eye plaque brachytherapy for uveal melanomas. *Brachytherapy*. 2022 Sep 19:S1538-4721(22)00148-9. doi: 10.1016/j.brachy.2022.08.006. Epub ahead of print. PMID: 36137939.
4. Zhang MG, Kuznetsoff JN, Owens DA, Gallo RA, Kalahasty K, Cruz AM, Kurtenbach S, Correa ZM, Pelaez D, **Harbour JW**. Early mechanisms of chemoresistance in retinoblastoma. *Cancers* (Basel). 2022 Oct 10;14(19):4966. doi: 10.3390/cancers14194966. PMID: 36230889; PMCID: PMC9563111.
5. Sepulveda-Beltran PA, Levine H, Gibbons AG, Maharaj A, Choi, DS Martinez JD, Correa ZM, Amescua G, **Harbour JW**. Post-radiation cataract management: outcomes in individuals with uveal melanoma. *Current Ophthalmology Reports*. 2022 10:218–227.
6. Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, **Harbour JW,** Chieng ND, Patel SP, Joshua AM, Piperno-Neumann S. Advances in the clinical management of uveal melanoma. *Nat Rev Clin Oncol*. 2023 Jan 4. doi: 10.1038/s41571-022-00714-1. Epub ahead of print. PMID: 36600005.
7. Gurayah AA, Peters VA, Jin W, Kalahasty K, Kwon D, Zhao W, Patel NV, Markoe AM, Correa ZM, Studenski MT, **Harbour JW**, Samuels SE. Predictors of local recurrence and progression-free survival in Iodine-125 brachytherapy-treated uveal melanomas: A modern institutional study. *Ocul Oncol Pathol*. 2022 Nov;8(3):175-180. doi: 10.1159/000526771. Epub 2022 Aug 29. PMID: 37431398; PMCID: PMC10329746.
8. Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, Davies MA, Kurtenbach S, **Harbour JW**, Schug ZT, Aplin AE. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. *Cancers* (Basel). 2023 Jun 30;15(13):3451. doi: 10.3390/cancers15133451. PMID: 37444561; PMCID: PMC10341317.
9. Richards JR, Shin D, Pryor R, Sorensen LK, Sun Z, So WM, Park G, Wolff R, Truong A, McMahon M, Grossmann AH, **Harbour JW**, Zhu W, Odelberg SJ, Yoo JH. Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis. *Oncogene*. 2023 Jul 27. doi: 10.1038/s41388-023-02792-6. Epub ahead of print. PMID: 37500798.
10. Global Retinoblastoma Study Group; Berry JL, Pike S, Rajagopalan A, Reid MW, Fabian ID, Afshar AR, Alejos A, Alemany-Rubio E, Carreras YA, Arazi M, Astbury NJ, Bascaran C, Binkley E, Blum S, Boldt HC, Bonanomi MTBC, Bowman R, Brennan RC, Burton MJ, Calderón-Sotelo P, Jara DAC, Cano MR, Castillo L, Cavieres I, Cerna DQ, Chandramohan A, Chantada GL, Corson TW, Cowan-Lyn KE, Davanzo JM, Demirci H, Coronado RYD, Dimaras H, Macedo CRD, Ericksen C, Fandiño AC, Fernández DDPG, Foster A, Fu LD, Fuentes-Alabi SL, Garcia JL, Pacheco HNG, Girón AV, Goenz MA, Gold AS, Gomel N, Gonzalez E, Perez GG, González-Rodríguez L, Graells J, Grigorovski NDAK, Hamel P, Hansen ED, **Harbour JW**, Elizabeth Hartnett M, Hassan M, Hubbard GB, Kapelushnik N, Kim JW, Larson SA, Laurenti KD, Leverant AA, Li C, López JP, Luna-Fineman S, Magrath GN, Mallipatna A, Mattosinho CCDS, Mets MB, Miller A, Mruthyunjaya P, Murray TG, Oliver SCN, Oporto J, Ortega-Hernández M, Ossandon D, Morales CRP, Paton KE, Plager DA, Polania RA, Ponce J, Quintero D K, Ramasubramanian A, Ramirez-Ortiz MA, Randhawa JK, Romero L, Salas B, Sánchez GL, Orozco AJS, Sgroi M, Shah AS, Shields CL, Singh AD, Skalet AH, Stacey AW, Stahl ED, Strahlendorf C, Suarez MEC, Superstein R, Leiva FFT, Teixeira LF, Uner OE, Anchaya JKV, Vaughan LO, Villegas VM, Wilson MW, Yaghy A, Yee RI, López AM, Zondervan M. Retinoblastoma Outcomes in the Americas: a prospective analysis of 491 children with retinoblastoma from 23 American countries. *Am J Ophthalmol*. 2023 Nov 8:S0002-9394(23)00460-9. doi: 10.1016/j.ajo.2023.11.004. Epub ahead of print. PMID: 37949286.
11. Kurtenbach S, Sanchez MI, Kuznetsoff J, Rodriguez DA, Weich N, Dollar JJ, Cruz A, Kurtenbach S, Field MG, Durante MA, Decatur C, Sorouri M, Lai F, Yenisehirli G, Fang B, Shiekhattar R, Pelaez D, Correa ZM, Verdun RE, **Harbour JW**. PRAME induces genomic instability in uveal melanoma. Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02887-0. Epub ahead of print. PMID: 38030788.

Book Chapters

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Minna JD, Kaye FJ, Takahashi T, **Harbour JW**, Rosenberg R, Nau M, Whang-Peng J, Johnson B, Birrer M, Gazdar AF. “Recessive oncogenes and chromosomal deletions in human lung cancer.” IN Cavenee W, Hastie N, Stanbridge E (eds): Current Communications in Molecular Biology: Recessive Oncogenes and Tumor Suppression. Cold Spring Harbor Press (1989).
2. Faye FJ, Barksdale SA, **Harbour JW**, Minna JD. “Oncogenes in human lung cancer.” IN Sluyser M (ed): Molecular Biology of Cancer Genes. Ellis Horwood, Ltd (1990).
3. **Harbour JW**. “Ocular Trauma.” IN Cullom RD, Chang B (eds): The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 2nd edition. JB Lippincott (1994).
4. **Harbour JW**, Char DH. “Intraocular lymphoid tumors.” IN Chang S, Shields J, Green WR (eds): Retina, Vitreous, Macular: A Comprehensive Text. WB Saunders (1998).
5. Augsburger JJ, **Harbour JW**. “Uveal nevus.” IN Yanoff M, Duker J (eds): Ophthalmology. Mosby (1998, 2003).
6. **Harbour JW**, Murray TG: “Management of intraocular tumors.” IN Albert D (ed): Ophthalmic Surgery: Principles and Techniques. Blackwell Co. (1998).
7. **Harbour JW**. “Retinoblastoma: pathogenesis and diagnosis.” IN Char DH (ed): Tumors of the Eye and Orbit. BC Decker, Inc. (2001).
8. **Harbour JW**. “Retinoblastoma: treatment.” IN Char DH (ed): Tumors of the Eye And Orbit. BC Decker, Inc. (2001).
9. Moulds JRB, Petersen-Jones S, Peruccio C, Ratto A, Sassani JW, **Harbour JW**. “Uveal melanocytic tumors.” IN Peiffer RL, Jr, Simons KB (eds): Ocular Tumors in Animals and Humans (2002).
10. **Harbour JW**. “Intraocular tumors.” IN Quillen D, Blodi B. (eds): Clinical Retina. AMA Press (2002).
11. **Harbour JW**. “Clinical overview of uveal melanoma: introduction to tumors of the eye.” IN Albert DM, Polans A (eds): Ocular Oncology. Marcel Dekker (2003).
12. **Harbour JW**. “Oncogenes and Tumor Suppressor Genes in Uveal Melanoma.” IN Jager M, Niederkorn JY, Ksander BR (eds): Uveal melanoma: a model for exploring fundamental cancer biology (2004).
13. Cornelius LA, Carlson JA, Linette GP, **Harbour JW**. “Cancer of the Skin and Melanoma,” IN Govindan R (ed): Cancer: Principles & Practice of Oncology Review, 1st edition. Lippincott, Williams & Wilkins (2004).
14. Dyer MA, **Harbour JW**. “Cellular and Genetic Events in Retinal Tumorigenesis,” IN Singh AD, Damato BE, Pe’er J, Murphree AL, Perry JD (eds): Clinical Ocular Oncology. Elsevier (2006).
15. Onken MD, **Harbour JW**. “Cancer Genetics,” IN Singh AD, Damato BE, Pe’er J, Murphree AL, Perry JD (eds): Clinical Ocular Oncology. Elsevier (2006).
16. **Harbour JW**, Murphree AL. "Retinoblastoma," IN Ryan SA (ed): Retina, 4th edition. Elsevier (2006).
17. Onken MD, **Harbour JW**. “Genetic Therapy for Ocular Tumors,” IN Peyman GA, Meffert SA, Conway MD (eds): Vitreoretinal Surgical Techniques, 2nd edition. Taylor & Francis (2006).
18. **Harbour JW**. “Molecular Predictive Testing of Uveal Melanoma,” IN Peyman GA, Meffert SA, Conway MD (eds): Vitreoretinal Surgical Techniques, 2nd edition. Taylor & Francis (2006).
19. **Harbour JW**, Wickens J. “Choroidal Nevus and Melanocytoma,” IN Albert DM and Jakobiec FA (eds): Principles & Practice of Ophthalmology, 3rd edition. WB Saunders (2008).
20. **Harbour JW**, Feiner L. “Intraocular Lymphoma,” IN Albert DM and Jakobiec FA (eds): Principles & Practice of Ophthalmology, 3rd edition. WB Saunders (2008).
21. Ehlers JP, **Harbour JW**. “Uveal Melanoma,” IN Schwab M (ed): Encyclopedia of Cancer, 2nd Edition. Springer (2008).
22. Matatall K, **Harbour JW**. “Molecular Basis of Low-Penetrance Retinoblastoma,” IN Levin & Albert (eds): Ocular Disease: Mechanisms and Management (2010).
23. Correa ZM, **Harbour JW**. “Uveal Melanoma,” IN Levin & Albert (eds): Ocular Disease: Mechanisms and Management (2010).
24. Primary Co-Author. “Malignant Melanoma of the Uvea.” IN Edge, SB, Byrd, DR, Compton, CC, Fritz, AG, Greene, FL, Trotti A (eds): AJCC Cancer Staging Manual, 7th edition. Springer (2009).
25. Primary Co-Author. “Retinoblastoma.” IN Edge, SB, Byrd, DR, Compton, CC, Fritz, AG, Greene, FL, Trotti A (eds): AJCC Cancer Staging Manual, 7th edition. Springer (2009).
26. **Harbour JW**, Chao DL. “Cancer Genetics,” IN Singh AD, Damato BE, Pe’er J, Murphree AL, Perry JD (eds): Clinical Ocular Oncology 2nd Edition. Elsevier (2013).
27. Dyer MA, **Harbour JW**. “Cellular and Genetic Events in Retinal Tumorigenesis,” IN Singh AD, Damato BE, Pe’er J, Murphree AL, Perry JD (eds): Clinical Ocular Oncology, 2nd Edition. Elsevier (2014).
28. **Harbour JW**. Mohsenin A. “Second Primary Tumors in Retinoblastoma,” IN Karcioglu ZA (ed): Orbital Tumors: Diagnosis and Treatment, 2nd Edition, Springer (2014).
29. **Harbour JW**, Walter SD. “Retinoblastoma: Clinical and Molecular Perspectives,” IN Coleman WB (ed): The Molecular Basis of Human Cancer, 2nd edition. Springer (2015).
30. Walter SD, **Harbour JW.** “Molecular Biology of Retinoblastoma,” IN Francis JH and Abramson DH (eds): Recent Advances in Retinoblastoma Treatment. Springer (2015).
31. Ehlers JP, **Harbour JW**. “Uveal Melanoma,” IN Schwab M (ed.) Encyclopedia of Cancer, 4th edition, Springer-Verlag Berlin Heidelberg, Vol. 6, 4767-4772 (2017).
32. Paez-Escamilla M, Walter S, **Harbour JW**. “Genomics and Precision Medicine in the Management of Ocular Tumors,” IN Peyman G, Conway M, Moshfeghi D, Berrocal N (eds): Vitreoretinal Surgical Techniques, 3rd Edition, CRC Press (2018).
33. Paez-Escamilla M, Andreoli M, **Harbour JW.** “Intraocular Lymphoma: A Clinical Approach,” IN Ehlers JP (ed.): The Retina Illustrated, 1st Edition, Publisher Thieme Publishers (2018).
34. **Harbour JW**, Shih HA. “Initial management of uveal and conjunctival melanomas,” IN Atkins MB, Berman RS (eds): *UpToDate* (2018). <https://www.uptodate.com/contents/initial-management-of-uveal-and-conjunctival-melanomas?csi=6b3b6b40-70aa-4e13-b4f3-20d893aa7f57&source=contentShare#H4241265126>. Updated Aug 31, 2022.
35. Paez-Escamilla M, Andreoli M, **Harbour JW.** “Intraocular Lymphoma,” IN Ehlers JP (ed.): The Retina Illustrated, 2nd Edition; 21.05.19 – 14:40, Publisher Thieme Publishers (2019).
36. Echegaray JJ, **Harbour JW**. “Intraocular Lymphoma,” IN Albert D, Miller J, Azar D, Young L (eds): Albert and Jakobiec's Principles and Practice of Ophthalmology, 4th Edition, Springer (2020).
37. Alhumaid S, **Harbour JW**. “Choroidal Nevus and Melanocytoma,” IN Albert D, Miller J, Azar D, Young L (eds): Albert and Jakobiec's Principles and Practice of Ophthalmology, 4th Edition, Springer (2021). https://doi.org/10.1007/978-3-319-90495-5\_258-1
38. Echegaray JJ, **Harbour JW**. “Intraocular Lymphoma,” In: Albert D, Miller J, Azar D, Young L (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology, 4th Edition, Springer (2021). https://doi.org/10.1007/978-3-319-90495-5\_257-1
39. **Harbour JW** and Correa ZM. "Molecular Basis of Uveal Melanoma and Emerging Therapeutic Targets," IN Bernicker EH (ed): Uveal Melanoma Biology and Management, Springer (2021).

# Non-Peer Reviewed Scientific Publications

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Hatzistergos KE, Durante MA, Valasaki K, **Harbour JW**, Hare JM. Fate of developmental mechanisms of myocardial plasticity in the postnatal heart. *bioRxiv* 842864; doi: https://doi.org/10.1101/842864 (2019).
2. Kurtenbach S, **Harbour JW**. SparK: A Publication-quality NGS Visualization Tool. *bioRxiv* 845529; doi: https://doi.org/10.1101/845529 (2019).
3. Peng H, Cassel J, McCracken DS, Prokop JW, Collop PR, Polo A, Joshi S, Mandell JP, Ayyanathan K, Hinds D, Malkowicz SB, **Harbour JW**, Bowcock AM, Salvino J, Kennedy EJ, Testa JR, Rauscher III FJ. Kinetic characterization of ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase. *bioRxiv* 2020.02.24.962464; doi: https://doi.org/10.1101/ 2020.02.24.962464 (2020).
4. Kurtenbach S, Rodriguez DA, Durante MA, **Harbour JW**. UPhyloplot2: Visualizing Phylogenic Trees from Single-Cell RNA-seq Data. *bioRxiv* 2020.05.25.115550; doi: <https://doi.org/10.1101/2020.05.25.115550> (2020).
5. Kurtenbach S, Dollar JJ, Durante MA, **Harbour JW**. PieParty: Visualizing cells from scRNA-seq data as pie charts. *bioRxiv*. 2020 Aug 26; 2020.08.25.267021. Preprint. doi: <https://doi.org/10.1101/2020.08.25.267021>. (2020)

# Other Publications

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **Harbour JW**. “Pearls for imaging and diagnosis in ocular oncology.” Retina Today (2009).
2. **Harbour JW**, Correa ZM. “The role of biopsy in the management of intraocular tumors.” Retina Times (2009).
3. **Harbour JW**, Correa ZM. “Intra-arterial chemotherapy for retinoblastoma – learning from personal experience.” Retina Times (2009).
4. **Harbour JW**. “Bench to bedside in uveal melanoma genetics: the future is now.” Retina Today (2010).
5. **Harbour JW**, Correa ZM. “Controversies in the management of primary intraocular lymphoma.” Retina Times (2010).
6. **Harbour JW**. “Molecular research in uveal melanoma: ushering in a new standard of care.” Retina Times (2011).
7. **Harbour JW**, Correa ZM. “Posterior segment complications of radiation therapy.” Retina Times (2011).
8. **Harbour JW**, Correa ZM. “Pseudoangiomatous retinal gliosis (PARG): familiar retinal lesion, confusing terminology.” Retina Times (2013).
9. **Harbour JW**, Correa ZM. “Intraocular metastasis from systemic cancer: what the retina specialist needs to know.” Retina Times (2015).
10. **Harbour JW**, Correa ZM. “Suspicious choroidal melanocytic tumors— how useful are those risk factors anyway?” Retina Times (2016).
11. **Harbour JW**. “Exploring genetic prognostic testing for uveal melanoma.” Retina Times (2017).
12. **Harbour JW**, Murray TG, Shields CL. “Retinoblastoma: advances in diagnosis and treatment.” Retina Times (2017).
13. **Harbour JW**, Correa ZM. “Radiotherapy for benign intraocular tumors and pseudotumors.” Retina Times (2017).
14. **Harbour JW**, Correa ZM. “Challenges in the differential diagnosis of leukocoria in children.” Retina Times (2019).
15. **Harbour JW**, Correa ZM. “Scientific collaboration advances ocular oncology." Retina Times (2019).
16. **Harbour JW**, Correa ZM. “Using OCT to detect and interpret the significance of retinal and RPE changes associated with choroidal nevi." Retina Times (2020).
17. **Harbour JW**, Correa ZM. "What happens to patients with ocular tumors during the coronavirus pandemic?" Retina Times (2020).
18. **Harbour JW**, Correa ZM. "Performing vitreoretinal surgery in eyes with posterior uveal melanoma." Retina Times (2021).
19. **Harbour JW**, Correa ZM. “Challenges in setting up and managing an ocular oncology practice.” Retina Times (2022).

# Commentaries, Reviews & Interviews

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Commentary: “Response of the normal eye to high dose radiotherapy.” *Oncology* 1996; 10:847-848.
2. Interview: “Treating eye cancer.” *Coping Magazine* (2000, September/October).
3. Commentary: “An update on uveal melanoma.” *Review of Ophthalmology* (2003).
4. Book review: “Radiotherapy of intraocular and orbital tumors, 2nd revised edition.” *Arch Ophthalmol* 2003; 121:1517.
5. Interview: “Rethinking retinoblastoma: treatment update.” *EyeNet* 2004; p. 29-30.
6. Commentary: “Molecular prognostic testing in uveal melanoma: has it finally come of age?” *Arch Ophthalmol* 2007; 125:1122-1123.
7. Interview: “Cancer stem cells and metastasis.” *BioWorld Today* (July 10, 2007).
8. Interview: “Will my eye cancer metastasize or not?” *Checkbiotech* 2008.
9. Commentary: “Update on uveal melanoma.” *EyeNet* 2008.
10. Interview: “A life and death predictor adds to a cancer’s strain.” *New York Times* (July 9, 2012, front page). <http://www.nytimes.com/2012/07/10/health/genetic-test-changes-game-in-cancer-prognosis.html>
11. Interview: “A need to know the worst news you will ever hear.” *CBS News Sunday Morning* (December 2, 2012). <http://www.cbsnews.com/8301-3445_162-57556650/a-need-to-know-the-worst-news-you-will-ever-hear/>
12. Interview: “A molecular test of ocular melanoma.” Charles Adler Show [nationally syndicated Canadian radio show] (December 3, 2012).
13. Commentary: “Solving the riddle of advanced uveal melanoma.” *The Melanoma Letter*, Vol. 34, No. 3 (2016).

Invited Lectures

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Invited Lecture: “Analysis of gene expression in uveal melanoma and retinoblastoma.” Vision Research Group. University of Tennessee. Memphis, TN (1996)
2. Invited Lecture: “Genetic approaches in ophthalmology research.” Department of Ophthalmology, University of Tennessee. Memphis, TN (1997)
3. Invited Lecture: “Regulation of Rb by progressive phosphorylation.” St Jude Children’s Research Hospital. Memphis, TN (2000)
4. Invited Lecture: “Management of intraocular tumors.” Grand Rounds. Department of Radiation Oncology, Washington University School of Medicine. St. Louis, MO (2000).
5. Invited Lecture: “The role of Rb in G1 and beyond.” Decisions in G1 Cell Cycle Meeting. Rome, Italy (2000).
6. Invited Lecture: “The Rb and p53 tumor suppressor pathways in uveal melanoma and retinoblastoma.” Ocular Oncology Mini-symposium, Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2001).
7. Invited Lecture: “Tumor suppressor inactivation in uveal melanoma.” Uveal Melanoma Genetics Special Interest Group, ARVO Annual Meeting. Ft. Lauderdale, FL (2001).
8. Invited Lecture: “Oncogenes and tumors suppressor genes in uveal melanoma.” Uveal Melanoma Research Workshop, University of Leiden, The Netherlands (2001).
9. Invited Lecture: “Status of the Rb protein in uveal melanoma.” International Congress of Eye Research, Geneva, Switzerland (2002).
10. Invited Lecture: “Ocular melanoma.” Siteman Cancer Center Melanoma Seminar. Washington University School of Medicine, St. Louis, Missouri (2002).
11. Invited Lecture: “Targeted molecular therapy for eye cancer.” Pharmacia Corporation (2003).
12. Invited Lecture: "Genetics of ocular tumors: possibilities for gene therapy." Progress in Gene Therapy Symposium, American Academy of Ophthalmology Annual Meeting. Anaheim, CA (2003).
13. Invited Commentary: "Transpupillary thermotherapy for small retinoblastoma." American Academy of Ophthalmology Annual Meeting. Anaheim, CA (2003).
14. Invited Lecture: “Update on retinoblastoma.” Ophthalmology Update. Punta Cana, Dominican Republic (2004).
15. Invited Lecture: "Ocular melanoma." Missouri State Medical Association Annual Convention. St. Louis, MO (2004).
16. Invited Commentary: "Iris Melanocytoma: Clinical Features and Natural Course In 47 Cases." American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2004).
17. Invited Lecture: “Gene expression profiling in ocular melanoma.” Cancer Genetics Seminar Series, Siteman Cancer Center, Washington University. St. Louis, MO (2004).
18. Invited Lecture: "Uveal melanoma genetics." International Melanoma Study Group. Palm Springs, CA (2005).
19. Invited Lecture: “Retinoblastoma From Bench To Bedside.” St Jude Children’s Research Hospital Symposium. Memphis, TN (2005).
20. Invited Lecture: “Eye Cancer: Unique Insights Into Molecular Oncogenesis.” Cogan Award Lecture, Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2005).
21. Invited Lecture (Keynote Speaker): “A Molecular Paradigm Shift In Uveal Melanoma: Implications For Clinical Management And Future Research.” International Congress of Ocular Oncology. Whistler, Canada (2005).
22. Invited Lecture: "Genetics Of Ocular Melanoma." American Academy of Ophthalmology Annual Meeting. Chicago, IL (2005).
23. Invited Lecture: "Molecular predictive testing of uveal melanoma." Retina Subspecialty Day, American Academy of Ophthalmology Annual Meeting. Chicago, IL (2005).
24. Invited Panelist: “Ocular tumors and pathology” paper session. American Academy of Ophthalmology Annual Meeting. Chicago, IL (2005).
25. The 2005 Dario Lorenzetti Memorial Invited Lecture: "Individualized patient care through molecular phenotyping in uveal melanoma." McGill University. Montreal, Canada (2005).
26. The 40th Annual C.S. O'Brien Lecture: "Molecular management of uveal melanoma." Tulane University. New Orleans, LA (2005)
27. Invited Lecture: “Molecular profiling and predictive testing for uveal melanoma.” Macula 2006/East Coast Retina Club Annual Meeting. New York, NY (2006).
28. Invited Lecture: “Genetics of ocular tumors: possibilities for gene therapy.” World Congress of Ophthalmology. Sao Paulo, Brazil (2006).
29. The Paul A. Cibis Professorship Lecture: “Ocular melanoma as a model for
genome-guided cancer management.” Washington University. St. Louis, MO (2006).
30. The 2006 Charles Dyson Invited Lecture: “COMS update and ocular melanoma.” Clinical Day in Ophthalmology. London Health Sciences Center. London, Ontario (2006).
31. Invited Lecture: “Masquerade syndromes.” Clinical Day in Ophthalmology. University of Western Ontario. London, Ontario (2006).
32. Invited Lecture: “Melanoma and retinoblastoma.” Clinical Day in Ophthalmology. University of Western Ontario. London, Ontario (2006).
33. Invited Lecture: “Molecular genetics in melanoma: implications of microarray analysis.” Ocular Oncology Course, Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2006).
34. The 2006 Alice McPherson Memorial Lecture: “Management of uveal melanoma in the era of molecular medicine.” Wisconsin Ophthalmology Society (2006).
35. Invited Lecture: “Contemporary management of intraocular lymphoma.” Wisconsin Ophthalmology Society (2006).
36. Invited Lecture: “Transpupillary thermotherapy.” Ophthalmic Oncology Symposium, University of North Carolina, Chapel Hill, NC (2006).
37. Invited Lecture: “Choroidal metastasis.” Ophthalmic Oncology Symposium, University of North Carolina, Chapel Hill, NC (2006).
38. Invited Lecture: “Vascular hamartomas of the retina and choroid.” Ophthalmic Oncology Symposium, University of North Carolina, Chapel Hill, NC (2006).
39. The 2006 David Eifrig Keynote Lecture: “Prognosis of choroidal melanoma.” Ophthalmic Oncology Symposium, University of North Carolina, Chapel Hill, NC (2006).
40. Invited Lecture: "Molecular predictive testing of uveal melanoma using fine needle biopsy samples." Retina Subspecialty Day, American Academy of Ophthalmology Annual Meeting. Las Vegas, NV (2006).
41. Invited Commentary: “Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study." Editor’s choice symposium. American Academy of Ophthalmology Annual Meeting. Las Vegas, NV (2006).
42. Invited Lecture: “Ocular oncology update.” American Academy of Optometry Annual Meeting. Denver, CO (2006).
43. The 2007 Samuel J. Kimura Visiting Professor: “Management of uveal melanoma in the era of genomic medicine.” University of California at San Francisco (2007).
44. Invited Lecture: “Genomics and genetics of ocular melanoma.” Melanoma Research Program, University of Colorado. Denver, CO (2007).
45. Invited Lecture: “Contemporary Management of Primary Intraocular Lymphoma.” American Uveitis Society Winter Meeting. Snowmass, CO (2007).
46. Invited Lecture: “Management of ocular melanoma in the era of genomic medicine.” Ocular Melanoma Think Tank. Memorial Sloan-Kettering Cancer Center, New York (2007).
47. Invited Lecture: “Management of ocular melanoma in the era of genomic medicine.” Journée Annuelle De La Recherche En Ophtalmologie. Laval University, Quebec City, Canada (2007).
48. Invited Lecture: “Management of ocular melanoma in the era of genomic medicine.” Vienna Ophthalmological Society Meeting. Vienna, Austria (2007).
49. Invited Lecture: “Management of ocular melanoma in the era of genomic medicine.” Karolinska Institute. Stockholm, Sweden (2007).
50. Invited Lecture: “Update in ocular oncology.” University of Missouri. St. Louis (2007).
51. Invited Lecture: “Ophthalmic ultrasonography.” Ellex Coorporation. St. Louis (2007).
52. Invited Lecture: “Integrative genomic analysis of metastasis in ocular melanoma.” Society for Melanoma Research Annual Meeting. New York City (2007).
53. Invited Lecture: "The management of primary intraocular lymphoma." Retina Subspecialty Day, American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2007).
54. Invited Lecture: “Importance of ophthalmic ultrasonography to the vitreoretinal surgeon.” Ellex Coorporation. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2007).
55. Invited Lecture: “Management of ocular melanoma in the era of genomic medicine.” Ophthalmic Photography Society Annual Meeting. New Orleans, LA (2007).
56. Invited Lecture: “Primary intraocular lymphoma.” University of Virginia. Charlottesville, VA (2008).
57. Invited Lecture: “Ocular conditions associated with systemic disorders.” University of Virginia. Charlottesville, VA (2008).
58. Invited Lecture: “Management of uveal melanoma.” University of Virginia. Charlottesville, VA (2008).
59. Invited Lecture: “Management of uveal melanoma in the era of genomic medicine.” Mayo Clinic. Rochester, MI (2008).
60. Invited Lecture: “Uveal melanoma: prognostication.” Cleveland Clinic Ocular Oncology Seminar. Cleveland, OH (2008).
61. The 2008 Rosenthal Foundation Award Lecture: “Genome-guided management of uveal melanoma.” Macula Society Annual Meeting. Palm Beach, FL (2008).
62. Invited Lecture: “Uveal melanoma: insights into tumorigenesis and metastasis using genomic approaches.” University of Pennsylvania. Philadelphia, PA (2008).
63. Invited Lecture: “Ophthalmic ultrasonography.” Ellex Seminar. World Congress of Ophthalmology. Hong Kong (2008).
64. Invited Lecture: “Molecular classification of uveal melanoma and its impact on
clinical management.” Extraordinary Ophthalmology Symposium. Madison, WI (2008).
65. Invited Faculty. Heed Ophthalmic Foundation Resident Retreat. Denver, CO (2008).
66. Invited Lecture: “Surgical management of ocular tumors.” Association of Surgical Operating Room Nurses. St. Louis, MO (2008).
67. Invited Lecture: “Clinically and prognostically relevant molecular classification of uveal melanoma.” American Association of Ocular Pathologists Annual Meeting. Atlanta, GA (2008).
68. Invited Lecture: "Clinically and prognostically relevant molecular classification of uveal melanoma." Retina Subspecialty Day, American Academy of Ophthalmology Annual Meeting. Atlanta, GA (2008).
69. Invited Lecture: “Ocular imaging conference.” American Academy of Ophthalmology Annual Meeting. Atlanta, GA (2008).
70. Invited Lecture: “Update on uveal melanoma.” Turkish American Ophthalmology Association Annual Meeting. Atlanta, GA (2008).
71. Invited Lecture: "Clinically and prognostically relevant molecular classification of uveal melanoma." The Best of the Best Symposium. American Academy of Ophthalmology Annual Meeting. Atlanta, GA (2008).
72. The 2008 Francis Heed Adler Lecture: “Oncogenomics of uveal melanoma and relevance to clinical practice.” University of Pennsylvania. Philadelphia, PA (2008).
73. The 2009 Fund For Ophthalmic Knowledge Invited Lecture: “New molecular observations in uveal melanoma.” New York Macula Meeting. New York City, NY (2009).
74. The 2009 Joseph M. Bryan Research Lecture: “New insights in uveal melanoma.” Duke University. Durham, NC (2009).
75. Invited Lecture: “Challenging ocular oncology cases.” Duke University. Durham, NC (2009).
76. Invited Lecture: “Investigations of uveal melanoma: model of clinician-scientist initiated research.” Washington University MD-PhD Medical Scientist Training Program. St Louis, MO (2009).
77. The 2009 John Dickerson Memorial Lecture: “New innovations in the management of uveal melanoma.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
78. Invited Lecture: “Contemporary management of uveal melanoma.” University of Michigan. Ann Arbor, MI (2009).
79. Invited Lecture: “Novel pathway linking Rb degradation and p53-mediated apoptosis.” University of Louisville Brown Cancer Center. Louisville, KY (2009).
80. Invited Lecture: “Update on uveal melanoma.” University of Louisville Department of Ophthalmology & Visual Sciences. Louisville, KY (2009).
81. Invited Lecture: “Uveal melanoma: merger of clinical and genomic medicine.” University of Louisville Department of Ophthalmology & Visual Sciences. Louisville, KY (2009).
82. Invited Lecture: “Uveal melanoma: genetics of malignant transformation, progression and metastasis.” University of Michigan. Ann Arbor, MI (2009).
83. Invited Lecture: “Challenging ocular oncology cases.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
84. Invited Lecture: “Primary epithelial cysts of the iris and pars plicata.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
85. Invited Lecture: “Management of primary intraocular lymphoma.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
86. Invited Lecture: “Update on retinoblastoma.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
87. Invited Lecture: “Retinal & choroidal vascular tumors.” East Virginia Medical University Department of Ophthalmology. Norfolk, VA (2009).
88. Invited Lecture: “Animals Models In Ocular Oncology Research.” Leiden University. Leiden, The Netherlands (2009).
89. Invited Lecture: “Current Understanding Of Uveal Melanoma In Light Of Recent Genomics Research.” European Society for Ophthalmology (SOE) Annual Meeting. Amsterdam, The Netherlands (2009).
90. Invited Lecture: “Epigenetic profiling reveals distinct patterns of DNA methylation in class 2 uveal melanomas.” Basic Research Day. International Congress of Ocular Oncology. Cambridge, United Kingdom (2009).
91. Keynote Address: “A decade of discovery, innovation and hope in the management of uveal melanoma.” International Congress of Ocular Oncology. Cambridge, United Kingdom (2009).
92. Invited Lecture: “Present and future research directions in uveal melanoma.” Royal Liverpool Hospital. Liverpool, United Kingdom (2009).
93. Invited Lecture: “Uveal melanoma: genomic research and individualized.” University of Pittsburgh Cancer Center. Pittsburgh, PA (2009).
94. Invited Lecture: “Role of radiation therapy in the treatment of ocular melanoma.” Department of Radiation Oncology, Washington University, St. Louis (2009).
95. Invited Lecture: “Prognosis of uveal melanoma.” Poster Segment Tumor Symposium. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
96. Invited Lecture: “Clinical overview of uveal melanoma.” Ocular Melanoma Scientific Working Group Symposium. Dana Farber Cancer Institute. Boston, MA (2009).
97. Invited Lecture: “Genetics and genomics of uveal melanoma.” Ocular Melanoma Scientific Working Group Symposium. Dana Farber Cancer Institute. Boston, MA (2009).
98. Invited Lecture: "Molecular profiling and prognosis of choroidal melanoma." Retina Subspecialty Day. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
99. Invited Lecture: “Prognosis of uveal melanoma.” Pan-American Association of Ophthalmology Symposium on Posterior Segment Tumors. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
100. Invited Poster: “Prospective validation of the uveal (ocular) melanoma gene expression profile prognostic assay in fine needle biopsy specimens.” National Cancer Institute Translational Science Symposium. Bethesda, MD (2009)
101. Invited Lecture: “Ocular (uveal) melanoma: genomics of metastasis and targeted therapy.” Yale University, Department of Pathology Grand Rounds. New Haven, CT (2010).
102. Invited Lecture: “Impact of research in ocular oncology.” Yale University, Department of Ophthalmology Resident Research Day. New Haven, CT (2010).
103. Invited Lecture: “Update on uveal melanoma.” Yale University, Department of Ophthalmology Grand Rounds. New Haven, CT (2010).
104. Invited Lecture: “Molecular genetics of uveal melanoma.” Yale University, Department of Dermatology, Melanoma SPORE Program. New Haven, CT (2010).
105. Invited Lecture: “Genomics of uveal melanoma: insights into the metastatic process.” Johns Hopkins University, Department of Pathology. Baltimore, MD (2010).
106. Invited Lecture: “Genomic approaches to target therapy in uveal melanoma.” Ocular Melanoma Foundation Workgroup Meeting. Washington D.C. (2010).
107. Keynote Address: “Genomics of uveal melanoma: insights into the metastatic process.” Gained in Translation Vision Science Retreat. University of Washington. Seattle, WA (2010).
108. Invited Lecture: “Ocular melanoma.” Clinical Problems in Oncology Session on Ocular Melanoma. American Society of Clinical Oncology Annual Meeting. Chicago, IL (2010).
109. Invited Lecture: “The end of the beginning: new directions in uveal melanoma management and research.” Extraordinary Ophthalmology Symposium. University of Wisconsin. Madison, WI (2010)
110. Invited Lecture: “Management of ocular tumors.” American Society of Ophthalmic Registered Nurses Meeting. St. Louis, MO (2010).
111. Invited Lecture: “Update on uveal melanoma.” Fall Update in Ophthalmology. Washington University. St. Louis, MO (2010).
112. Invited Lecture: “Update on uveal melanoma research.” Grand Rounds. Department of Ophthalmology & Visual Sciences. Washington University. St. Louis (2010).
113. Invited Lecture (Keynote Speaker): “Gene expression profiling in uveal melanoma.” American Association of Ocular Pathologists Annual Meeting. Chicago, IL (2010).
114. Invited Lecture: “Genetic analysis for prognosis in uveal melanoma.” Pathology Symposium. American Academy of Ophthalmology Annual Meeting. Chicago, IL (2010).
115. Invited Lecture: “Complete exome resequencing reveals inactivating mutations in a novel metastasis suppressor on chromosome 3 in uveal melanoma.” Society for Melanoma Research Annual Meeting. Sydney, Australia (2010).
116. Invited Lecture: “The role of genetics in research and clinical care.” Advanced Retina Therapy Meeting. Vienna, Austria (2010).
117. Invited Lecture: “Role of radiation therapy in the treatment of primary vitreoretinal lymphoma.” Primary CNS Lymphoma Collaborative Group Meeting. American Society of Hematology Annual Meeting. Orlando, FL (2010).
118. Invited Lecture: “Uveal melanoma: genomics meets clinical practice.” St. Louis Ophthalmological Society. St. Louis, MO (2011).
119. Invited Lecture: “Identifying metastasis suppressor genes in uveal melanoma using exome sequencing.” Siteman Cancer Center/Washington University Cancer Biology Pathway Lecture Series. St. Louis, MO (2011).
120. Invited Lecture: “Treatment of eye tumors.” Ophthalmic Personnel Educational Seminar. St. Louis, MO (2011).
121. Invited Lecture: “Genomics of uveal melanoma.” Dana Farber/Brigham and Women’s Hospital Cancer Center Melanoma Lecture Series. Boston, MA (2011).
122. The 2011 Lorand V. Johnson Lecture: “Clinical implications of recent genetic research in uveal melanoma.” Cleveland Ophthalmological Society. Cleveland, OH (2011).
123. Invited Lecture: “Update on primary vitreoretinal lymphoma.” Cleveland Ophthalmological Society. Cleveland, OH (2011).
124. Invited Lecture: “Molecular profiling and prognostication of uveal melanoma.” Perspectives in Melanoma XV. New York, NY (2011).
125. Invited Lecture: “Update on the management of intraocular tumors.” Annual meeting of the Missouri, Arkansas, Kansas, and Oklahoma state ophthalmological societies. Ridgedale, MO (2011).
126. The 2011 F. Phinizy Calhoun Sr Lecture: “The genetic causes of uveal melanoma: finally coming into focus.” Emory University. Atlanta, GA (2011).
127. Invited lecture: “Retinal detachment and other disorders of the back of the eye.” Washington University Mini-Medical School. St. Louis, MO (2011).
128. The 2011 Paul R. Fink Lecture: “Uveal melanoma: new insights into cancer genetics and metastasis.” Melanoma Program. Memorial Sloan-Kettering Cancer Center. New York, NY (2011).
129. Invited Lecture: “BAP1 mutations in melanoma.” Society for Melanoma Research Annual Meeting. Tampa, FL (2011).
130. Invited Lecture: “Sporadic and germline BAP1 mutations in uveal and cutaneous melanoma: new insights into cancer evolution.” Mesothelioma-Melanoma Cancer Syndrome Seminar. University of Hawaii Cancer Center. Honolulu, HA (2011).
131. Invited Lecture: “Intraocular biopsy: indications and techniques.” Department of Ophthalmology. Case Western Reserve University. Cleveland, OH (2011).
132. Invited Lecture: “Recent progress in uveal melanoma.” New York Eye and Ear Infirmary. New York, NY (2011).
133. Invited Lecture: “Case presentations in ocular oncology.” Department of Ophthalmology. Emory University. Atlanta, GA (2011).
134. Invited Lecture: “Contemporary management of primary vitreoretinal lymphoma.” Retina 2012. Maui, HI (2012).
135. Invited Lecture: “Intraocular tumors and pseudotumors that can masquerade as uveal melanoma.” Retina 2012. Maui, HI (2012).
136. Invited Lecture: “Contemporary management of posterior uveal melanoma.” Retina 2012. Maui, HI (2012).
137. Invited Lecture: “Genetic discoveries in uveal melanoma and their clinical importance.” Retina 2012. Maui, HI (2012). \*\*Voted Speaker of the Day
138. Invited Lecture: “Management of intraocular tumors.” Hawaiian Eye Nursing and Allied Health Program. Maui, HI (2012). \*\*Voted Speaker of the Day
139. Keynote Address: “Introduction to uveal melanoma biology.” Symposium on Uveal Melanoma. Curie Institute. Paris, France (2012).
140. Keynote Address: “BAP1 mutations in uveal melanoma.” European Ocular Oncology Group Meeting. Paris, France (2012).
141. Invited Lecture: “Retinal detachment and other disorders of the back of the eye.” Washington University Mini-Medical School. St. Louis, MO (2012).
142. Keynote Address: “Prospects for new targeted therapies in melanoma.” Melanoma Research Foundation Seminar. Siteman Cancer Center. Washington University. St. Louis, MO (2012).
143. The 2012 J.D. Allen Lecture: “Recent genetic discoveries in uveal melanoma.” University of Ottawa. Department of Ophthalmology. Ottawa, Ontario (2012).
144. Invited Lecture: “Recent molecular discoveries in ocular melanoma.” Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine. Miami, FL (2012).
145. Invited Lecture: “Recent molecular discoveries in ocular melanoma.” Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. Miami, FL (2012).
146. Invited Lecture: “Recent advances in uveal melanoma.” New York City Ophthalmic Laser Society. New York, NY (2012).
147. Invited Lecture: “Recent advances in uveal melanoma.” Society for Melanoma Research Annual Meeting. Hollywood, CA (2012).
148. Invited Lecture: “Update on intraocular tumors.” Johns Island Club 5 O’Clock Seminar Series. Vero Beach, FL (2012).
149. Invited Lecture: “Recent discoveries in uveal melanoma and impact on patient care.” Department of Ophthalmology. Columbia University. New York, NY (2012).
150. Invited Lecture: “Survey of intraocular tumors.” University of Ottawa. Department of Ophthalmology. Ontario, Canada (2012).
151. Invited Lecture: “The genomic landscape of ocular (uveal) melanoma: finally coming into focus.” Mount Sinai School of Medicine and Tisch Cancer Institute. New York, NY (2013).
152. Invited Lecture: “Overview of ocular tumors.” Palm Beach Medical Forum. Palm Beach, FL (2013).
153. Invited Lecture: “Anti-VEGF therapy in ocular oncology.” Angiogenesis, Exudation, and Degeneration 2013. Miami, FL (2013).
154. Invited Lecture: “BAP1 in uveal melanoma.” International Symposium on Malignant Mesothelioma. Las Vegas, NV (2013).
155. Invited Lecture: “Future of Genetics in the Management of Retinal Diseases.” Vit-Buckle Society Annual Meeting. Miami Beach, FL (2013).
156. Invited Lecture: “The Mutational Landscape in Uveal Melanoma: Clues to Tumorigenesis and Targeted Therapy.” Genentech. South San Francisco, CA (2013).
157. Invited Lecture: “Optic disc tumor.” Reality Retina Meeting. Seattle, WA (2013).
158. Invited Lecture: “Mutational Landscape in Uveal Melanoma.” Melanoma Research Foundation CureOM Scientific Meeting. Seattle, WA (2013).
159. Invited Lecture: “Clinical update on retinoblastoma.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
160. Invited Lecture: “Research and genetics update on uveal melanoma.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
161. Invited Lecture: “Primary vitreoretinal and uveal lymphomas.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
162. Invited Lecture: “Vascular tumors and pseudotumors of the retina and choroid.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
163. Invited Lecture: “Tumors and pseudotumors of the RPE.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
164. Invited Lecture: “The role of ultrasonography in ocular oncology practice.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
165. Invited Lecture: “The role of anti-VEGF therapy in ocular tumors.” King Saud University 39th Ocular Oncology Symposium. Riyadh, Saudi Arabia (2013).
166. Invited Lecture: “Genomic, diagnostic, and cell signaling advances in ocular melanoma.” American Society of Clinical Oncology Annual Meeting. Chicago, IL (2013).
167. Invited Lecture: “Update on intraocular tumors.” Florida Society of Ophthalmology Annual Meeting. Palm Beach, FL (2013).
168. Invited Lecture: “The mutational landscape in uveal melanoma: clues to tumorigenesis and targeted therapy.” MD Anderson Cancer Center. Houston, TX (2013).
169. Invited Lecture: “Personalized Genome-Guided Management In Ocular Oncology: Improving Care While Reducing Costs.” Pan-American Congress of Ophthalmology Annual Meeting. Rio De Janeiro, Brazil (2013).
170. Invited Lecture: “Genomic Research In Uveal Melanoma.” McKnight Vision Research Series. Bascom Palmer Eye Institute. Miami, FL (2013).
171. Invited Lecture: “Scientific And Professional Development For MD-PhD Students.” University of Miami Miller School of Medicine MD-PhD Program. Miami, FL (2013).
172. Invited Lecture: “BAP1 Mutations And The Uveal Melanoma Epigenome.” Epigenetics Work Group. University of Miami Sylvester Comprehensive Cancer Center. Miami, FL (2013).
173. Invited Discussant: “Intraocular Tumors.” Retina Sub-Specialty Day. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
174. Panelist: “Pediatric Intraocular Tumors.” Retina Sub-Specialty Day. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
175. Invited Lecture: “Association Between Genetic Mutations And Clinical Outcomes In Uveal Melanoma.” Best of the Posterior Segment Symposium. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
176. Invited Lecture: “Clinical Update on Important Intraocular Tumors.” XXXV Inter-American Course in Clinical Ophthalmology. Miami, FL (2013).
177. Invited Lecture: “Clinical Update on Retinoblastoma.” Fundación Oftalmológica Los Andes. Santiago, Chile (2013).
178. Invited Lecture: “Clinical Update on Uveal Melanoma.” Fundación Oftalmológica Los Andes. Santiago, Chile (2013).
179. Invited Lecture: “Vascular tumors and pseudotumors of the retina and choroid.” Fundación Oftalmológica Los Andes. Santiago, Chile (2013).
180. Invited Lecture: “Contemporary management of primary vitreoretinal lymphoma.” Retina 2014. Kauai, HI (2014).
181. Invited Lecture: “Intraocular tumors and pseudotumors that can masquerade as uveal melanoma.” Retina 2014. Kauai, HI (2014).
182. Invited Lecture: “Contemporary management of posterior uveal melanoma.” Retina 2014. Kauai, HI (2014).
183. Invited Lecture: “Genetic discoveries in uveal melanoma and their clinical importance.” Retina 2014. Kauai, HI (2014). \*\*Voted Speaker of the Day
184. Invited Lecture: “Management of intraocular tumors.” Hawaiian Eye Nursing and Allied Health Program. Retina 2014. Kauai, HI (2014). \*\*Voted Speaker of the Day
185. The 2014 Robert M. Ellsworth Memorial Lecture: “Uveal Melanoma – Current Status and Future Directions.” Weill Cornell Medical College Department of Ophthalmology. New York, NY (2014).
186. The 2014 Paul Henkind Memorial Lecture: “Uveal Melanoma – The Present And The Future.” The 37th Annual Macula Society Meeting. Key Largo, FL (2014).
187. Invited Lecture: “Genetic Prognostication in Uveal Melanoma.” Oculoplastics Subspecialty Day. World Ophthalmology Congress. Tokyo, Japan (2014).
188. Invited Lecture: “Could FNAB Results Change the Management of Uveal Melanoma?” Ocular Oncology Symposium. World Ophthalmology Congress. Tokyo, Japan (2014).
189. Invited Lecture: “Retinoblastoma.” Operating Room Nurses. Bascom Palmer Eye Institute and Anne Bates Leach Eye Hospital. Miami, FL (2014).
190. Invited Lecture: “Current Research in Uveal Melanoma.” Solid Tumor Grand Rounds. Memorial Sloan Kettering Cancer Center. New York, NY (2014).
191. Invited Lecture: “Ocular Melanoma.” Melanoma Awareness Day. Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine. Miami, FL (2014).
192. Invited Lecture: “Modern Molecular Management Of Uveal Melanoma.” Department of Ophthalmology. Boston University School of Medicine. Boston, MA (2014).
193. The 7th Robert Haimovici Memorial Lecture: Tumors And Pseudotumors Of The Retinal Pigment Epithelium.” Department of Ophthalmology. Boston University School of Medicine. Boston, MA (2014).
194. Invited Lecture: “Retinoblastoma.” Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital. Surgical Nursing Department. University of Miami Miller School of Medicine. Miami, FL (2014).
195. The 2014 James E. McDonald, MD Lecture: "Uveal Melanoma: Current Status and Future Directions.” Department of Ophthalmology. Loyola University School of Medicine. Chicago, IL (2014).
196. Invited Lecture: “Benign Tumors and Pseudotumors of the Retina and Retinal Pigment Epithelium." Department of Ophthalmology. Loyola University School of Medicine. Chicago, IL (2014).
197. Invited Case Presentation: “Iris Medulloepithelioma.” 100 Year Celebration of New York Retinoblastoma Center. New York, NY (2014).
198. Invited Lecture: “Molecular Biology of Retinoblastoma.” 100 Year Celebration of New York Retinoblastoma Center. New York, NY (2014).
199. Invited Lecture: “Molecular and Genomic Landscape of Uveal Melanoma.” AACR Advances in Melanoma: From Biology to Therapy Special Conference. Philadelphia, PA (2014).
200. Invited Lecture: “Molecular Prognostic Testing in Cancer: Insights From Melanoma of the Eye.” BioFlorida Conference. Ft. Lauderdale, FL (2014).
201. Invited Lecture: “Uveal Melanoma: Emerging Treatments for Metastasis.” Ocular Oncology and Pathology Subspecialty Day. American Academy of Ophthalmology Annual Meeting. Chicago, IL (2014).
202. Invited Lecture: “Uveal Melanoma: The Present and The Future.” Best of Retina Meeting. New York, NY (2014).
203. Invited Lecture: “Uveal Melanoma: The Present and The Future.” North Shore-Long Island Jewish Medical Center. Long Island, NY (2014).
204. Invited Lecture: “Personalized Management of Uveal Melanoma in the Genomic Era.” Macula 2015 Meeting. Boston, MA (2015).
205. Invited Lecture: “Update on Uveal Melanoma.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
206. Invited Lecture: “Update on Retinoblastoma.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
207. Invited Lecture: “Common Intraocular Pseudotumors in Ophthalmic Practice.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
208. Invited Lecture: “Guide to Imaging Modalities in the Evaluation of Intraocular Tumors.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
209. Invited Panelist: “Ocular Oncology.” 3rd Annual Vit-Buckle Society (VBS) Meeting. Miami Beach, FL (2015).
210. Invited Lecture: “Uveal Melanoma:  Intersection of Science and Patient Care.” McKnight Vision Science Seminar Series. Bascom Palmer Eye Institute. University of Miami Miller School of Medicine (2015).
211. Invited Lecture: “Emerging Insights in Uveal Melanoma.” Department of Ophthalmology. Vanderbilt University. Nashville, TN (2015).
212. Invited Lecture: “The Role of BAP1 Mutations in Uveal Melanoma.” Epigenetics Research Symposium. Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine. Miami, FL (2015).
213. Invited Lecture: “Intraocular Tumors: A Primer for Allied Health Professionals in Ophthalmology.” Allied Health Professionals Seminar. Miami, FL (2015).
214. Invited Lecture: “The Role of BAP1 Mutations in Uveal Melanoma.” University of Michigan Kellogg Eye Center. Ann Arbor, MI (2015).
215. Invited Lecture: “Role of BAP1 Mutations in Uveal Melanoma.” University of Florida Cancer Center. Gainesville, FL (2015).
216. Invited Panelist: “Controversy of the Day: What Type of Genetic Testing Should Be Performed for Uveal Melanoma?” International Society of Ocular Oncology Biennial Meeting. Paris, France (2015).
217. Invited Lecture: “Uveal Melanoma Prognostication.” Oncology Subspecialty Day: Case-Based Presentations. The 31st Pan-American Congress of Ophthalmology. Bogota, Colombia (2015).
218. Invited Lecture: “Case Presentation of Atypical Medulloepithelioma Presenting in the Iris of a Young Child.” Ocular Oncology Session: Interpreting the Subtle and Hidden Clues. The 31st Pan-American Congress of Ophthalmology. Bogota, Colombia (2015).
219. Invited Panelist: “Bascom Palmer Eye Institute Symposium.” The 31st Pan-American Congress of Ophthalmology. Bogota, Colombia (2015).
220. Invited Lecture: “Impact of size, staging, and molecular insights on the outcome of uveal melanoma.” Ocular Oncology Symposium. The 31st Pan-American Congress of Ophthalmology. Bogota, Colombia (2015).
221. The 2015 Retina Research Foundation/Kayser Global Award Lecture: “The Harbour Laboratory: Two Decades of Discovery in Uveal Melanoma.” 31st Pan-American Congress of Ophthalmology. Bogota, Colombia (2015).
222. The 2015 Bryan St L. Liddy Lecture: “Precision Molecular Medicine in the Management of Uveal Melanoma.” The 47th Annual Sally Letson Symposium. Ottawa, Canada (2015).
223. Invited Lecture: “Advances in the Diagnosis and Treatment of Vitreoretinal Lymphoma.” The 47th Annual Sally Letson Symposium. Ottawa, Canada (2015).
224. Invited Lecture: “Current State of Uveal Melanoma.” Ocular Melanoma Foundation (September 8, 2015).
225. Invited Lecture: “Recent Advances in the Management of Retinoblastoma.” The 47th Annual Sally Letson Symposium. Ottawa, Canada (2015).
226. Invited Lecture: “Personalized medicine for ocular melanoma using genomic profiling.” 2nd Annual Personalized Medicine Conference. Moffitt Cancer Center. Tampa, FL (2015).
227. Invited Lecture: “Personalized medicine for ocular melanoma using genomic profiling.” SRI International. Menlo Park, CA (2015).
228. Invited Lecture: “Uveal Melanoma:  Intersection of Molecular Research and Patient Care.” Society for Melanoma Research Annual Meeting. San Francisco, CA (2015).
229. Invited Lecture: “Class 1 and Class 2 Uveal Melanoma.” Atlantic Coast Retina Club and Macula 2016. New York, NY (2016).
230. Invited Lecture: “Current Management of Uveal Melanoma.” Retina 2016. Hawaii, HI (2016).
231. Invited Lecture: “Current Management of Retinoblastoma.” Retina 2016. Hawaii, HI (2016).
232. Invited Lecture: “Personalized Genomic Medicine in Retina.” Retina 2016. Hawaii, HI (2016).
233. Invited Lecture: “Lymphomas of the Retina, Vitreous and Uveal Tract.” Retina 2016. Hawaii, HI (2016).
234. Invited Lecture: “Tumors and Pseudotumors of the RPE.” Retina 2016. Hawaii, HI (2016).
235. Invited Lecture: “Personalized Medicine in Ocular Tumors: Role of Next Generation Sequencing and Molecular Genetics in the Management of Cancer.” Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Center Inaugural Colloquium on Orbital Diseases. Miami, FL (2016).
236. Invited Lecture: “The State of Uveal Melanoma.” Eye Am Not Alone Patient Advocacy Meeting 2016. Miami, FL (2016).
237. Invited Lecture: “Application of Genomic Medicine to the Care of Patients with Uveal Melanoma.” Ophthalmology at the Crossroads. University of Texas Southwestern Medical School Department of Ophthalmology Annual Meeting (2016).
238. Invited Lecture: “Association Between Choroidal Nevus Risk Factors and Gene Expression Profile Prognostic Class.” The Retina Society 49th Annual Scientific Meeting. San Diego, CA (2016).
239. Invited Lecture: “Genetics of Ocular tumors.” Retina Subspecialty Day. American Academy of Ophthalmology 2016 Annual Meeting. Chicago, IL (2016).
240. Invited Lecture: “Future Applications of Uveal Melanoma Genetic Testing.” Ocular Oncology and Pathology Subspecialty Day. American Academy of Ophthalmology 2016 Annual Meeting. Chicago, IL (2016).
241. Invited Lecture: “Genomic Landscape of Uveal Melanoma.” SMR 2016 Congress. Boston, MA (2016).
242. Invited Lecture: “Customized Therapy for Uveal Melanoma.” University of Southern California Roski Eye Institute #Trending Topics in Ophthalmology. The Terranea, CA (2017).
243. Invited Contributor: World Health Organization (WHO) Classification of Tumours of the Eye, 4th Edition (2017).
244. Invited Lecture: “Intraocular Tumors: How Cancers Usurp Normal Developmental Pathways.” Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Center 2nd Annual Colloquium on Orbital Diseases. Miami, FL (2017).
245. Invited Lecture: “Interpretation of Subtle and Hidden Clues in Melanoma and Retinoblastoma.” Academica XIV Congresso Internacional. Cali, Colombia (2017).
246. Invited Lecture: “Melanoma Uveal: Update.” Academica XIV Congresso Internacional. Cali, Colombia (2017).
247. Invited Lecture: “Everything You Need To Know About the Multidisciplinary Approach.” Academica XIV Congresso Internacional. Cali, Colombia (2017).
248. Invited Lecture: “Melanoma.” Sylvester Comprehensive Cancer Center Distinguished Collaborations Series. Miami, FL (2017).
249. Invited Lecture: “Cutting Edge Discoveries In the Genetics of Uveal Melanoma.” Retina Subspecialty Day. American Academy of Ophthalmology 2017 Annual Meeting. New Orleans, LA (2017).
250. Invited Lecture: “Update on Uveal Melanoma.” University of Texas Southwestern Medical School. Dallas, TX (2018).
251. Invited Lecture: “Update on Retinoblastoma.” University of Texas Southwestern Medical School. Dallas, TX (2018).
252. Invited Lecture: “Peering Into The Past: New Insights Into The Metastatic Propensity Of Uveal Melanoma.” University of Texas Southwestern Medical School. Dallas, TX (2018).
253. Invited Lecture: “New Insights Into Cancer Metastasis: Bioinformatic Modeling Of Tumor Evolution Using Next Generation Sequencing Data In Uveal Melanoma.” BD2K-LINCS DCIC Systems Biology & Data Science Symposium. Miami, FL (2018).
254. Invited Lecture: “Eye Cancers from Melanoma to Retinoblastoma.” Southeastern Educational Congress of Optometry. Atlanta, GA (2018).
255. Invited Lecture: “Chromosomal Dysregulation by PRAME in Uveal Melanoma.” Cancer Epigenetics Faculty Meeting. University of Miami Sylvester Comprehensive Cancer Center. Miami, FL (2018).
256. Invited Lecture: “Two Decades of Discovery and Progress in Uveal Melanoma." Alcon Research Institute Bi-Annual Meeting. Chicago, IL (2018).
257. Invited Lecture: “Benefits of PRAME Testing in Uveal Melanoma.” Oncology & Pathology Subspecialty Day. American Academy of Ophthalmology 2018 Annual Meeting. Chicago, IL (2018).
258. Invited Lecture: “BAP1 in Vertebrate Development, Eye Formation and Cancer.” Interdisciplinary Stem Cell Institute Symposium. Miami, FL (2019).
259. Invited Lecture: “Genes in uveal melanoma.” Pan-American Congress of Ophthalmology. Cancun, Mexico (2019).
260. Invited Lecture: “Ocular Oncology.” Pan-American Congress of Ophthalmology. Cancun, Mexico (2019).
261. Invited Lecture: “Encouraging a Career in Medical Education.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
262. Invited Lecture: “Research in Residency Programs.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
263. Invited Lecture: “Translating Basic Science Research into Patient Care.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
264. Invited Lecture: “The Impact of Ancestry in the Outcome of Uveal Melanoma.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
265. Invited Lecture: “Anti-VEGF for Radiation Complications.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
266. Invited Lecture: “Intraocular Vascular Tumors.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
267. Invited Lecture: “Panel Discussion: Integration between Ocular Oncology and Clinical Oncology.” Brazilian Congress of Ophthalmology. Rio De Janiero, Brazil (2019).
268. Invited Lecture: “How PRAME Worsens the Prognosis in Uveal Melanoma.” American Association of Ophthalmic Oncologists and Pathologists Annual Meeting. San Francisco, CA (2019).
269. Invited Lecture: “Uveal Melanoma Prognostication Panel: GEP/PRAME.” American Association of Ophthalmic Oncologists and Pathologists Annual Meeting. San Francisco, CA (2019).
270. Invited Lecture: “Molecular Insights into Uveal Melanoma.” American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day. San Francisco, CA (2019).
271. Invited Lecture: “Role of BAP1 in Development and Uveal Melanoma.” Society for Melanoma Research Annual Meeting CURE OM Session. Salt Lake City, UT (2019).
272. Invited Lecture: “Single cell sequencing reveals new evolutionary complexity in uveal melanoma.” Society for Melanoma Research Annual Meeting. Salt Lake City, UT (2019).
273. Invited Lecture: “COOG2 as a Collaborative Model.” International Rare Cancer Initiative Meeting. Virtual Meeting (2020).
274. Keynote Address: “New Horizons in OM Discovery and Patient Care.” A Cure In Sight Eye On A Cure Patient Survivorship Virtual Seminar (2020).
275. Invited Lecture: “The Collaborative Ocular Oncology Group Uveal Melanoma Validation Study Number 2 Survey of Ocular Oncology COVID-19 Practice Patterns.” American Academy of Ophthalmology Annual Meeting Subspecialty Day. Virtual (2020).
276. Invited Panelist: Session. Research: An International Overview Live Panel Discussion. MRF CURE OM Patient & Caregiver Symposium. Virtual Meeting (2020).
277. Invited Lecture: "Genomic Evolution and Tumor Microenvironment in Uveal Melanoma." University of Utah Huntsman Cancer Institute Seminar Series. Virtual Webinar (December 16, 2020).
278. Invited Lecture: “Using Single-Cell Multiomics to Reveal New Insights into Uveal Melanoma Evolution and Therapeutic Resistance.” 10x Genomics (May 19, 2020). https://event.on24.com/wcc/r/2282615/9E8B898BBCD1C810A269FB8E5A258CCE?partnerref=10xgenomicsod
279. Invited Lecture: “Recent Patient-Oriented Research Discoveries in Uveal Melanoma.” Melanoma Research Foundation CURE OM (May 20, 2020). https://event.on24.com/wcc/r/2341082/058F5FE946DB6106A9EEFBE6B785D773
280. Invite Lecture: “PRAME and Uveal Melanoma.” International Council of Ophthalmology. World Ophthalmology Congress Virtual Webinar (May 30, 2020).
281. Invited Lecture: “What is the Molecular Basis of Malignancy in Uveal Melanoma.” International Council of Ophthalmology. World Ophthalmology Congress Virtual Webinar (June 6, 2020).
282. Invited Lecture: “Ocular Oncology for Retina Specialists.” Retina Grand Rounds. University of San Paulo (June 18, 2020). https://www.retinagrandrounds.com/aula-15-ocularoncologycasesforretin
283. Invited Lecture: “Recent Discoveries and Advances in Uveal Melanoma.” CURE OM MRF 9th Annual Science Meeting. Virtual Webinar (October 27, 2020).
284. Invited Lecture: “Molecular Cytogenetics in Uveal Melanoma.” Pan-American Ocular Oncology Society. Virtual Webinar (November 10, 2020).
285. Invited Lecture: “Applications of Single-Cell Sequencing Technology in Eye Cancer.” Illumina Single-Cell Sequencing Virtual Symposium-South (November 11, 2020).
286. Invited Lecture: “An Overview of Clinical Trials and Research in Ocular Melanoma.” Melanoma Research Foundation Ask the Expert Series. Virtual Webinar (November 24, 2020).
287. Invited Lecture: “Genetic Ancestry in Ocular Oncology.” Curso Interamericano en Oftalmología Clínica. Virtual (2020).
288. Invited Panelist: Ocular Oncology Session. Tumor Management Panel: How Would You Manage These Ocular Oncology Cases in 2021? Macula 2021. Virtual Meeting (2021).
289. Invited Lecture: “Genetics and Uveal Melanoma.” Ocular Melanoma Support Alliance Meeting. Virtual Webinar (February 25, 2021).
290. Invited Lecture: “Update on Ocular Melanoma Genetics.” A Cure In Sight Ocular Melanoma Virtual Seminar (May 12, 2021).
291. The 2021 Andrew P. Schachat Distinguished Keynote Lecture. “Uveal Melanoma Prognostication.” 3rd Annual Ohio Ocular Oncology Symposium (September 18, 2021).
292. Invited Lecture: "Uveal Melanoma: LAG3 in the Ecosystem." International Melanoma Working Group Virtual Fall Meeting (October 3, 2021).
293. Invited Lecture: “Update on Uveal Melanoma and Retinoblastoma.” Dallas Academy of Ophthalmology Spring Meeting (March 31, 2022).
294. Invited Lecture: “Update on Uveal Melanoma and Retinoblastoma.” Texas Ophthalmological Association Annual Meeting (April 29, 2022).
295. Invited Lecture: “Perspectives on Vision Health.” UT Southwestern Medical Center Patient Services Committee Quarterly Meeting (May 2, 2022).
296. Invited Lecture: “Metastatic Drivers in Uveal Melanoma.” UT Southwestern Medical Center Cellular Networks in Cancer Program (May 3, 2022).
297. Invited Lecture: “Update on Uveal Melanoma and Retinoblastoma.” University of Nebraska Medical Center Truhlsen Eye Institute Distinguished Lecture Series (May 6, 2022).
298. Invited Lecture: “Liquid Biopsy in Ocular Oncology – Ready for Prime Time?” Retina World Congress Annual Meeting (May 15, 2022).
299. The 2022 Herman Knapp Symposium Lecture: “Gene-Based Prognosis and Beyond in Ocular Oncology.” 138th Annual Meeting of the American Ophthalmological Society (May 20, 2022).
300. Invited Lecture: “Metastatic Drivers in Uveal Melanoma.” University of Louisville Brown Cancer Center Seminar Series (June 8, 2022).
301. The 2022 Prof. dr. A.J. van der Eb Lecture: “Metastatic Drivers in Uveal Melanoma.” 20th Congress of the International Society of Ocular Oncology. Leiden, The Netherlands (June 17, 2022).
302. Invited Lecture: “Contemporary Precision Diagnosis and Management of Vitreoretinal Lymphoma.” American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day. Chicago, IL (September 30, 2022).
303. Invited Lecture: “Interaction of Tumor Genome and Microenvironment in Uveal Melanoma.” Pan American Society for Pigment Cell Research (PASPCR) Virtual Seminar Series (November 15, 2022).
304. Invited Lecture: “Cancer of the Eye: Intersection of Genomics, Immunity and Precision Medicine.” UT Southwestern Medical Center President’s Research Council Series, Dallas, TX (January 24, 2023).
305. Invited Lecture: “Interaction of Tumor Genome and Microenvironment in Uveal Melanoma”. UT Southwestern Medical Center McDermott Center Works-In-Progress and Huma Genetics Series (February 10, 2023).
306. Invited Lecture: “Comprehensive Molecular Characterization of 288 Small Uveal Melanomas: New Insight to Inform Clinical Management”. 46th Annual Macula Society Meeting, Miami, FL (February 15, 2023).
307. Invited Lecture: “Update in Intra-Ocular Tumors”. 35th Annual Pan American Congress of Ophthalmology, Buenos Aires, Argentina (March 18, 2023).
308. Invited Lecture: “Minimally Invasive Eye Surgery: A View to Better Vision.” UT Southwestern Medical Center Carolyn P. Horchow Women’s Health Symposium, Dallas, TX (March 23, 2023).
309. Invited Lecture: “The History and Future of Ocular Melanoma.” A Cure In Sight: The Eye Believe Podcast (September 28, 2023).
310. The 2023 Drouilhet Lecture: “Latest Advances in Uveal Melanoma.” Dept. of Ophthalmology and Visual Science, UTHealth Houston McGovern Medical School, Houston, TX (March 31, 2023).
311. Invited Lecture: “Research Leads to Hope in Uveal Melanoma.” IMPACT Melanoma Summer 2023 Symposium Webinar (June 28, 2023).
312. Invited Lecture: “Discovering New Therapeutic Targets in Retinoblastoma.” Alex’s Lemonade Stand Foundation (ALSF) Childhood Cancer Series Webinar (August 9, 2023).
313. Invited Lecture: “The History & Future of Ocular Melanoma.” A Cure in Sight Webinar (September 28, 2023).
314. Invited Lecture: “PRAME and Other Markers.” Ocular Oncology and Pathology Subspecialty Day, American Academy of Ophthalmology Annual Meeting. San Francisco, CA (November 3, 2023).
315. Invited Panelist: “Roundtable Discussion: When, Who, and How.” Ocular Oncology and Pathology Subspecialty Day. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (November 3, 2023).
316. Invited Panelist: “Oncology Panel Discussion.” Retina Subspecialty Day. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (November 3, 2023).
317. Invited Lecture: “Single-cell elucidation of the immune microenvironment and its association with canonical genetic aberrations in uveal melanoma.” Society for Melanoma Research. Philadelphia, PA (November 7, 2023).
318. Invited Lecture: “Advances in Precision Medicine for Uveal Melanoma.” Ocular Oncology Happy Hour 6th Episode Webinar (January 13, 2024)
319. Invited Lecture: “Eye On COOG – An Ocular Melanoma Update.” A Cure in Sight – The Eye Believe Mini Seminar Podcast (January 6, 2024).
320. Invited Lecture: “How Driver Mutations Allow Uveal Melanomas to Evade the Immune System: The Latest Insights from Single-Cell Sequencing.” Wills Eye Conference, Philadelphia, PA (March 7, 2024).
321. Invited Lecture: “Precision Ocular Oncology: Harnessing the Power of Modern Genetics.” Wills Eye Conference, Philadelphia, PA (March 7, 2024).

Visiting Professorships

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Visiting Professor: Dept. of Ophthalmology. Emory University. Atlanta, GA (2001).
2. Visiting Professor: Dept. of Ophthalmology & Visual Sciences. University of Wisconsin, Madison, WI (2002).
3. Visiting Professor: Dept. of Ophthalmology & Visual Sciences. University of Illinois at Chicago, IL (2003).
4. Visiting Professor: Dept. of Pediatric Oncology. Memorial Sloan Kettering Cancer Center. New York, NY (2003).
5. Visiting Professor: Dept. of Ophthalmology. University of Louisville. Louisville, KY (2003).
6. Visiting Professor: Dept. of Ophthalmology. University of Washington. Seattle, WA (2003).
7. Visiting Professor: Dept. of Ophthalmology. University of Pennsylvania. Philadelphia, PA (2004).
8. Visiting Professor: Dept. of Ophthalmology. Tulane University. New Orleans, LA (2005).
9. Visiting Professor: Dept. of Ophthalmology. University of Missouri. Kansas City, MO (2007).
10. Visiting Professor: Dept. of Ophthalmology. University of California. San Francisco, CA (2007).
11. Visiting Professor: Melanoma Research Program. University of Colorado. Denver, CO (2007).
12. Visiting Professor: Dept. of Ophthalmology. University of Virginia. Charlottesville, VA (2008).
13. Visiting Professor: Dept. of Ophthalmology. Mayo Clinic. Rochester, MI (2008).
14. Visiting Professor: Dept. of Ophthalmology. University of Pennsylvania. Philadelphia, PA (2008).
15. Visiting Professor: Dept. of Ophthalmology. Duke University. Durham, NC (2009).
16. Visiting Professor: Dept. of Ophthalmology. University of Michigan. Ann Arbor, MI (2009).
17. Visiting Professor: Dept. of Ophthalmology and Brown Cancer Center. University of Louisville, KY (2009).
18. Visiting Professor: Dept. of Ophthalmology. East Virginia Medical University. Norfolk, VA (2009).
19. Visiting Professor: Ocular Oncology Service. Royal Liverpool Hospital. Liverpool, UK (2009).
20. Visiting Professor: University of Pittsburgh Cancer Center. Pittsburgh, PA (2009).
21. Visiting Professor: Dept. of Pathology. Johns Hopkins University. Baltimore, MD (2010).
22. Visiting Professor: Dept. of Pathology, Ophthalmology, Dermatology and Melanoma SPORE Program. Yale University. New Haven, CT (2010).
23. Visiting Professor: Markey Cancer Center and Dept. of Ophthalmology. University of Kentucky. Lexington, KY (2011).
24. Visiting Professor: Dept. of Ophthalmology. Case Western Reserve Univ. Cleveland, OH (2011).
25. Visiting Professor: New York Eye and Ear Infirmary. New York, NY (2011).
26. Visiting Professor: Dept. of Ophthalmology. Emory University. Atlanta, GA (2011).
27. Visiting Professor: Dept. of Ophthalmology. Columbia University. New York, NY (2012).
28. Visiting Professor: Dept. of Ophthalmology. University of Ottawa. Ontario, Canada (2012).
29. Visiting Professor: Mount Sinai School of Medicine and Tisch Cancer Institute. New York, NY (2013).
30. Visiting Professor: Dept. of Ophthalmology. King Saud University. Riyadh, Saudi Arabia (2013).
31. Visiting Professor: Dept. of Ophthalmology. Boston University. Boston, MA (2014).
32. Visiting Professor: Dept. of Ophthalmology. North Shore-Long Island Jewish Medical Center. Long Island, NY (2014).
33. Visiting Professor: Dept. of Ophthalmology. Vanderbilt University. Nashville, TN (2015).
34. Visiting Professor: Dept. of Ophthalmology & Visual Sciences. University of Michigan Kellogg Eye Center. Ann Arbor, MI (2015).
35. Visiting Professor: University of Florida Cancer Center. Gainesville, FL (2015).
36. Visiting Professor: Division of Surgical Oncology and Dept. of Ophthalmology & Visual Sciences. Washington University. St. Louis, MO (2016).
37. Visiting Professor: Dept. of Ophthalmology. University of Texas Southwestern Medical School. Dallas, TX (2018).
38. Visiting Professor: Dept. of Ophthalmology and Visual Sciences. University of Nebraska. Omaha, NE (May 20, 2022).
39. Visiting Professor: Dept. of Ophthalmology, Shiley Eye Institute, University of California, San Diego Grand Rounds Visiting Professor (November 14, 2022).
40. Visiting Professor: Dept. of Ophthalmology and Visual Science, UTHealth Houston McGovern Medical School, Houston, TX (March 31, 2023).

Educational Courses and Seminars

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Instructor: Uveitis Course. “Masquerade syndromes.” American Academy of Ophthalmology Annual Meeting (1998).
2. Instructor: Diseases of the Retina and Vitreous Course. “Intraocular tumors.” American Academy of Ophthalmology Annual Meeting (2000-2003).
3. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2004).
4. Instructor: Retinoblastoma Course. “Molecular update on retinoblastoma.” American Academy of Ophthalmology Annual Meeting (2004-2007).
5. Instructor: Diagnostic Imaging of Ocular Tumors Course. “Cytologic and molecular diagnostics in ocular oncology.” American Academy of Ophthalmology Annual Meeting (2004).
6. Breakfast With The Experts: “Ocular tumors.” American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2004).
7. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2005).
8. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2006).
9. Course Director and Senior Instructor: LEO Clinical Update Course on Ocular Oncology. American Academy of Ophthalmology Annual Meeting (2006-2009).
10. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2007).
11. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2008).
12. Instructor: Ocular Oncology Course. “Clinical trials in uveal melanoma.” American Academy of Ophthalmology Annual Meeting. Atlanta, GA (2008).
13. Instructor: Ocular Oncology Course. “AJCC TNM Classification: Retinoblastoma.” American Academy of Ophthalmology Annual Meeting. Atlanta, GA (2008).
14. Course Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2009).
15. Senior Instructor: Ocular Oncology Course. “Prognostic Factors for Metastasis from Primary Choroidal Melanoma.” American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
16. Instructor: Ocular Oncology Course. “Persisting Controversies in Management of Posterior Uveal Melanomas.” American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
17. Instructor: Ocular Oncology Course. “Spectrum Of Choroidal Melanocytic Lesions.” American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2009).
18. Course Co-Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2010).
19. Instructor: Ocular Oncology Course. “Controversies in Retinoblastoma.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2010).
20. Instructor: Ocular Oncology Course. “Controversies in Uveal Melanoma.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2010).
21. Course Co-Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2011).
22. Course Co-Director and Instructor: Ocular Oncology Course. Association for Research in Vision and Ophthalmology Annual Meeting (2012).
23. Instructor: “Update on Posterior Segment Tumors.” Curso Interamericano en Oftalmología Clínica. Miami, FL (2012).
24. Course Co-Director and Instructor: Ocular Oncology Course. “Controversies in Retinoblastoma.” Association for Research in Vision and Ophthalmology Annual Meeting (2013).
25. Instructor: “Challenges Cases in Ocular Oncology.” Pan-American Congress of Ophthalmology Annual Meeting. Rio De Janeiro, Brazil (2013).
26. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
27. Meet The Expert: “Ocular tumors.” Retina Subspecialty Day. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
28. Instructor: “Lumps and bumps in the eye.” Curso Interamericano en Oftalmología Clínica. Miami, FL (2013).
29. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2014).
30. Instructor: “A tumor on the eye: benign or malignant?” Curso Interamericano en Oftalmología Clínica. Miami, FL (2014).
31. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. Las Vegas, NV (2015).
32. Invited Lecture: “Update on Uveal Melanoma.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
33. Instructor: “Update on Retinoblastoma.” El Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
34. Instructor: “Common Intraocular Pseudotumors in Ophthalmic Practice.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
35. Instructor: “Guide to Imaging Modalities in the Evaluation of Intraocular Tumors.” El I Curso Conjunto Entre El Bascom Palmer Eye Institute y La Sociedad Nacional de Oftalmología y Ortóptica Ecuador. Guayaquil, Ecuador (2015).
36. Invited Lecture: “Recent Advances in the Management of Retinoblastoma.” Curso Interamericano en Oftalmología Clínica. Miami, FL (2015).
37. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2016).
38. Instructor: “Current Management of Choroidal Nevus and Melanoma.” Curso Interamericano en Oftalmología Clínica. Miami, FL (2016).
39. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2017).
40. Instructor: “Lumps and Bumps in the Eye – Differential Diagnosis of Intraocular Tumors.” Curso Interamericano en Oftalmología Clínica. Miami, FL (2017).
41. Instructor: Ocular Oncology Course. “Practical Ocular Oncology for the Comprehensive Ophthalmologist.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2018).
42. Instructor: Ocular Oncology Course. “The Great Controversies in Ocular Oncology.” American Academy of Ophthalmology Annual Meeting. Chicago, IL (2018).
43. Instructor: "The Great Controversies in Ocular Oncology: A Course for Non-Ocular Oncologists.” American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2019).
44. Instructor: Ocular Oncology Course. Practical Ocular Oncology for the Comprehensive Ophthalmologist: What You Should Know. “Primary Vitreoretinal Lymphoma.” American Academy of Ophthalmology Annual Virtual Meeting. (2020).
45. Instructor: The Great Controversies in Ocular Oncology: A Course for Non-Ocular Oncologists. “Proton Beam for Uveal Melanoma - Con.” American Academy of Ophthalmology Annual Meeting. Virtual (2020).
46. Instructor: “Genetic Ancestry in Ocular Oncology.” Curso Interamericano en Oftalmología Clínica. Virtual (2020).
47. Faculty Discussant: Ocular Oncology Clinicopathologic Correlation Conference. Bascom Palmer Eye Institute. Virtual Webinar (August 27, 2020)
48. Faculty Discussant: Ophthalmology Grand Rounds. "Multiple Retinal Lesions in Asymptomatic 40-Year-Old Patient." Bascom Palmer Eye Institute. Virtual Webinar (September 17, 2020).
49. Pediatric Oncology Site Disease Group. "Retinoblastoma Program." Sylvester Comprehensive Cancer Center. Virtual Webinar (October 1, 2020).
50. Faculty Discussant: Ocular Oncology Clinicopathologic Correlation Conference. Bascom Palmer Eye Institute. Virtual Webinar (November 4, 2020).
51. Instructor: “Practical Ocular Oncology for the Comprehensive Ophthalmologist: What You Should Know.” On Demand Course (Abstract 30066067). American Academy of Ophthalmology (2021).
52. Faculty Discussant: Ophthalmology Grand Rounds. Bascom Palmer Eye Institute. Virtual Webinar (April 8, 2021).
53. Faculty Discussant: Ophthalmology Grand Rounds. Bascom Palmer Eye Institute. Virtual Webinar (May 20, 2021). Instructor: “Practical Ocular Oncology for the Comprehensive Ophthalmologist: What You should Know”. American Academy of Ophthalmology Annual Meeting. Chicago, IL (October 1, 2022).
54. Instructor: “Keys to the Management of Suspicious Choroidal Nevi”. 36th Mid-Winter Sarasota Vitreo-Retinal Update Course (February 17, 2023).
55. Instructor: “Breakthroughs in the Management of Uveal Melanoma”. 36th Mid-Winter Sarasota Vitreo-Retinal Update Course (February 17, 2023).
56. Instructor: “Differential Diagnosis of Non-Melanocytic Pigmented Intraocular Lesions”. 36th Mid-Winter Sarasota Vitreo-Retinal Update Course (February 18, 2023).
57. Instructor: “Practical Ocular Oncology for the Comprehensive Ophthalmologist: What You Should Know.” American Academy of Ophthalmology Annual Meeting. San Francisco, CA (November 5, 2023).

Meetings Organized, Chaired & Moderated

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Moderator: Ocular Oncology Paper Sessions. ARVO Annual Meeting. Ft. Lauderdale, FL (1999-2006).
2. Moderator: Uveal Melanoma Genetics Special Interest Group. Ft. Lauderdale, FL (2000).
3. Moderator: Paper session. ISGED/International Retinoblastoma Meeting. Ft. Lauderdale, FL (2000).
4. Moderator: Uveal Melanoma Research Symposium. Leiden, The Netherlands (2001).
5. Co-organizer. Molecular Technologies in Ocular Oncology ARVO Symposium. Ft. Lauderdale, FL (2002).
6. Organizer: Washington University Cancer Biology Study Group (2004).
7. Moderator: Ocular Oncology Paper Session. Retina Society Annual Meeting. San Francisco, CA (2004).
8. Moderator: Chromosome 3 in Uveal Melanoma Paper Session. International Congress of Ocular Oncology. Whistler, Canada (2005).
9. Moderator: Metastatic Risk Paper Session. International Congress of Ocular Oncology. Whistler, Canada (2005).
10. Moderator: Genetic and Pathologic Basis Of Eye Disease Symposium. American Academy of Ophthalmology Annual Meeting. Chicago, IL (2005).
11. Moderator: Ocular Oncology Session. New York Retina Meeting. New York, NY (2006).
12. Moderator: Ocular Oncology Paper Session. Macula Society Annual Meeting. San Diego, CA (2006).
13. Moderator: Contemporary Management of Primary Intraocular Lymphoma Session. American Uveitis Society Winter Meeting. Snowmass, CO (2007).
14. Organizer: International Society of Ocular Oncology Research Day. Sienna, Italy (2007).
15. Moderator: Melanoma Research Paper Session. International Society of Ocular Oncology Biennial Meeting. Sienna, Italy (2007).
16. Chair & Moderator: Oncology Paper Session. Macula Society. Palm Beach, FL (2008).
17. Organizer & Chair: International Congress of Ocular Oncology Research Day. Cambridge, United Kingdom (2009).
18. Moderator: International Congress of Ocular Oncology Uveal Melanoma Session. Cambridge, United Kingdom (2009).
19. Chair: Genetics of Uveal Melanoma Session. Ocular Melanoma Scientific Working Group Symposium. Dana Farber Cancer Institute. Boston, MA (2009).
20. Chair: Clinical Problems in Oncology Session on Ocular Melanoma. American Society of Clinical Oncology Annual Meeting. Chicago, IL (2010).
21. Organizer & Chair: International Society of Ocular Oncology Research Day. Buenos Aires, Argentina (2011).
22. Moderator: European Ocular Oncology Group Meeting. Paris, France (2012).
23. Section Leader: Personalized Medicine Section, Sylvester Comprehensive Cancer Center Retreat. Miami, FL (2013).
24. Session Chair: Diagnostic, and Therapeutic Advances for Ocular Melanoma. American Society of Clinical Oncology Annual Meeting. Chicago, IL (2013).
25. Moderator: Uveal Melanoma Session. International Society of Ocular Oncology Biennial Meeting. Cleveland, OH (2013).
26. Session Chair: Advances in Melanoma Pathogenesis and Risk. AACR Special Conference – Advances in Melanoma: From Biology to Therapy. Philadelphia, PA (2014).
27. Moderator: Retina Subspecialty Day. Ocular Oncology Panel Discussion. American Academy of Ophthalmology Annual Meeting. Las Vegas, NV (2015).
28. Moderator: Oculoplastics Paper Session. American Academy of Ophthalmology Annual Meeting. Las Vegas, NV (2015).
29. Moderator: Uveal Melanoma: Translating Research into Clinical Advances for Patients. Society for Melanoma Research Annual Meeting. San Francisco, CA (2015).
30. Session Chair: Uveal Melanoma: Biology, Immunology, and Therapy. Society for Melanoma Research Annual Meeting. Boston, MA (2016).
31. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Working Group Meeting. Dallas, TX (January 2017).
32. Moderator: Oncology Paper Session. Macula Society. Beverly Hills, CA (2018).
33. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Working Group Meeting. Dallas, TX (January 2018).
34. Session Chair: Ocular Oncology. Retina World Congress. Fort Lauderdale, FL (2019).
35. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Working Group Meeting. Dallas, TX (February 2019).
36. Moderator: Principles & Practice of Pan-American Ocular Oncology #2. Pan-American Congress of Ophthalmology. Cancun, Mexico (2019).
37. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Working Group Meeting. Dallas, TX (February 2020).
38. Moderator & Speaker: Single Cell Technologies and Application, Session 6. FACCA Virtual Retreat. (2020).
39. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Virtual Working Group Meeting. (January 2021).
40. Moderator and Co-Organizer: Collaborative Ocular Oncology Group/Castle Biosciences Winter Working Group Meeting. Dallas, TX (January 2022).
41. Moderator: Genetics and Epigenetics. 20th Congress of the International Society of Ocular Oncology. Leiden, The Netherlands (June 2022).
42. Chair: Physicians’ Education Resource, “Ophthalmology and Oncology Perspectives on Bispecific Antibodies for Uveal Melanoma Treatment.” Chicago, IL (October 2022).
43. Organizer and Moderator: Collaborative Ocular Oncology Group Annual Investigators’ Meeting/Castle Biosciences Advisory Meeting. Dallas, TX (January 2023).

Meeting Presentations and Posters

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 1. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the retinoblastoma gene in small cell lung cancer. Fifth World Conference on Lung Cancer. Interlaken, Switzerland. Lung Cancer 1988; 4A:26.

 2. Minna J, Battey J, Birrer MJ, Carmichael J, Cuttitta F, DeGreve J, Glatstein E, Harbour JW, et al. Lung cancer cell lines, autocrine growth factors, chromosomal deletions, and oncogene activation int he study of the biology and pathogenesis of lung cancer. Int J Radiat Oncol Biol Phys 1988; 15S:111-112.

 3. Wanless IR, Harbour JW, Boitnott JK, Moore GW. Non-cirrhotic portal hypertension: an autopsy study of 32 patients from the Johns Hopkins Hospital, 1910-1984. Hepatology 1988; 8:1345.

 4. Harbour JW, Johnson BE, Gazdar AF, Minna JD, Kaye FJ. Abnormalities of the retinoblastoma gene in small cell cancer of extrapulmonary origin. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1989; 8A:213.

 5. Minna JD, Kaye F, Takahashi T, Nau M, Birrer M, Rosenberg R, Vinacour M, Johnson B, Levitt M, Harbour JW, Whang-Peng J, Miller Y, Gazdar A. Inactivation of the RB, p53 and 3p21 genes in human lung cancer. Proceedings of the National Cancer Institute Meeting on T-Antigen & Protooncogene Interactions. Bethesda, MD (1989).

 6. Harbour JW, DePotter P, Shields CL, Shields JA. Metastasis of carcinoid tumors to the eye and orbit. Association for Research in Vision and Ophthalmology Annual Meeting. Sarasota, FL (2004).

 7. Harbour JW, Eagle RC Jr, Augsburger JJ. Initial management and follow-up of melanocytic iris tumors. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (1994).

 8. Maumenee IH, Harbour JW. Linkage analysis in the Swiss family with vitreoretinopathy originally described by Wagner. American Academy of Ophthalmology Annual Meeting. San Francisco, CA (1994).

 9. O’Brien JM, Harbour JW, Smith B, Cohen J, Char DH, Kroll S, Murray TG. Utility of initial metastatic tests and serial bone scans in patients with retinoblastoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (1995).

 10. Harbour JW, Murray TG, Markoe A, Valor N, Hernandez E, Markoe A, Keller B, Schoenike S, Smith B, O’Brien JM. In vivo efficacy of locally delivered carboplatin and external beam irradiation in murine retinoblastoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (1995).

 11. Harbour JW, Char DH, Kroll S, Quivey JM. Metastatic risk for distinct patterns of post-irradiation local recurrence of posterior uveal melanoma. American Academy of Ophthalmology Annual Meeting. Atlanta, GA (1995).

 12. Harbour JW, Luo RX, Dean DC. Regulation of retinoblastoma protein activity by the C-terminal domain. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (1997).

13. Harbour JW. Overview of RB gene mutations in retinoblastoma patients: implications for clinical genetic screening. American Academy of Ophthalmology Annual Meeting (1997).

 14. Busquets M, Cousins S, Harbour JW. Photoreceptor apoptosis in giant retinal tears. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (1999)

 15. Harbour JW. New molecular insights into the pathogenesis of retinoblastoma. International Congress of Ocular Oncology. Philadelphia, PA (1999).

1. Harbour JW. Tumor suppressor genes in the pathogenesis of intraocular tumors. International Congress of Ocular Oncology. Philadelphia, PA (1999).
2. Harbour JW, Brantley MA, Jr. Functional inactivation of the retinoblastoma protein in posterior uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2000).
3. Brantley MA, Jr, Harbour JW. Functional inactivation of the p53 tumor suppressor pathway in posterior uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2000).
4. Brantley MA, Jr, Harbour JW. Molecular changes associated with local therapy of uveal melanomas. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2001).
5. Harbour JW, Cohen M, Worley L. Targeted molecular therapy for uveal melanoma and retinoblastoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2001).
6. Brantley M, Harbour JW, Gordon ME, Hollingsworth H. Uveal pigmentation as a risk factor for posterior uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2002).
7. Foster WJ, Harbour JW. Alterations of the neurofibromatosis type 1 tumor suppressor locus in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2003).
8. Harbour JW, Worley L, Wu J. Disruption of the Rb and p53 tumor suppressor checkpoints occurs early in the transformation of uveal melanocytes. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2003).
9. Harbour JW, El-Bash M, Ahmad S. Rate of resolution of exudative retinal detachment following plaque radiotherapy for uveal melanoma. Combined Meeting of the Retina and Vitreous Societies. San Francisco, CA (2002).
10. Foster WJ, Harbour JW, Shah G. Pars plana vitrectomy in eyes previously treated for uveal melanoma. Combined Meeting of the Retina and Vitreous Societies. San Francisco, CA (2002).
11. Harbour JW, Meredith TA. Transpupillary thermotherapy versus plaque radiotherapy for uveal melanoma. Combined Meeting of the Retina and Vitreous Societies. San Francisco, CA (2002).
12. Harbour JW, Worley L, Onken M, Ma D, Zhou P. Phosphorylation status of Rb in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2003).
13. Harbour JW, Worley L. Gene expression microarray analysis in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2003).
14. Harbour JW, Espinoza G, Rosenblatt B. Optical coherence tomography in the evaluation of suspicious choroidal melanocytic tumors. Retina Society Annual Meeting (2003).
15. Harbour JW. Potential for gene therapy in ocular tumors. American Academy of Ophthalmology Annual Meeting (2003).
16. Farkas T, Harbour JW, Davila RM. Vitreous fluid cytology in the diagnosis of malignant intraocular lymphoma. American Society for Cytopathology Annual Meeting (2003).
17. Harbour JW, Onken MD. Molecular predictive testing in uveal melanoma. Retina Society Annual Meeting. San Diego, CA (2004).
18. Harbour JW, Onken MD, Worley LA. Molecular prediction of time to metastasis from ocular melanoma fine needle aspirates. AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development (2006).
19. Harbour JW. Young patient with large uveal tumor. Ocular Imaging Conference. Las Vegas, NV (2006).
20. Harbour JW, Onken MD, Worley LA, Onken MD. Link between melanoma stem cell and metastasis. Keystone Symposium on Stem Cells and Cancer (2007).
21. Sharma K, Gould JE, Harbour JW, Linette GP, Dayani PN, Brown DB. Survival following hepatic arterial chemoembolization for liver dominant melanoma metastases. Society of Interventional Radiology 32nd Annual Meeting (2007).
22. Stroud JS, Harbour JW, Ramaiya KJ, Mansur DB, Lin HS, Grigsby PW. Treatment outcomes after iodine-125 plaque brachytherapy for uveal melanoma. GEC-ESTRO-ISIORT Europe Meeting (2007).
23. Harbour JW. Choroidal nerve sheath tumor. Ocular Imaging Conference. New Orleans, LA (2007).
24. Landreville S, Agapova O, Harbour JW. Isolation and characterization of cancer stem cells in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2009).
25. Rajagopal R, Harbour JW. Silencing of mitf, the master regulatory gene for melanocyte differentiation located on chromosome 3, results in profound changes in the phenotype of uveal melanoma cells. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2009).
26. Correa ZM, Augsburger JJ, Simoes CC, Harbour JW. Association between gene expression profile classification and cytopathologic cell type of melanocytic uveal tumors evaluated by FNAB. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2009).
27. Simoes CC, Augsburger JJ, Correa ZM, Harbour JW. Association between gene expression profile classification and thickness of melanocytic uveal tumors evaluated by FNAB. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2009). Awarded the Santen Prize for outstanding abstract from a Pan-American country.
28. Augsburger JJ, Correa ZM, Simoes CC, Harbour JW. Heterogeneity of gene expression (GEP) signature in melanocytic uveal tumors sampled at two sites by FNAB. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2009).
29. Harbour JW. Iris metastasis. Ocular Imaging Conference. Atlanta, GA (2009).
30. Correa ZM, Augsburger JJ, Harbour JW. Association between gene expression profile classification (GEP) and cytopathologic cell type of melanocytic uveal tumors evaluated by fine needle aspiration biopsy (FNAB). 17th Congress of the European Society of Ophthalmology (2009). Amsterdam, the Netherlands. Selected as Best Poster to be presented at special paper session.
31. Harbour JW. A novel oncogene mutation in uveal melanoma. International Congress of Ocular Oncology. Cambridge, United Kingdom (2009).
32. Harbour JW. Prospective validation of the uveal melanoma gene expression profile prognostic assay in fine needle biopsy and enucleation specimens. Combined Meeting of the Macula Society, Retina Society and American Society of Retina Specialists. New York, NY (2009).
33. Correa ZM, Augsburger JJ, Harbour JW. Gene expression profile class versus tumor thickness, cytopathology and sample heterogeneity of melanocytic uveal tumors evaluated by FNAB. Combined Meeting of the Macula Society, Retina Society and American Society of Retina Specialists. New York, NY (2009).
34. Harbour JW. A middle-aged woman with recent onset diplopia. Ocular Imaging Conference. San Francisco, CA (2009).
35. Harbour JW, Worley LA, Onken MD. Prospective validation of the uveal (ocular) melanoma gene expression profile (UM-GEP) prognostic assay in fine needle biopsy specimens. National Cancer Institute Translational Science Meeting. Vienna, VA (2009).
36. Hou P, Harocopos G, Harbour JW, Ylagan LR. The role of fine needle aspiration biopsy in management of uveal melanoma patients. 17th International Congress of Cytology. Edinburgh, United Kingdom (2010).
37. Harbour JW, Onken MD, Worley LA. Association between gene expression profile, proliferative index and metastasis in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2010).
38. Landreville S, Agapova OA, Harbour JW. The cell surface glycoprotein ABCB1 identifies a highly aggressive subpopulation of uveal melanoma cells. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2010).
39. Asnaghi L, Coonfield M, Schreck K, Bar E, Handa J, Merbs S, Ebrahimi K, Harbour JW, Eberhart CG. Notch signaling: a new potential target in the treatment of ocular melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2010).
40. Correa ZM, Augsburger JJ, Harbour JW. Gene expression profile class versus cytopathologic diagnosis of melanocytic uveal tumors evaluated by fine needle aspiration biopsy. American Academy of Ophthalmology Annual Meeting. Chicago, IL (2010).
41. Correa ZM, Augsburger JJ, Harbour JW. Correlation between gene expression profile class, cytology, and size of melanocytic uveal tumors evaluated by FNAB. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2011).
42. Simoes CC, Harbour JW, Halaban R, Bacchiocchi A, Materin MA. Comparative study of oncogenic mutations and standard prognostic risk factors for metastasis in uveal melanomas cell lines established by FNAB. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2011).
43. Rajagopal R, Rao PK, Harbour JW. Safety of pars plana vitrectomy in eyes containing a treated uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Ft. Lauderdale, FL (2011).
44. Kim IK, MacConaill L, Palescandolo E, Lu S, Lee JE, Adams S, Van Hummelen P, Daniels A, Garraway L, Harbour JW, Gragoudas ES. Oncogene mutation profiling in ocular melanoma. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
45. Corrêa ZM, Augsburger JJ, Harbour JW. Correlation between GEP and other prognostic factors for metastatic death in 205 patients with posterior uveal melanoma evaluated by FNAB. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
46. Eberhart C, Ebrahimi K, Schreck K, Bar E, Harbour JW, Handa J, Merbs S, Asnaghi L. Notch signaling promotes uveal melanoma growth. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
47. Wilson DJ, Harbour JW. Use of a microcatheter to obtain biopsies from uveal melanoma. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
48. Harbour JW, Onken MD, Worley WA, Bowcock AM, Roberson E. Inactivating mutations in BAP1 in metastasizing class 2 uveal melanomas. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
49. Materin MA, Simoes, Halaban R, Harbour JW. BAP 1 mutation in two families with uveal melanoma. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
50. Harbour JW. 65-year old woman with diffuse conjunctival neoplasm. International Congress of Ocular Oncology. Buenos Aires, Argentina (2011).
51. Harbour JW. Risk of metastasis associated with fine needle biopsy in uveal melanoma. Retina Society Annual Meeting. Washington D.C. (2012).
52. Kumar G, Kymes S, Harbour JW. A cost-effectiveness approach to treatment of medium-sized choroidal melanomas. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, FL (2012).
53. Badiyan S, Grigsby P, Harbour JW. Incidence and treatment of toxicity following i-125 episcleral plaque brachytherapy for uveal melanoma. American Brachytherapy Society Annual Meeting. New Orleans, LA (2013).
54. Harbour JW. Association between genetic mutations and clinical outcomes in
uveal melanoma. Macula Society Annual Meeting. Dana Point, CA (2013).
55. Rao RC, Badiyan SN, Harbour JW. Association between regression rate and gene expression profile class in uveal melanomas undergoing iodine-125 plaque brachytherapy. American Society of Retina Specialists Annual Meeting. Toronto, Canada (2013).
56. Harbour JW. Update on the gene expression profile prognostic test for posterior uveal melanoma, iris melanoma and small choroidal melanocytic tumors. International Society of Ocular Oncology Biennial Meeting. Cleveland, OH (2013).
57. Harbour JW. Mutational landscape in uveal melanoma. International Society of Ocular Oncology Biennial Meeting. Cleveland, OH (2013).
58. Harbour JW. Patient referred for presumed ring melanoma. International Society of Ocular Oncology Biennial Meeting. Cleveland, OH (2013).
59. Chen RW, Harbour JW. Acute inflammatory regression of class 1 posterior uveal melanomas following I-125 plaque radiotherapy. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
60. Rao R, Harbour JW. Acute inflammatory regression of class 1 posterior uveal melanomas following I-125 plaque radiotherapy. American Academy of Ophthalmology Annual Meeting. New Orleans, LA (2013).
61. Chao D, Harbour JW. Relationships between clinical features, molecular classification, and driver gene mutation status in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Orlando, FL (2014).
62. Walter SD, Harbour JW. Clinical predictors of survival after hepatic arterial chemoembolization for stage IV uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Orlando, FL (2014).
63. Ortiz AG, Gonzalez MA, Harbour JW, Ayres B. Natural history of circumscribed choroidal hemangiomas. Association for Research in Vision and Ophthalmology Annual Meeting. Orlando, FL (2014).
64. Tenzel P, Gonzalez MA, Bermudez A, Harbour JW. Ciliary body melanocytomas: ultrasonographic characteristics and natural course in 9 patients. Association for Research in Vision and Ophthalmology Annual Meeting. Orlando, FL (2014).
65. Walter SD, Harbour JW. Factors associated with better ocular and systemic outcomes in primary vitreoretinal lymphoma. American Society of Retina Specialists Annual Meeting. San Diego, CA (2014).
66. Field MG**,** Dien P, Decatur C, Kuznetsov JN, Harbour JW. Detecting immune cell infiltration in metastatic uveal melanoma based on gene expression. University of Miami Cancer Symposium: Cancer Prevention & Treatment. Miami, FL (2014).
67. Decatur CL, Gonzalez M, Zuchner S, Harbour JW. Whole exome sequencing of retinoblastomas. Sylvester Comprehensive Cancer Center Cancer Retreat, University of Miami Miller School of Medicine. Miami, FL (2014).
68. Field MG,Dien P, Decatur C, Kuznetsov JN, Harbour JW. Detecting immune cell infiltration in metastatic uveal melanoma based on gene expression. 6th Annual MD/PhD Research Symposium. University of Miami Miller School of Medicine. Miami, FL (2014).
69. Field MG,Pelaez D, Harbour JW**.** Retinoblastoma as a model for retinal differentiation and neural invasion. 23rd Annual Neuroscience Research Day. University of Miami Miller School of Medicine. Miami, FL (2014).
70. Field MG, Decatur CL, Harbour JW. Whole genome DNA methylation profiling distinguishes prognostically distict subtypes of uveal melanoma. Internal Epigenetics and Cancer Colloquium, University of Miami Miller School of Medicine. Miami, FL (2014).
71. Walter SD, Harbour JW. Tumor diameter contributes prognostic information that enhances the accuracy of gene expression profile molecular classification in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Denver, CO (2015). ***\*\*Chosen as top 6% of abstracts as a “Hot Topic”***
72. Kozak K, Kurtenbach S, Decatur C, Harbour JW. Predicting metastatic risk in uveal melanoma. University of Miami’s Third Annual CaneSearch Research Symposium. Miami, FL (2015).
73. Kozak K, Kurtenbach S, Decatur C, Harbour JW. BAP1 screening: Predicting metastasis in uveal melanoma. Research, Creativity, Innovation Forum. University of Miami. Miami, FL (2015).
74. Kurtenbach S, Kuznetsov JN, Decatur CL, Harbour JW. Genomic localization of BAP1 and interacting proteins in uveal melanoma and effects on histone H2A ubiquitination. Miami Winter Symposium. Miami, FL (2015).
75. Field MG, Decatur CL, Harbour JW. Integrated clinical, histopathologic and genomic analysis defines a new molecular subclass of uveal melanoma. Miami Winter Symposium 2015: Towards Personalized Cancer Medicine. Miami, FL (2015).
76. Cai L, Kuznetsov J, Kozak K, Kurtenbach S, Decatur C, Pham D, Field M, Harbour JW. Development of a cell-based model to study BAP1 loss in uveal melanoma. 16th Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2015).
77. Field MG, Decatur CL, Kurtenbach S, Kozak K, Harbour JW. PRAME as a biomarker for metastasis in uveal melanoma. 7th annual MD/PhD Research Symposium. University of Miami Miller School of Medicine. Miami, FL (2015). \****Best Poster Award\****
78. Field MG,Decatur CL, Harbour JW. PRAME as a biomarker for a new molecular subclass of uveal melanoma. American Association for Cancer Research Annual Meeting. Philadelphia, PA (2015).
79. Kurtenbach S, Harbour JW. BAP1 loss deregulates neural crest guidance cue signaling in uveal melanoma. American Association for Cancer Research Annual Meeting. Philadelphia, PA (2015).
80. Harbour JW. A new subset of Class 1 uveal melanoma with distinct clinical and molecular features. International Society of Ocular Oncology Biennial Meeting. Paris, France (2015).
81. Harbour JW. Management of a choroidal melanoma with intraocular dissemination. International Society of Ocular Oncology Biennial Meeting. Paris, France (2015).
82. Field MG, Decatur CL, Kurtenbach S, Harbour JW. Specific patterns of DNA methylome remodeling in Class 2 uveal melanomas harboring BAP1 mutations. Society for Melanoma Research Annual Meeting. San Francisco, CA (2015).
83. Gezgin G, Luk S, Cao J, Dogrusoz M, Krijgsman D, van der Velden P, Luyten G, Harbour JW, Jordanova E, Heemskerk M, Jager MJ. PRAME: a potential target for immunotherapy in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Seattle, WA (2016).
84. Seider MI, Schefler AC, Demirci H, Materin MA, Aaberg TM, Skalet AH, Harbour JW, Hovland PG, Berry JL, Stinnett SS, Mruthyunjaya P. Multi-center analysis of intraocular biopsy technique for uveal melanoma. American Society of Retinal Specialists Annual Meeting. San Francisco, CA (2016).
85. Ong E, Decatur CL, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW. Recurrent mutations in uveal melanoma: associations with gene expression profile, clinicopathologic features and patient outcomes. 42nd Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2016). ***\*Honorable Mention\****
86. Cai L, Alawa K, Field MG, Harbour JW. Development of an RNA sequencing pipeline for uveal melanoma. 42nd Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2016).
87. Ong E, Decatur CL, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. 17th Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2016).
88. Ong E, Dermarkarian CR, Barbarite E, Murray CR, Myslicki FA, Sinha V, Straker RJ, Villegas VM, Harbour JW. Prediction of vision loss following I-125 plaque brachytherapy for uveal melanoma using baseline clinical features. 43rd Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2017). \****First Place Outstanding Clinical Science Poster Presentation\****
89. Bussies P, Kurtenbach S, Field MG, Kuznetsov JN, Decatur CL, Harbour JW. DNA methylation pattern differentiates between class 1 and class 2 uveal melanoma. 43rd Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2017).
90. Kuznetsov JN, Aguero T, Kurtenbach S, Field MG, King ML, Harbour JW. The tumor suppressor BAP1 promotes a developmental switch from pluripotency to differentiation. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
91. Sanchez MI, Field MG, Kuznetsov JN, Kurtenbach S, Pham D, Harbour JW. The role of PRAME in promoting uveal melanoma metastasis. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
92. Durante M, Field M, Kurtenbach S, Bussies P, Decatur C, Harbour JW. Methylation analysis of uveal melanoma reveals definitive patterns in tumors harboring BAP1 mutations. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
93. Field MG, Anbunathan H, Durante MA, Cai L, Alawa K, Decatur CL, Kurtenbach S, Bowcock A, Harbour JW. Clonal evolution in uveal melanoma. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
94. Escandon J, Field MG, Kurtenbach S, Kuznetsov J, Decatur CL, Harbour JW. Potential role of DLL4 in uveal melanoma vascular mimicry. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
95. Kurtenbach S, Kuznetsov JN, Field MG, Reddy R, Sanchez MI, Decatur CL, Harbour JW. Epigenetic, transcriptomic and ubiquitomic changes associated with BAP1 loss in uveal melanoma. American Association for Cancer Research Annual Meeting. Washington, D.C. (2017).
96. Bagheri N, Fortun J, Townsend JH, Flynn Jr. HW, Harbour JW. Surgical approach and outcomes of pars plana victrectomy in eyes harboring a treated posterior uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Baltimore, MD (2017).
97. Bagheri N, Fortun J, Townsend JH, Flynn Jr. HW, Harbour JW. Surgical approach and outcomes of pars plana victrectomy in eyes harboring a treated posterior uveal melanoma. American Society of Retina Specialists Annual Meeting. Boston, MA (2017).
98. Bagheri N, Fortun J, Townsend JH, Flynn Jr. HW, Harbour JW. Surgical approach and outcomes of pars plana victrectomy in eyes harboring a treated posterior uveal melanoma. 53rd Annual Residents’ Days. Miami, FL (2017).
99. Harbour JW. Presentation of a case of primary uveal lymphoma. 50th Retina Society Annual Meeting. Boston, MA (2017).
100. Harbour JW. Peering into the past with next generation sequencing: new insights into the origins and metastatic propensity of uveal melanoma. 50th Retina Society Annual Meeting Boston, MA (2017).
101. Harbour JW. Comparison of the prognostic accuracy of gene expression-based classification versus TNM staging in uveal melanoma. American Association of Ocular Oncologists and Pathologists Annual Meeting. New Orleans, LA (2017).
102. Harbour JW. Choroidal nevus risk factors: weighted relevance based on molecular prognostication. Macula Society Annual Meeting. Beverly Hills, CA (2018).
103. Rodriguez DA, Sanchez MI, Decatur CL, Harbour JW. Ancestral analysis of uveal melanoma patients. Advancing the Science of Cancer in Latinos. San Antonio, TX (2018).
104. Walter SD, Paez-Escamilla M, Dean M, Samuels S, Studenksi M, Markoe A, Harbour JW. 3D dosimetry simulation for plaque selection in uveal melanoma: comparison of COMS versus Eye Physics plaques. American Society of Retina Specialists Annual Meeting. Vancouver, Canada (2018).
105. Dean M, Studenksi M, Paez-Escamilla M, Walter SD, Markoe A, Harbour JW, Samuels S. Dosimetric comparison of COMS and circular plaques to treat uveal melanoma. American Society for Radiation Oncology Annual Meeting. San Antonio, TX (2018).
106. Covington KR, Meldi-Sholl LE, Wilkinson JK, Durante MA, Decatur CL, Vargas DA, MS, Plasseraud KM, Oelschlager KM, Harbour JW, Stone JF, Monzon FA. Analytic validation of a clinical next-generation (NGS) panel for somatic mutations in uveal melanoma. Association for Molecular Pathology. San Antonio, TX (2018).
107. Smiddy WE, Barsam A, Gibbons A, McClellan A, Harbour JW. Follow the nevus: The cost-utility of screening for growth of choroidal nevi. Macula Society Annual Meeting. Bonita Springs, FL (2019).
108. Rodriguez DA, Sanchez MI, Decatur CL, Harbour JW. The influence of genetic ancestry on risk, prognosis, and outcomes in uveal melanoma. 45th Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2019). \****First Place Outstanding MD/PhD Trainee Presentation\****
109. Zhang MG, Kuznetsov J, Field M, Pelaez D, Harbour JW. Novel role of CBP in the etiology of retinoblastoma. 45th Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2019).
110. Harbour, JW. Choroidal nevus risk factors: weighed relevance based on molecular prognostication. Retina World Congress Meeting. Fort Lauderdale, FL (2019).
111. Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, Harbour JW. Genomic evolution of uveal melanoma arising in ocular melanocytosis. American Association for Cancer Research Annual Meeting. Atlanta, GA (2019).
112. Rodriguez DA, Sanchez MI, Kuznetsov JN, Kurtenbach S, Harbour JW. Novel expressed long non-coding RNAs in uveal melanoma. American Association for Cancer Research Annual Meeting. Atlanta, GA (2019).
113. Owens DA, Kuznetsov JN, Kurtenbach S, Aguero T, King ML, Harbour JW. A novel role for BAP1 in development and tumor suppression. American Association for Cancer Research Annual Meeting. Atlanta, GA (2019).
114. Sanchez MI, Kurtenbach S, Kuznetsov JN, Rodriguez DA, Pham DG, Barreras H, Harbour JW. PRAME misexpression alters protein ubiquitination and leads to increased invasion and metastasis in uveal melanoma. American Association for Cancer Research Annual Meeting. Atlanta, GA (2019).
115. Faiao-Flores F, Emmons M, Durante M, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Licht J, Harbour JW, Smalley K. HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling. American Association for Cancer Research Annual Meeting. Atlanta, GA (2019).
116. Field M, Bussies P, Cai L, Decatur C, Kuznetsov J, Kurtenbach S, Harbour JW. Class 2 metastasizing uveal melanomas arise through BAP1 loss and epigenetic reprogramming to a migratory neural crest-like state. Association for Research in Vision and Ophthalmology Annual Meeting. Vancouver, Canada (2019).
117. Rodriguez DA, Sanchez MI, Decatur CL, Harbour JW. Addressing disparities in Hispanic patients with uveal melanoma using global and local ancestry analysis. Association for Research in Vision and Ophthalmology Annual Meeting. Vancouver, Canada (2019). ***\*MIT Poster Competition Finalist\****
118. Mehrizy-Sanati A, Harbour JW. Intra-arterial chemotherapy for retinoblastoma: a 7-year single institution experience. American Society of Pediatric Hematology/Oncology’s Annual Conference. New Orleans, LA (2019).
119. Echegaray JJ, Harbour JW. Multimodal treatment for multifocal metastatic pulmonary carcinoid to the choroid. American Society of Retina Specialists Annual Meeting. Chicago, IL. (2019).
120. Echegaray JJ, Berrocal AM, Harbour JW. Fluorescein angiographic characteristics after primary intra-arterial chemotherapy for advanced retinoblastoma. American Society of Retina Specialists Annual Meeting. Chicago, IL. (2019).
121. Echegaray JJ, Harbour JW. Chorioretinal vascular side effects on intra-arterial chemotherapy for retinoblastoma. American Society of Retina Specialists Annual Meeting. Chicago, IL. (2019). \****Paper on Demand\****
122. Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, Harbour JW. Genomic evolution of uveal melanoma arising in ocular melanocytosis. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Miami, FL (2019).
123. Zhang MG, Kuznetsov J, Owens D, Field M, Pelaez D, Harbour JW. Role of CREBBP in the etiology of retinoblastoma. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Miami, FL (2019).
124. Rodriguez DA, Sanchez MI, Decatur CL, Harbour JW. The influence of genetic ancestry on risk, prognosis, and outcomes in uveal melanoma. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Miami, FL (2019).
125. Aaberg TM, Mruthyunjaya P, Schefler AC, Correa ZM, Decatur CL, Harbour JW. Prospective evaluation of genomic prognostic risk factors in 921 uveal melanomas: report from the Collaborative Ocular Oncology Group Study Number 2. Retina Society Annual Meeting. London, United Kingdom (2019).
126. Mruthyunjaya P, Aaberg TM, Correa ZM, Schefler AC, Harbour JW. Association of uveal melanoma (UM) clinical features with PRAME oncogene expression in the Collaborative Ocular Oncology Group Study No. 2 (COOG2). American Academy of Ophthalmology Annual Meeting. San Francisco, CA (2019).
127. Correa ZM, Aaberg Jr TA, Schefler AC, Mruthyunjaya P, and Harbour JW for the COOG2 study group.  The Collaborative Ocular Oncology Group Study No. 2 (COOG2). Poster #31. Society for Melanoma Research Annual Meeting. Salt Lake City, UT (2019).
128. Zhang MG, Acosta Z, Owens D, Suter R, Ayad NG, Harbour JW, Pelaez D. Fate mapping retinal organoids for studying developmental bifurcations. University of Miami Department of Medicine’s 6th Annual Eugene J. Sayfie, MD Research Day. Miami, FL (2020).
129. Gordon G, Rodriguez DA, Durante MA, Sanchez MI, Kuznetsov JN, Harbour JW. Uveal melanoma specific novel long non-coding RNAs network analysis. 46nd Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2020).
130. Dollar JJ, Kurtenbach S, Durante MA, Harbour JW. Development of a pan-cancer testis antigen transcriptional atlas. 46th Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2020).
131. Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW. Single cell analysis reveals new evolutionary complexity in uveal melanoma. 21st Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2020).
132. Owens D, Kurtenbach S, Kuznetsov JN, Harbour JW. Effect of GNAQ/11 pathway mutations on the transcriptome, proteome, and phosphotome in uveal melanoma. 21st Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2020).
133. Diaz JD, Patel N, Harbour JW. Uveal melanoma exudative retinal detachment repair. 8th Annual Vit-Buckle Society Meeting. Miami Beach, FL (2020).
134. Decatur CL, Durante MA, Correa ZM, Aaberg TM, Mruthyunjaya P, Schefler AC, Harbour JW. The Collaborative Ocular Oncology Group study number 2: a prospective multi-center evaluation of uveal melanoma prognostic biomarkers. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
135. Rodriguez D, Sanchez MI, Decatur CL, Harbour JW. Heterogeneity in population structure of Hispanic uveal melanoma patients reveals ancestrally driven loci of susceptibility. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
136. Owens D, Kuznetsov JN, Lopez A, Kurtenbach S, Bilboa D, Roberts ER, Harbour JW. New candidate therapy for BAP-1 mutant cancer identified using novel screen. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
137. Dollar JJ, Kurtenbach S, Durante MA, Harbour JW. Transcriptional characterization of cancer testis antigens. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
138. Sanchez MI, Kurtenbach S, Rodriguez D, Kuznetsov JN, Field MG, Barreras H, Harbour JW. Misexpression of PRAME sensitizes uveal melanoma cells to PARP inhibition. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
139. Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW. Single cell analysis reveals new evolutionary complexity. American Association for Cancer Research Annual Meeting. Virtual Meeting (2020).
140. Rodriguez D, Sanchez MI, Kuznetsov JN, Kurtenbach S, Harbour JW. Novel long non-coding RNAs associated with BAP1 mutations in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2020).
141. Weis E, Mruthyunjaya P, Schefler A, Aaberg T, Durante MA, Decatur C, Harbour JW. Analysis of small choroidal melanocytic tumors with and without identifiable driver mutations. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2020).
142. Grossniklaus HE, Mendoza P, Stalhammar G, Dubovy S, Harbour JW. Severe anaplasia in retinoblastoma correlates with gain of 6p by whole genome sequencing. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2020).
143. Kaler C, Kurtenbach S, Harbour JW. Aberrant expression of PROS1 as potential mechanism for macrophage dysfunction in BAP1-mutant Class 2 uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2020).
144. Dollar JJ, Kurtenbach S, Durante MA, Harbour JW. Transcriptional characterization of cancer testis antigens. American Association for Cancer Research Annual Meeting. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2020).
145. Studenski MT, Patel NV, Markoe A, Harbour JW, Samuels SE. Influence of tumor shape and location in eye plaque brachytherapy dosimetry. World Congress of Brachytherapy Meeting. Vienna, Austria (2020).
146. Patel NV, Studenski MT, Markoe A, Harbour JW, Samuels SE. A dosimetric analysis of dose de-escalation using BED modeling for eye plaque therapy. World Congress of Brachytherapy Meeting. Vienna, Austria (2020).
147. Diaz JD, Patel N, Harbour JW. Uveal melanoma exudative retinal detachment repair. American Society of Retina Specialists Annual Meeting. Virtual Meeting (2020).
148. Albini TA, Ashkenazy N, Dubovy S, Sridhar J, Harbour JW. Diagnosis, treatment and outcomes in cases of intravitreal metastasis of cutaneous melanoma. XXXIInd Meeting of the Club Jules Gonin. Dubrovnik, Croatia (2020).
149. Patel NV, Studenski MT, Markoe A, Harbour JW, Samuels SE. The impact of BED modeling on dose de-escalated eye plaque brachytherapy. American Society for Radiation Oncology Meeting. Virtual Meeting (2020).
150. Ashkenazy N, Dubovy S, Albini TA, Sridhar J, Patel N, Uchiyama E, Harbour JW. Diagnosis, treatment, and outcomes in patients with vitreous metastasis from cutaneous melanoma. Retina Society Annual Meeting. Virtual Meeting (2020).
151. Lutzky J, Feun L, Harbour JW. A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094). Society for Immunotherapy of Cancer Annual Meeting. Virtual Meeting (2020).
152. Zhang MG, Owens D, Kurtenbach S, Pelaez D, Harbour JW. Epigenetic regulation of BCOR in retinal development. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Virtual Meeting (2020).
153. Zhang MG, Owens D, Kurtenbach S, Kuznetsov J, Fields M, Pelaez D, Harbour JW. Role of BCOR in retinoblastoma. American Association for Cancer Research Annual Meeting. Virtual Meeting (2021).
154. Bennett RL, Monagle D, Sobh A, Smalley KSM, Harbour JW, Licht JD. Identification of essential proliferation and trametinib resistance mechanisms in GNAQ mutant uveal melanoma. American Association for Cancer Research Annual Meeting. Virtual Meeting (2021).
155. Kaler C, Dollar JJ, Kurtenbach S, Kuznetsov JN, Durante MA, Harbour JW. Mechanisms of genomic-microenvironmental interactions in uveal melanoma. American Association for Cancer Research Annual Meeting. Virtual Meeting (2021).
156. Jones N, Zhang M, Kuznetsoff J, Harbour JW, Pelaez D. Establishing VSX2-mcherry tagged iPSC-derived retinal organoid platform for studying progenitor cells. 47th Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2021).
157. Kalahasty K, Zhang M, Harbour JW, Pelaez D. The viability of lysine-specific demethylase 5 inhibitor (CPI-455) as a targeted retinoblastoma chemotherapy. 47th Annual Eastern-Atlantic Student Research Forum. University of Miami Miller School of Medicine. Miami, FL (2021).
158. Cruz A, Kurtenbach S, Harbour JW. Deconvolution of tumor immune microenvironment in uveal melanoma. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2021).
159. Schefler AC, Mruthyunjaya P, Decatur CL, Materin M, Correa ZM, Aaberg TM, Marr B, Semenova E, Harbour JW. Design, methods, and rationale for the Collaborative Ocular Oncology Group 2 (COOG2) study. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2021).
160. Semenova E\*, Decatur CL, Schefler AC, Aaberg TM, Marr B, Correa ZM, Harbour JW, Mruthyunjaya P, Materin M. Clinical characteristics and gene expression profile status in young patients with uveal melanoma: Collaborative Ocular Oncology Group 2 (COOG2) study. Association for Research in Vision and Ophthalmology Annual Meeting. Virtual Meeting (2021). ***\*ARVO Retina Research Foundation/Joseph M. and Eula C. Lawrence Travel Grant Recipient\****
161. Owens D, Kurtenbach S, Kuznetsov JN, Rodriguez D, Harbour JW. A multi-omic approach to deciphering the effects of GNAQ/11 pathway mutations in uveal melanoma. 22nd Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2021).
162. Kaler CJ, Rodriguez DA, Harbour JW. Mechanisms of BAP1-mediated transcriptional influence on ocular tissue development. 22nd Annual Sylvester Comprehensive Cancer Center in honor of Dr. Zubrod. University of Miami Miller School of Medicine. Miami, FL (2021).
163. Gurayah AA, Peters VA, Kwon D, Jin W, Patel N, Markoe A, Correa Z, Studenski MT, Harbour JW, Samuels SE. Predictors of outcomes and survival in Iodine-125 brachyterapy-related uveal melanomas: A modern institutional study. American Society for Radiation Oncology Annual Meeting. Chicago, IL (2021).
164. Lutzky J, Feun L, Harbour JW. NCT04552223. A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094). American Society of Clinical Oncology Annual Meeting. Virtual Meeting (2021).
165. Lutzky J, Feun L, Kwon D, Magallanes N, Harbour JW. A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094). American Association for Cancer Research Annual Meeting. Virtual Meeting (2021).
166. Sayegh Y, Kuznetsoff J, Kurtenbach S, Dollar J, Harbour JW. Analysis of Canonical Uveal Melanoma Aberrations in Murine Uveal Melanocytes. European Society of Medical Oncology Annual Meeting. Virtual Meeting (2021).
167. Zhang MG, Owens D, Kurtenbach S, Kuznetsov J, Fields M, Pelaez D, Harbour JW. Role of BCOR in retinoblastoma. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Virtual Meeting (2021).
168. Dollar J, Durante M, Kurtenbach S, Kuznetsoff J, Sanchez M, Rodriguez D, Cruz A, Harbour JW. Illuminating Genetic Determinants of the immunosuppressed tumor immune microenvironment of uveal melanoma with single cell sequencing. University of Miami Miller School of Medicine MD/PhD Medical Scientist Training Program Annual Symposium. Virtual Meeting (2021).
169. Cruz AM, Kurtenbach S, Harbour JW. Deconvolution of tumor immune microenvironment in uveal melanoma. NCI Center to Reduce Cancer Health Disparities (CRCHD) Professional Development Workshop and Mentored Mock Review (PDW & MMR) Workshop Transitioning to Independence: Charting Your Course to a Cancer Research Career. Virtual Meeting (2021).
170. Baqai U, Harbour JW, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Experimental Biology Meeting. Philadelphia, PA (2022).
171. Lutzky J, Durante MA, Feun LG, Hernandez-Aya L, Correa ZM, Decatur C, King J, Dollar J, Bisbal-Loubriel E, Magallanes N, Reis I, Harbour JW. Phase 2 trial of nivolumab/relatlimab in metastatic uveal melanoma. Society for Melanoma Research. Edinburgh, Scotland (2022).
172. Dollar JJ, Decatur CL Cruz A, Durante MA, Huuhtanen J, Mustjoki S, Correa ZM, Harbour JW, Lutzky J. Single Cell Analysis of Phase II Study of Nivolumab and Relatlimab in Metastatic Uveal Melanoma Reveals Tumor and Immune Response to Dual PD-1 and LAG-3 Inhibition. Society for Immunotherapy of Cancer (SITC); November 3-5, 2023; San Diego, CA.